EUROPEAN LIFE SCIENCE CEO FORUM for Conference Guide

Transcription

S C I E N C E
L I F E
05-06 March 2013
Hilton Zurich Airport Hotel
Conference Guide
ORGANISERS
www.sachsforum.com
SUPPORTING ORGANISATIONS
E U R O P E A N
for PARTNERING & INVESTING
PRESENTING COMPANIES
EUROPEAN LIFE SCIENCE
CEO FORUM
SPEAKERS
C E O
F O R U M
WELCOME
6th Annual
WELCOME
t back :: next u
Welcome
Sachs Associates are delighted to welcome you to the:
6th Annual
5th - 6th March 2013
Hilton Zurich Airport Hotel
This exclusive and transactional event compliments our Annual Biotech in Europe Investor
Forum, held later in the year, but with added focus on Partnering & the pharmaceutical industry,
feature presentations from Big Pharma representatives demonstrating their current and future
partnering strategies through thought-provoking case studies.
General Information
• The registration desk is open from 8am on both days although you are welcome to join the
event at any time. Please collect a copy of the agenda for information on timing and room
allocation for each session.
• Wireless Internet connection is available throughout the venue for the duration of the event.
Please ask for an access code at the registration desk.
• The one-to-one meetings are being held in the La Place A and B. Please bring with
you a copy of your diary. Should you have any queries about your schedule, the laptop
situated by the meeting tables is available for your assistance.
This year’s programme features a series of panels and presentations from leading investment,
pharmaceutical and biotech companies, highlighting the current issues surrounding the evolving
Finance and M&A market, Partnering activity, Vaccines, Oncology and Biomedical Investment,
and includes special keynote speeches, providing an expert outlook on Europe’s Biotech
industry. In addition, the event holds exclusive Partnering Workshop Presentations and more
than 60 exclusive company presentations from an exciting and diverse range of publicly listed
and private life science companies, looking to raise finance and/or find partners.
Sachs Associates are delighted to welcome you to the 6th Annual European Life Science CEO
Forum for Partnering & Investing. Following its success from previous years, the forum once
again provides access to an exciting cross-section of venture-funded and small-cap companies
with leading investors and pharmas.
SPEAKERS
European Life Science CEO
Forum for Partnering & Investing
Request for Presentations
ORGANISERS
Please use the agenda to mark off presentations that you are interested in and email your request
to [email protected] after the conference. We will endeavour to send you the requested
presentations as soon as we have been granted permission to do so by that specific presenter.
Please note that we DO NOT have copies of the slides that are shown during the conference.
WELCOME
t back :: next u
Events Diary
For regular updates, sponsorship, presenting and attending opportunities
and further information regarding any of our future events please contact
Zoe Harris on [email protected]
SPEAKERS
Annual
CANCER BIO PARTNERING FORUM
Promoting Public & Private Sector,
Collaboration & Investment in Drug Development
21st - 22nd May 2013 • The Westin Copley Place • Boston
13th Annual
Biotech in Europe Investor Forum
30th September - 1st October 2013 • Zurich
Back for its 13th year, the Biotech in Europe Investor Forum will once again be held in Zurich. Featuring our core
sponsors, an audience of over 400 investors, analysts & media, with presenting opportunities for over 60 public
and private companies and panel themes including Finance & Investment, Partnering and more, this event is a
must for all key players in the Biotech and Pharma industry.
View last year’s event at: www.sachsforum.com/zurich12/index.html
ORGANISERS
The forum will be an excellent platform for companies to raise their profile by promoting their interests to the
larger financial community. Facilitated by its successful one-on-one meeting system and networking receptions,
the event will help build strong and meaningful business relationships through face to face communication, and
promises to be a great opportunity to meet emerging companies, leading global investors, analysts, advisors
and Big Pharma representatives. Panel discussions with participation from industry leaders and experts in their
sector, makes the Biotech In Europe Investor Forum an excellent way to gain insight and keep up to date with
partnering and investment and current industry trends.
Sachs Cancer Bio Partnering Forum will cover the following topics in the program:
• Big Pharma Approach to Innovation
• Cancer Stem Cells
• Cancer Tech – Device, Diagnostics & Image Technologies
• Deal Making and Investment
• Immunotherapies & Cancer Vaccines
• Israel Bio-Med
• Personalised Oncology and Diagnostics
• Public-Private Partnerships
• Translational Research – Advances & Directions
The Sachs Cancer Bio Partnering Forum is designed to bring together thought leaders from cancer research
institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We
expect around 300 delegates and there is an online meeting system and meeting facilities to make the event
transactional. There will also be a track of presentations by research institutes, patient advocacy groups,
pharmaceutical companies on partnering and biotech’s seeking licensing/investment.The Forum will feature an
online one-to-one meeting system with designated meeting space available to all attendees.
WELCOME
Speakers
Alexandra Goll, General Partner, TVM Capital
Prior to her affiliation with TVM Capital, Dr. Goll was the Global Business Leader for HIV and CMV, and was responsible
for strategic marketing and business development for Virology at Roche Ltd. in Basel. She had been involved in clinical
development and managing commercialization strategies of products such as Neupogen® (under an agreement with Amgen),
Hivid®, Cymevene® and Valcyte®. Dr. Goll holds a degree in pharmacy from the Free University of Berlin, and wrote her
doctoral dissertation in natural sciences at Philipps University of Marburg. She was also honored with a post-doctoral position
supported by the Boehringer-Ingelheim Foundation for fundamental research in medicine.
Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the
Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry
and venture capital.
Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in
Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry,
University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later
Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The
company used a novel drug discovery technology developed in several academic labs, including Eliseev’s group in Buffalo.
He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos
was acquired by Amgen in 2007 for $300 million.
Andrew Slade, President, Menarini Pharma
Dr. Andrew Slade is President of Menarini Biotech. In this role, he is responsible for the biotechnology R&D and manufacturing
undertaken by Menarini and in the in-licensing of biotech products.
Dr. Slade was previously Head of Manufacturing for a major Biologics company and before that was employed by GSK in
various senior product development and operational roles.
He studied biochemistry and enzymology.
Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC
Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture
Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous
deals with portfolio companies in the US and Europe.
Alexey Eliseev, Managing Director, Maxwell Biotech Venture Fund
SPEAKERS
Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Sweden), Biovertis AG (Vienna, Austria) and
Cerenis Therapeutics (Toulouse, France and Ann Arbor, MI). She also represents the interests of TVM Capital with Addex
Pharmaceuticals SA (Geneva, Switzerland), MediGene AG (Martinsried), Newron Pharmaceuticals SpA, (Bresso, Italy) and
Wilex AG (Munich, Germany).
t back :: next u
Alexandra joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital life science investments.
She initiated TVM Capital’s lead investment in Actelion Ltd (Allschwil, Switzerland) and led the firm’s successful investments
in Idenix Pharmaceuticals, Inc. sold to Novartis, and Pharmasset Inc. which was sold to Gilead Sciences – TVM Capital acted
as a lead investor in both cases. She also initiated and managed the investment in EUSA Pharma Ltd., recently sold to Jazz
Pharmaceuticals Inc.
ORGANISERS
WELCOME
Speakers
Anja Konig, Managing Partner in Basel, Novartis Venture Fund
Anthony Hartley is a Managing Director in UBS Investment Bank’s Global Healthcare Group. He is based in London and mainly
focuses on pharmaceutical and biotechnology companies in Europe.
SPEAKERS
Anthony Hartley, Managing Director, Investement Banking, USB
t back :: next u
Dr Anja Konig is active in Switzerland and Europe and also responsible for expanding the fund’s presence to Asia Pacific. Prior
to joining Novartis she was an Associate Partner at McKinsey and Company, a global consultancy, where she worked with
companies in health care in the US, Europe and Emerging Markets. Anja König is a scientist by training and holds a PhD in
physics from Cornell University. Anja serves on the boards of Bicycle, Covagen, Diagnoplex, Heptares, and Nabriva, and works
with Destiny, MerLion, Neomics, PharmAbcine, Polyphor, Qurient Therapeutics and S*BIO.
Anthony joined UBS in 2012 from Morgan Stanley and has spent 12 years in healthcare investment banking, predominantly
advising healthcare clients with a primary focus on the pharmaceutical and biopharma sectors.
Anthony received a Doctorate (D.Phil) in Pharmacology from The University of Oxford, and an MBA (Distinction) from
Manchester Business School. Prior to his career in investment banking, Anthony spent a total of 7 years in the pharmaceutical
industry working in a variety of research and commercial roles at Pfizer, GSK and AstraZeneca
Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine has been an initial investor
and active board member in public companies like Actelion, Addex, Orexo, NovusPharma (then sold to CTI), Movetis (then
sold to Shire) and Stentys, which went public respectively on the Zürich stock exchange, the Stockholm stock exchange,
the Milan Nuovo Mercato, the Belgium Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to
Actelion), CoreValve (sold to Medtronic) and Fovea (sold to Sanofi Aventis). He has also invested in and is a board member of
private companies MD Start, CoAxia, EOS, Mainstay and Recor. Antoine has an MBA from the Wharton School of Business,
University of Pennsylvania.
Antoine Papiernik, Managing Partner, Sofinnova Partners
Arin Ghasparian, CEO, Virometix
Ben Cons, Vice President, Corporate Development, Quintiles
Ben Cons PhD, Global Vice President Quintiles Corporate Development structures and delivers managed partnerships with
pharmaceutical and biotechnology industries.
Dr Arin Ghasparian co-invented and developed Virometix Synthetic Virus-Like Particle technology. Before becoming Virometix’
CEO in 2012, he served as Chief Scientific Officer and was responsible for all R&D activites of company, established R&D
partnerships and brought Virometix programs from research to proof-of-concept in animals. Prior to founding Virometix
he worked as a researcher at the University of Zurich, where he developed new approaches to vaccine design. He has
a background in organic chemistry and received a Doctorate in biochemistry from the University of Zurich. He has also
participated in several entrepreneurship and business courses to expand his knowledge base in this area.
An innovative team leader, he is adept in developing partnership solutions between companies that realize value for all parties.
Dr. Cons joined Quintiles in 1996, bringing his expertise in pharmaceutical drug development and commercialization to drive
corporate development goals. Early on in his career, Dr. Cons expanded his research experience in molecular pharmacology
through a position in drug development for Schering AG. Later, at Glaxo Wellcome, he developed an expertise in marketing
and business development.
ORGANISERS
Educated in the U.K., Dr. Cons acquired a bachelor’s degree in biological sciences with honors from Portsmouth Polytechnic,
and then continued his studies to earn a doctorate in molecular pharmacology within the physiology and pharmacology
department of Southampton University.
WELCOME
Speakers
Carles Domènech, Founder & CEO, Ability Pharmaceuticals
Carles Domènech obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and
also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has
additional business training at ESADE business school and other business programs.
Carles has also 4 years’ experience in biotech venture capital and business angels associations and has also been
collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the
seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government
of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth.
He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs
Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.
SPEAKERS
Carles has 15 years international experience in business development and licensing in the pharmaceutical industry. He
held senior positions at the Barcelona pharmaceutical companies Almirall, SA (1992-2003, Manager and Head, Business
Development and Licensing) and Lacer, SA (2005-2007, Director, Business Development and Licensing).
t back :: next u
Carles started developing his career in cancer research at CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering
Cancer Center in New York (1990-1992).
In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009.
Charles Wilson serves as the Global Head of Strategic Alliances, leading a group responsible for research partnering at
Novartis. Partnering efforts include academic relationships to understand disease processes, biotech collaborations to access
drug discovery technologies, and in-licensing of compounds prior to clinical proof-of-concept. Prior to joining Novartis, Chuck
founded and led Archemix, a company focused on aptamer therapeutics. Responsible initially as its Chief Technology Officer
for developing the company’s technology platform and managing its drug discovery efforts, he moved into a business role
focused on partnering with pharma and biotech companies. Before moving into industry, Chuck was a professor in the
Department of Molecular, Cellular, and Developmental Biology at the University of California, Santa Cruz where his group
determined the first x-ray structures of aptamers bound to their targets. Formally trained in structural biology and molecular
biology, Chuck received his PhD from UCSF and his post-doctoral training at MGH.
Chris Britten is the Managing Director of Vantage Life Science. He has a scientific background, a PhD in biochemistry and an
MBA. Chris has gained huge experience and contacts in the Life Sciences market having negotiated a variety of acquisitions,
licences, divestments and strategic alliances with partners around the world.
Chris Janssen, Director of Science and Innovation, Biomedical Cluster, Skolkovo Foundation
ORGANISERS
Starting with a career in BioMedical research, Chris Janssen has extensive experience in science development. After
spending some years in academia, Chris moved on to business, founding a biotech company. Following on from success
in research and business, he has led national development efforts in BioMedical technologies, lastly as director for the
national development program for quantitative biology and medicine at Scotland’s national academy, the Royal Society of
Edinburgh, with particular emphasis on commercialisation and business integration. Chris has participated in governmental
and parliamentary advisory groups, and in oversight groups at the National Health Service. His achievements include creating
access for business to integrated health care and science information, focusing public-private partnership support funding
for development of cutting edge science research in SMEs, and setting up collaborative networks between health care,
academia, and industry. Since mid-2011 Chris has held the position of Director for Science & Innovation at the BioMedical
Technologies Cluster Skolkovo, Russia. His remits include setting priority thematic areas for support, overseeing the Cluster’s
part in the due diligence process for grants, working with major multi-nationals, and facilitating the creation of appropriate
infrastructure for the Cluster’s participants. Chris sees his primary goals as identifying excellent science in the biomedical
area in Russia, and facilitating its commercialisation, bringing cutting edge start-up companies to Russia, and assisting in
creating the right infrastructure to necessary for successful growth of biomed business in Russia.
Chris Britten, Managing Director, Vantage Life Sciences
Charles Wilson, Vice Presdient, Global Head of Strategic Alliances,
Novartis Institute for BioMedical Research, Inc.
WELCOME
Speakers
Christina Takke, Partner, Forbian Capital Partners
SPEAKERS
Daniel Bach, Associate, Life Sciences, Index Venture
t back :: next u
Christina Takke holds a PhD in Molecular Biology from the University of Cologne. She specialized in Functional Genomics
and focused on early embryonic development. Christina completed a PhD thesis on cell-cell interactions during zebra fish
neurogenesis and somitogenesis. After her internationally oriented academic career, she worked at Bio-Gen-Tec, NRW, a
German Governmental Agency as a Business Consultant. She joined the Life Science team in 2000 and has been responsible
for conducting scientific and clinical due diligence investigations and providing scientific support to our portfolio companies.
Furthermore she holds non-executive board positions with Pieris AG, arGEN-X BV and Amakem NV. Christina acts as Forbion’s
Compliance Officer.
Daniel Bach is an Associate in the life sciences team, having joined the firm in 2007.
Dani’s areas of interest range from metabolic diseases to virology and prior to joining Index, Dani was conducting research
at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked on the complex interactions between human
immunodeficiency virus (HIV) and the human immune system.
Dani holds a Master in Start-up Business Administration and a PhD in Molecular Biology from the Universitat de Barcelona.
Daniel Dornbusch has served in multiple management roles at pharmaceutical, biotechnology, and diagnostics companies
including Novartis, Genentech, and Genzyme. Daniel has spent over 15 years in the biopharmaceutical and diagnostics
industry in various roles including business development, sales, marketing, corporate development, and commercial
management. Daniel joined Nodality from Novartis Diagnostics where he held the position of Commercial Director of Latin
America. Daniel joined Novartis in business development where he completed numerous business development transactions.
Before Novartis, Daniel held roles in business development at Cerimon Pharmaceuticals Inc., led business development
and sales for an Amerisource Bergen company, and led a marketing team at Genentech, Inc. Daniel began his career at the
Genzyme Corporation and served in numerous roles including in business development, product management, and corporate
development. Daniel received his B.A. in Biology and English from Cornell University, M.A. from Tufts University School of
Medicine and Emerson College, and M.B.A. from the Harvard Business School.
Dr Daniel Teper is the founder and currently the Chief Executive Officer of Immune and has been such since 2010. From
2005 to 2010, Dr. Teper was a New York-based Managing Partner and Head of North America at Bionest Partners,a Global
Management Consulting firm, where he advised pharmaceutical and public biotechnology companies with respect to
Corporate Strategy, Business Development, Mergers & Acquisitions, New Product Development and Commercialization. he
had previously been a New York based Partner at ISO Healththcare Consulting, later acquired by Monitor Group. Dr.Teper
started his career in 1984 at at Novartis in Base, CH and then in the United States where he help growing management
responsibilities in sales, marketing and eventually as Head of New Product Development for Cardiovascular Products.
Dr.Teper returned to Europe as Senior Vice President and Head of Marketing & Sales at Glaxo France and then as President
and Chief Operating Officer of Laboratoires Delagrange which was acquired by Synthelabo (now Sanofi). He tehn founded
and was the CEO of WINTEC Pharma, a specialty Pharmaceutical company, which he sold part to Norgine (UK) and part to
Galephar (Belgium). Dr. Teper then joined HAVAS-EURO RSCG Healthcare Worldwide, as President, Global, where expanded
Euro Rscg operations internationally and advised pharmaceutical companies on Global Launches of major new drugs. Dr.
Teper co-founded Novagali (NYSE Euronext: NOVA), a pharmaceutical company specializing in ophthalmology and which was
recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree from Paris XI University and an MBA from
INSEAD where he was a J.Salomon scholar.
Daniel Teper CEO, Immune Pharmaceuticals
Daniel Dornbusch, VP BD, Nodality Inc.
ORGANISERS
WELCOME
Speakers
Donald McCaffrey, President and CEO, Resverlogix Corp.
SPEAKERS
Don’s career accomplishments have been recognized by the business community and peers, as he was nominated for Ernst
& Young Entrepreneur of the Year twice. He is a contributor to community non-profit organizations including the United Way,
Mount Royal College, Alberta Children’s Hospital, Education Matters, and Calgary Urban Project Society Literacy Program.
t back :: next u
Donald McCaffrey is Co-Founder, President, & CEO of Resverlogix Corp. He has over 30 years of experience in drug discovery
& development, and international conference and tradeshow management across multiple industries, including biotechnology.
Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming
a TSX listed company, including raising over $185 million. In addition to garnering appropriate financing for Resverlogix’s
aggressive development plan, Don has strategically directed the Company in its discussions with top global pharmaceutical
companies, while creating new therapeutic markets for its key technology platforms. Don’s expertise in corporate operations
has attracted an international team of R&D experts to Resverlogix. This scientific and operational expertise has pioneered
RVX-208, a drug which has the potential to be first in a new class of drugs for the treatment of cardiovascular disease. Under
his guidance Resverlogix has won multiple awards including the 2008 WEF Technology Pioneer award.
Einat Zisman, CEO, Bio-Holdings Ltd.
Enrico Bastianelli, CEO, Bone Therapeutics
Since June 2006, he is Chief Executive Officer of Bone Therapeutics; a leading international biotechnlology company
specialized in the treatment of osteo-articular diseases using cell therapy.
Erich Mohr, Chairman & Chief Executive Officer, MedGenesis Therapeutix Inc.
Erich Mohr, Ph.D., R.Psych. founded MedGenesis Therapeutix Inc. in 2006. He is an internationally recognized expert in
experimental therapeutics for central nervous system disorders and has served as the principal investigator on numerous
clinical trials. He has chaired and/or served on several regulatory advisory panels and has a lengthy history of service on medical
advisory boards for several of the world’s largest pharmaceutical firms as well as a number of biotechnology companies.
Dr Bastianelli has a long standing experience in pharmaceutical industry in fields as broad as Sales & Marketing, R&D,
Licensing, Corporate Development and Strategy. His career started in the Pathology Department of the Erasme University
Hospital in Belgium. Then he joined Procter & Gamble Pharmaceuticals in 1996, where he was involved in the marketing of
ethical and over-the-counter drugs in the field of bone diseases. In 1999, he became a Consultant for McKinsey & Co, where
he was involved in strategic and organizational missions for major pharmaceutical as well as biotechnology companies all
over Europe. From its creation in 2002 until mid-2006, Dr Bastianelli worked as VP Corporate Development for ProSkelia, the
spin-out of Aventis focused on bone diseases and hormone disorders (which then became ProStrakan, after the merger with
Strakan, a Scottish pharmaceutical company).
Dr Einat Zisman is the CEO of Hadasit Medical Research Services & Development Ltd., the technology transfer company and
commercial arm of Hadassah Medical Organization in Jerusalem, Israel. Prior to joining Hadasit, Dr. Zisman served as the
Chief Business Officer of Yeda, the technology transfer arm of the Weizmann Institute of Science. Dr. Zisman also served at
a range of senior positions in the Israeli bio-tech industry, among them managing projects, managing research and overall
development and promotion of projects that originated in the academia. Dr. Zisman holds an MBA from the Marshall Business
School, University of Southern California, USA, a PhD in Immunology from the Weizmann Institute of Science and a B.Pharm
degree from the Hebrew University of Jerusalem. Dr. Zisman’s expertise is in building value via licensing, partnering, initiating
start-ups, financing and marketing of early stage intellectual property.
In 1995, Dr. Mohr founded CroMedica, a Canadian based global, full service CRO with a strong focus on Central Nervous
System Disorders which became a global corporation with over 550 employees and offices in 5 continents. In 2002, the
company merged with PRA International where he served as Chief Scientific Officer for a period of almost 4 years. In 2004
PRA International achieved listing on Nasdaq (PRAI) and is now one of the top 5 CRO’s in the world.
Dr. Mohr earned his doctorate in neuropsychology in 1982 and master of science degree in neuropsychology in 1980, both
from the University of Victoria, British Columbia, Canada and obtained his undergraduate education at The University of the
Pacific, Stockton, California, USA. He is the recipient of a number of academic and industry awards, among them the Legacy
Award (Alumni of the Year) from the University of Victoria.
ORGANISERS
Dr. Mohr was trained at the National Institutes of Health in Bethesda, Maryland and was also on staff at the NIH for a period of
four years. He held an academic appointment as Professor of Medicine and Psychology at the University of Ottawa School of
Medicine until 2002 and is credited with over 150 publications, books, book chapters and abstracts
WELCOME
Speakers
Esteban Pombo Villar, Chief Operations Officer, Oxford BioTherapeutics AG
Florian Schödel, CEO, Phillimmune LLC
Florian Schödel is the founder of Philimmune LLC, a consulting firm which provides strategic advice in the development of
biologics, vaccines and pharmaceuticals. Florian has > 20 years of successful experience in leading teams in the development
of vaccines and biologics in the pharmaceutical and biotech industry and in academia.
Dr Fintan Walton is the Founder and CEO of PharmaVentures. He was educated at the University of Michigan (US) and Trinity
College (Dublin, Ireland), and subsequently he gained broad commercial experience in biotechnology in management positions
at Bass and Celltech plc (1982-1992). As an entrepreneur, Dr Walton co-founded CONNECT Pharma in 1992, a company
focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making including strategic
alliances, Mergers & Acquisitions and equity financing. In 1997 the company became PharmaVentures. His company has
worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 37 countries. Clients
have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical
device, generic and OTC companies. His clients have also included major banks, investment/merchant banks, and private
equity and venture capital groups. Although Fintan’s main focus is his role as Chief Executive Officer of PharmaVentures, he
actively participates in many consultancy assignments.
SPEAKERS
Fintan Walton, CEO and Founder, PharmaVentures
t back :: next u
Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20
years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of
Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept
in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz
Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative
projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.
His passion is preventative medicine and the use of modern science and technology for the improvement of public health –
especially in the development of preventative and therapeutic vaccines and biologics.
He has directed the design and execution of clinical studies for licensure and routinely interacts with international and national
regulatory agencies.
Florian has led the clinical teams responsible for several successful vaccine filings.
A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories
before he founded Philimmune.
Florian graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and
Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds adjunct faculty appointments at
the LMU and at the Biodesign Center of the ASU. Florian’s research at the Max-Planck Institute for Biochemistry, at Scripps,
WRAIR and INSERM focused on hepatitis B and on novel recombinant vaccines against diseases such as hepB, malaria and
typhoid.
Florian has a track record in running scientific and operational organizations, in business and strategic planning, for
forming international strategic partnerships and alliances, in target identification and in all steps of clinical and pre-clinical
development.
Florian joined Merck Research Laboratories in 1996 as Director Clinical Vaccine Research leading EU vaccine clinical trials
and the clinical development of rotavirus vaccines and varicella, measles, mumps, rubella combination and shingles vaccines.
As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines.
ORGANISERS
WELCOME
Speakers
Guillaume Vignon, Director Business Development Oncology, Global Licensing & Business Development,
Merck Serono
Guillaume holds an MBA from Hult International Business School, Cambridge, USA, and a Ph.D. in Biochemistry and Molecular
Biology from the University of Paris 6/ Pasteur Institute, Paris, France.
SPEAKERS
Before his positions as global transactor, Guillaume served as inhouse consultant for Merck KGaA, Damstadt, Germany,
leading several assignments in the field of management strategy, implementation, commercial operations BU Oncology, and
business planning BU Oncology.
t back :: next u
Mr Guillaume Vignon is Director of Business Development Oncology with Merck Serono, responsible for designing deal
structures and negotiating the terms of complex strategic transactions in the field of Oncology. Prior to this position, Guillaume
was Director of Strategic Transactions, responsible for partnerships of pre-clinical stage assets, enabling technologies, and
companion diagnostics. During his career at Merck Serono, Guillaume closed successfully several key partnerships for Merck
Serono in the field of Oncology, Companion diagnostic, and Antibody discovery.
Hampus Hillerstrom, Executive VP and Chief Business Officer, Neurophage Pharmaceuticals
Hampus Hillerstrom is a co-founder and board member of NeuroPhage and serves as Executive Vice President and Chief
Business Officer. Previously, he spent 3 years as an associate at leading European biotech venture capital firm HealthCap
where he participated in a large number of investment transactions including several IPOs. More recently Mr. Hillerstrom
spearheaded a project at AstraZeneca to evaluate decision-making leading to Phase III clinical trials. Previously Mr. Hillerstrom
was a partner in the Zurich-based consulting boutique Venture Valuation specialized in the assessment and valuation of
biotech companies. For a year prior to that he worked in mergers and acquisitions at the investment bank Lazard in the
pharmaceutical and chemicals industry teams. Mr. Hillerstrom holds a Masters in Economics and Finance from the University
of St. Gallen, an MBA from Harvard Business School, and an MSc in Health Sciences and Technology from MIT/Harvard
Medical School (HST).
Igor Pivovarov, CEO, HemaCore LLC
Igor Pivovarov is CEO & Co-Founder of HemaCore and Co-Founder & Member of Board of several companies.
HemaCore is a biotech company which develops medical devices and assays for hematology. The Company was invested
in by RUSNANO to bring it to the market. Thrombodynamics is a new global assay for monitoring and prognosis of blood
coagulation disorders and finding out risks of bleeding and thrombosis.
Irena Melnikova, Managing Director Russia, Burrill & Company
Irena Melnikova joined Burrill & Company in October 2012 as Managing Director, Russia. Prior to joining Burrill & Company,
she served as Director of Strategy and External Innovation at Sanofi.
Previously, Irena was a Principal in the Life Science team of TVM Capital, a global venture capital firm. At TVM, she was
involved in deal origination and new investment opportunity evaluation and actively participated in the management of TVM
Capital investments in the United States. Prior to TVM Capital, she was a member of the biopharma investment banking
team at Leerink Swann. She also produced and launched a new series of syndicated reports for the firm. Entitled Future in
Focus, these reports provided clients with insight and analysis of business and technology issues shaping corporate and R&D
strategies, pipelines and alliances.
Irena has published over 20 manuscripts in peer-reviewed journals and is a regular contributor to the “Analyst Couch” section
of Nature Reviews in Drug Discovery magazine. She holds an M.S. in chemical engineering from the Mendeleev University of
Chemical Technology of Russia and a Ph.D. in molecular medicine/molecular biology from the University of Texas.
ORGANISERS
Prior to Leerink Swann, Irena was a Research Manager at Life Science Insights, a subsidiary of IDC, the leading technology
market research company. As a project leader at TransForm Pharmaceuticals (acquired by Johnson & Johnson), she was
responsible for running several programs, including Engineered Tissue Constructs, funded by DARPA, and Amyloidoses.
Igor has 6 years basic research experience in biophysics, mathematical modeling. 15 years business experience as an
engineer, CTO, CMO, CEO and he has raised over $22M in investments.
WELCOME
Speakers
Jakob Knudsen, CEO, ViroGates
SPEAKERS
Jason Rushton, Head of Life Sciences Advisory Initiative, Deloitte
t back :: next u
Jakob Knudsen assumed his role as CEO of ViroGates in April 2011. Jakob was previously CCO & CFO of Egalet Ltd. a Danish
based biotech company focusing on development of pain products. Jakob oversaw all commercial operations including IP
and Financing, and was responsible for entering into multiple commercial collaborations (licensing and feasibility stage
agreements). Prior to this Jakob was heading the Corporate Business Development function at ALK-Abelló A/S, a Danish
biopharmaceutical company. Jakob was responsible for ALK’s licensing and M&A deals. Before this Jakob held positions
within sales and marketing with the company. Jakob is a lawyer by training and he also holds an MBA from Imperial
College, UK.
Jason leads the life science focus of Deloitte Corporate Finance in Switzerland.
He has 20 years of experience in the pharmaceutical sector spanning R&D, management consulting and venture capital.
Jason began his career in drug discovery with Eli Lilly and then moved to PA Consulting Group where he advised
pharmaceutical/biotech clients in technical, commercial due diligence and financial transactions. For 10 years Jason was a
venture capital investor with direct involvement in completing over 30 private life science transactions latterly with the venture
capital fund of Nestle.
Jeroen Tonnaer, xecutive Director, Head European External Scientific Affairs, Worldwide Licensing, MSD
Jeroen Tonnaer PhD obtained an MSc in biology from the University of Nijmegen and a PhD in pharmacology from the Medical
Faculty (Rudolf Magnus Institute for Pharmacology) of the University of Utrecht. Part of his PhD work was performed at the
INSERM laboratories in Paris.
Following Schering-Plough’s acquisition by Merck, Jeroen joined Merck’s Worldwide Licensing organization in February 2010
to become head of the European External Scientific Affairs team. Since then this team has been the driver in the identification
and execution of several major licensing and partnering deals including those with Ablynx, AiCuris and Delphi Genetics.
Johanna Holldack, CEO, Telormedix S.A.
Johanna Holidack has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in
both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke,
Chiron, MediGene and Borean Pharma.
Jeroen joined Organon as a neuroscientist in 1982. As Assistant-Manager of the CNS Program he was responsible for the
pre/early clinical development of SAPHRIS®/SYCREST® (asenapine). He held further positions as Head DMPK, Executive
Director Toxicology, Executive Director Global Research Alliances and, upon acquisition of Organon by Schering-Plough, Head
Discovery Collaborations Europe. In the latter role he led the team that facilitated licensing and collaborative efforts for the
Schering-Plough scientists based in Europe, focused personally on the Women’s Health field and was the business liaison for
Schering-Plough in the consortium TI Pharma.
Jason has been a board member of a number of biotech companies and has firsthand experience of business development
and licensing.
Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician.
In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche
Krebshilfe and a research associate at Harvard Medical School.
ORGANISERS
WELCOME
Speakers
John Cullity Principal, Torreya Partners
Jonathan Garen, Executive Director Business Development, Forest Laboratories
Jonathan Garen is an Executive Director of Business Development at Forest Laboratories, Inc., where he has worked since
2003. His responsibilities include the identification, evaluation, and negotiation of transactions for new business opportunities
in a wide range of therapeutic areas and stages of development, including licensing and acquisitions in the fields of neurology,
inflammation, oncology and metabolic diseases. Prior to Forest, Jonathan was a Director in the Global Licensing department
at Pharmacia Corporation. Jonathan was a founder and Vice President of TechEx, an online licensing exchange for early stage
opportunities, and was a Licensing Associate at the technology licensing office of Yale University. Jonathan earned his Master
of Environmental Sciences from Yale University and his Bachelor of Science in Physics from the Massachusetts Institute of
Technology.
Jorn Aldag joined uniQure’s predecessor company AMT in October 2009. He has led uniQure’s corporate development
including the build-up of its gene therapy pipeline, the marketing authorization process at EMA for Glybera, and several
dilutive and non-dilutive financing transactions. Before joining uniQure he was instrumental in building Evotec AG (FSE:
EVT), from 1997 to 2000 as CFO and from 2001 to 2009 as President and CEO. EVT designed and implemented a cutting
edge small molecule technology platform, became a leader in drug discovery services and developed a promising CNS
pipeline. Prior to Evotec, Jörn Aldag served in various financial management positions at MAN AG, and as Business Director
at Treuhandanstalt, the agency responsible for privatizing the East German economy after the German reunification. Jörn
Aldag is Chairman of Molecular Partners AG, Zurich, Switzerland, and a member of the Board of Directors of the DESERTEC
Foundation, Hamburg, Germany. He holds business degrees from the Harvard Business School and the European Business
School.
Jörn Aldag, CEO, uniQure
John Trizzino B.S., M.B.A., is a senior executive with more than 25 years of experience advancing strategic initiatives for
publicly traded biotechnology companies, primarily within the vaccine market. Prior to joining Immunovaccine, he was the
Senior Vice President at Novavax Inc., where he provided strategic direction and successfully negotiated profitable joint
venture and licensing agreements, including a $179M BARDA contract. Prior to joining Novavax, Mr. Trizzino held senior
executive positions at MedImmune Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of
GlaxoSmithKline Inc. He began his extensive career in vaccines at Henry Schein Inc. leading commercial marketing efforts
and executing a series of successful commercialization and distribution agreements. Mr. Trizzino is a graduate of Long Island
University and received his master’s degree in business administration from New York University’s Leonard N. Stern School
of Business.
SPEAKERS
John Trizzino, CEO, ImmunoVaccine, Inc.
t back :: next u
John Cullity works at the New York office of Torreya Partners, a life sciences advisory firm providing services in M&A, licensing,
and corporate finance. Previously he was at Sanofi Aventis where he coordinated $3 billion transactions in oncology and
diabetes. John led Sanofi Aventis’ strategic pricing department managing the $15 billion portfolio, and placing valuations on
the pipeline. He was previously at Schering-Plough in strategic pricing and health economics. John has also worked for AT
Kearney, World Bank, WHO and as an internist in UK and Australia. He holds MBA Wharton, MSc (Econs) from LSE, Medical
Boards from Royal College of Physicians UK, and medical degree from University of Western Australia.
ORGANISERS
WELCOME
Speakers
Julia Sardaryan, Head of Business Development, OCT Clinical Trials
Julia Sardaryan graduated from St-Petersburg State University in 2007. Julia holds a masters degree in English Linguistics,
Translation. Julia started her career in pharmaceutical business at OCT in 2007. Through the years she has demonstrated
career development being Clinical Trials Coordinator, Business Development Manager and then Director of Business
Development at OCT.
Julian is co-founder and CEO of Covagen. After his studies in molecular biology and biochemistry at ETH Zurich, Julian
Bertschinger joined the group of Prof. Dario Neri at the Institute of Pharmaceutical Sciences ETH Zurich as a Ph.D. student.
There he co-invented Covalent DNA Display technology. After obtaining his Ph.D. in May 2005, he continued developing
Covalent DNA Display as a postdoctoral fellow in Prof. Dario Neri’s group. In June 2006, Julian Bertschinger was selected
from more than 100 applicants as one of the winners of the Venture Leaders Prize founded by the Gebert Rüf Stiftung. This
enabled him to join a training program in the Boston area (USA) with a course in entrepreneurship at Babson College.
Julian Bertschinger, CEO and Co-Founder, Covagen AG
SPEAKERS
OCT is an experienced full-service CRO successfully working in Russia, Ukraine, Belarus, Bulgaria, Latvia, Lithuania, Estonia
since 2005. OCT provides the full-scale range of services to pharmaceutical, biotechnology and medical device companies.
OCT is experienced in a wide range of therapeutic areas (oncology, neurology, cardiology, autoimmune disorders, pulmonology,
gastroenterology, endocrinology, etc.); in phase I-IV studies, bioequivalence trials, pre-clinical studies. OCT has a record of
studies with drugs, which were approved by FDA and EMEA afterwards; some of the trials were conducted in the Russian
Federation exclusively.
t back :: next u
As Director of Business Development, Julia is responsible for new business opportunities assessment and management;
she supervises OCT’s advertising, client relations and budget negotiations. She manages development of new relations with
clients from all over the world. Ms. Sardaryan has dedicated much of her career to attracting pharmaceutical companies all
over the world to conduct clinical trials in Russia, CIS and CEE region. Julia knows the specifics and challenges of conducting
clinical trials in this region.
Katya Smirnyagina, Venture Partner, Capricorn Ventures
Kieran Murphy, President & CEO, GE Healthcare Life Sciences
Kieran Murphy joined GE in April 2008 as a result of the acquisition of Whatman plc where he had served as CEO since
early 2007. Following the acquisition he held a number of commercial roles before being appointed CEO of the Life Sciences
business in early 2011.
Dr Ekaterina (Katya) Smirnyagina PhD in Cellular & Molecular Biology (University of Wisconsin-Madison, USA), BS in
Biochemistry (Lomonosov Moscow State University, Russia). Katya completed her scientific training at the Stanford University
School of Medicine, then worked in management consulting and biotech business development. In 2002-12 she was with
Alta Partners, a healthcare focused venture capital fund in San Francisco, CA.
Prior to his position in Whatman, Kieran held a number of CEO positions in UK Biotechnology businesses including Adprotech,
ML Laboratories and Innovata plc.
He has been involved in the life sciences industry since joining Janssen Pharmaceutical in 1989. He served as CEO at
Mallinckrodt, Vericore and Novartis Animal Vaccines.
Born in Cork, Ireland, he is a graduate of University College Dublin and The University of Manchester Institute of Science and
Technology.
ORGANISERS
WELCOME
Speakers
Kieran Rooney, CBO, Amakem NV
Dr Kieran Rooney joined Amakem NV as Chief Business Officer in 2012. Over the past 6 years he has provided commercial
and transactional consulting support to over 30 pharma/biotech companies and life sciences investors through the
consultancy firm, Halo BioConsulting Ltd. Prior to founding Halo in 2007, he was a Consultant to the UK Government,
supporting commercial activities across a portfolio of UK-based life science companies.
SPEAKERS
t back :: next u
He has in over 25 years experience in the pharma/biotech space, having held drug discovery R&D, clinical, commercial and
Board positions across a diverse range of organizations from multinational pharmas to biotech and pharmaceutical service
organizations. He held senior commercial roles at Pharmaceutical Profiles Ltd, Pharsight Corporation and F2G Ltd and led
commercial activities at MDS Pharma in Europe. A pharmacist by profession, he holds a degree in Pharmacy, a Ph.D. in
neuropharmacology and began his career in CNS drug research.
Konstantinos Alevizopoulous, CEO, APIM Therapeutics AS
Konstantinos Alevizopoulous has thirteen years experience in the development and commercialization of therapeutic,
diagnostic and medical device products in the biomedical sector. Since 2010, he has served as the Chief Executive Officer
of APIM Therapeutics AS, a venture-capital financed oncology biotech (Norway). He is also a Partner of Ventac Partners, an
international business development & consulting corporation. Other important past positions include: Chief Scientific Officer
of Gerolymatos International SA (GR), Chief Executive Officer of Medexis SA (GR), Head of Preclinical R & D of Biovista Inc. (US)
and Head of R & D of Apotech Corporation (CH). Dr. Alevizopoulos consults for several biotech companies, academic institutes
and government associations; he is also a co-founder of Casigen Pharma (Hong Kong), Zestagen (CH), PharmaCellion (UK)
and of the Hellenic Biotechnology Cluster (Greece). Dr. Alevizopoulos received his Biology degree from the University of
Athens, Greece and his Ph.D. in Molecular Biology from the University of Lausanne, Switzerland. He has also conducted
post-doctoral studies in the Swiss Institute of Experimental Cancer Research (Switzerland) and the Schering Plough Research
Institute (USA) specializing in preclinical oncology research. Dr. Alevizopoulos is trained in European Patent Law (Robert
Schuman University of Strasbourg, France).
Laurent Choppe, Managing Partner, Life Sciences, Cukieman & Co.
Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d’Alfort,
CES of Veterinary Ophthalmology and earned a MBA from INSEAD in Fontainebleau (France). He is married, father of 3 and
lives in Lausanne (Switzerland).
Lieven A De Smedt, CEO, ERA Biotech SA
Lieven A De Smedt is an engineer in Agro and Food industries (WITH honors) at IHR-RUG, Gent, Belgium (‘75-’80) and
MBA (with honors) at KUL- Leuven, Belgium (‘84-’85) and he holds a Masters in Finance (cum laude) at Tilburg University,
Netherlands (’04-’05).
Laurent Choppe is leading CLS since 2008 and brings an extensive international life science experience in managing
multifunctional teams and setting up new businesses in pharmaceuticals, biotechnology, nutraceuticals, animal health and
direct-to-consumer markets. After a veterinary practice and a new venture management experience, he spent 10 years in
Schering-Plough in various marketing and general management positions in France, Israel and Canada. He then served as
international General Manager of BELLUS Health (ex-Neurochem NASDAQ & TSE), a Canadian biopharmaceutical company
mainly involved in orphan drugs and Alzheimer’s disease.
Lieven’s work experience can be summarized as follows: At ERA Biotech SA as: CEO (Feb-11 – YTD) and NED and interimCEO (2010)
At Revolymer Ltd. as: Chief Business Officer (Sept-08 to 2010), CFO and Company Secretary (2005 to Sept-08) and Cofounder (inception in Oct 2005)
Albemarle Corp (a $2.5 billion chemical and fine chemical global company), Global Business Manager (’93-’00) and Market
Manager, Pharmaceutical Fine Chemicals (’89-’93)
Amylum NV (became later Tate&Lyle, now Tereos), Market manager (‘84-‘89)
Sopura SA (mid-size chemical company, supplying the food industry), Market manager (‘82-’84)
ORGANISERS
InnoTune BVBA (Formerly ARS.21 BVBA), Jan 2000-Date, Founder and Managing Director
WELCOME
Speakers
Lloyd Diamond, CEO, BONESUPPORT
Lubor Gaal is the Head of Europe, Search and Evaluation, Strategic Transactions Group for Bristol-Myers Squibb, based at the
UK headquarters in Uxbridge (London). He is responsible for licensing and acquisition of drug programs, assets or companies
in support of the company’s BioPharma strategy.
Malcolm Weir, Founder, Director, CEO, Heptares Therapeutics
Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular
Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people
engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling
to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural
bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a
100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to
establish Heptares Therapeutics Ltd in July 2007, as co-Founder and CEO. Malcolm was elected Visiting Professor of
Biochemistry at Imperial College, London in 1997 and is on the Chemistry and Chemical Biology Advisory Boards at the same
university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 – 2011.
Lubor has extensive experience in evaluating and negotiating transactions with small and large companies, having worked
in the U.S. and in Europe. Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d in
France and CBO of Vectron Therapeutics AG in Germany. In the U.S., Lubor worked for Berlex Laboratories, where he was
responsible for worldwide licensing for Cardiovascular and Neuroscience for Schering AG (now Bayer HealthCare AG). Before
joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical
companies on business development strategies and execution. Lubor received his Ph.D. from the University of California at
Berkeley and his B.Sc. in Neuroscience from the University of Sussex in Brighton in United Kingdom.
Lubor Gaal, Head of Europe, Strategic Transactions Group, BMS
SPEAKERS
Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies
in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international
investment organisations. Equity Development brings together investors and companies by means of writing and distributing
detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and
appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have
built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA
approved and boast a cumulative 400 years of experience. Please visit www.equitydevelopment.co.uk for more details and
examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector
having worked for leading international investment organisations.
t back :: next u
Lorenza Castellón, Health & Biotech Equity Analyst, Equity Development Ltd
ORGANISERS
WELCOME
Speakers
Mark Bleckmann, Director & Head of Finance, immatics biotechnologies
Following degrees in business administration and philosophy, Mark Bleckmann started his career at IBM, where – over the
course of 9 years – he held roles of escalating responsibilities in various finance and planning functions. In his last position at
IBM he was Finance Manager of the Frankfurt office and one of Europe’s largest outsourcing contracts at the time.
Markus Hosang, General Partner, BioMedPartners AG
Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge
in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many
product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and
theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where
he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies.
Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma
R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the
President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and
Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Chief Scientific Officer of Genetics and
Integrated Medicine, and a member of the Roche Genetics Executive Committee.
Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting
He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University
Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular dieseases. Dr. Hosang
served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology
(SSMBS) as its Treasurer from 1994-2002. He currently is a member of the boards of Okairos AG, Suppremol GmbH and
Anergis SA (as interim Chairman of the Board). Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell),
IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on
several patents.
Markus is Managing Director, Novartis Venture Fund Markus Goebel started his career in the Health Care Industry in 1990.
An MD by training and certified, amongst others, in hematology/oncology he worked for Farmitalia Germany and later held
several global positions in R&D, Marketing and Strategy at Roche headquarters, partially in a ww alliance with Amgen. He
joined Novartis in 2000 and first worked as global head Nervous System BD&L Pharma and later as global head Pharma
Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US. Previously he received an
MD and a PhD from the Ludwig Maximilian’s University in Munich and an MBA from Henley Management College. Markus
serves on the boards of several Novartis Venture Fund portfolio companies, having exited, amongst others from Sirtris, FoldRx,
EraGen and Intellikine.
SPEAKERS
Markus Goebel, Managing Director in Basel, Novartis Venture Funds
t back :: next u
He joined immatics in 2008 where he is responsible for managing all finance matters and as well as other administrative
functions of the company. In 2010 immatics successfully closed a C financing round, raising €54m.
Dr Martina Kaufmann is founder and managing director of Martina Kaufmann Strategic Consulting offering individual solutions
for personalized medicine.
She is a pharmacist with scientific track record in molecular biology and >14 years of hands on experience in personalized
medicine from a technology / diagnostic as well as from a pharmaceutical perspective across the lifecycle.
She established and implemented consolidated project specific biomarker / diagnostic strategies for various oncology
development projects in exploratory and full development, as well as for market adoption and lifecycle management of
marketed targeted therapies/companion diagnostics, e.g. Herceptin®/HER2. She also has experience in molecular imaging
agent development, enabled market entry of a microarray based protein profiling system in Europe and successfully launched
a microarray based pharmacogenetic profiling system.
ORGANISERS
Dr. Kaufmann has a comprehensive, inter-divisional background with experience not only in drug development/translational
medicine, molecular diagnostics, and molecular imaging, but also in marketing, sales, project management, and business
development in biotech start-up as well as global pharmaceutical organizations.
WELCOME
Speakers
Mette Kirstine Agger, Managing Partner, Lundbeck Ventures
Neil Warma, President & CEO, Opexa Therapeutics Inc.
Prior to joining Viron, Mr. Warma was co-founder and President of MedExact USA, Inc., an Internet company providing clinical
information and services to physicians and pharmaceutical companies, which was ultimately sold to a large public European
firm. Prior to MedExact, Mr. Warma held several senior management positions at Novartis Pharmaceuticals at its corporate
headquarters in Basel, Switzerland in international policy and advocacy and in global marketing.
Mr. Warma obtained an honors degree specializing in neuroscience from the University of Toronto and an International M.B.A.
from the Schulich School of Management at York University in Toronto. He currently serves on the Board of Directors of
BioHouston, Inc.
Nicole Vitullo, Partner, Domain Associates
ORGANISERS
Nicole Vitullo joined Domain in 1999 and became a Partner in 2004. Present board memberships include Achillion
Pharmaceuticals, Celator Pharmaceuticals, Durata Therapeutics, Esperion Therapeutics, Marinus Pharmaceuticals and VentiRx
Pharmaceuticals. Past Board memberships include Calixa Therapeutics, Cerexa, Eunoe and Onyx Pharmaceuticals. In addition
to investment responsibilities, she is involved in the distribution/liquidation strategies for the public companies in Domain’s
venture capital portfolios. From 2000 to 2011, Ms. Vitullo was responsible for Domain Public Equity Partners L.P., a fund
focused on private investments in public companies. From 1992-1999, Ms. Vitullo was Senior Vice President at Rothschild
Asset Management, Inc. where she had responsibility for the U.S. public market investments of International Biotechnology Trust
plc and Biotechnology Investments Limited. From 1991-1992, Ms. Vitullo served as the Director of Corporate Communications
and Investor Relations at Cephalon, a publicly traded biotechnology company. Prior to Cephalon, Ms. Vitullo spent 12 years
at Eastman Kodak, most recently in Corporate Development where she was involved in the development and management of
Kodak’s venture capital activities.
Neil Warma was appointed President and Chief Executive Officer of Opexa Therapeutics, Inc. in June 2008. He has more than
19 years of executive level experience in the life sciences industry in the U.S., Europe and Canada. Prior to joining Opexa, Mr.
Warma served as President & CEO and a member of the Board of Directors of Viron Therapeutics Inc., a privately-held clinical
stage biopharmaceutical company developing a novel class of protein therapeutics. While at Viron, Mr. Warma positioned the
company as a leader in the treatment of serious inflammatory disorders.
Michael Kotsanis has over 20 years of experience in the pharmaceutical industry and has significant senior leadership
experience across the global pharmaceutical markets. He is the Chief Commercial Officer for Synthon, a position he has held
since mid 2010. Synthon is a fast growing specialty pharmaceutical company based in The Netherlands and is a leader in the
field of generic medicines. Synthon employs over 1400 people in 11 countries. At Synthon he is responsible for developing and
expanding its global business operations leveraging the company’s world class product portfolio and R&D capabilities. Until mid
2010, he served as President, Europe, Middle East and Africa for Hospira, where he was responsible for developing strategy,
delivering growth and attaining market leadership in the EMEA region. Kotsanis joined Hospira following its acquisition of Mayne
Pharma in 2007, where he served as President, Asia-Pacific. From 2002 he had responsibility for leading Mayne’s commercial
and technical operations and associated activities across the Asia Pacific region. He joined Mayne following their acquisition of
F H Faulding Pharmaceuticals in 2001, where he held responsibility for sales and marketing strategy and execution in Australia
and New Zealand. Prior to Faulding, Kotsanis began his career with Boehringer Ingelheim where he held a variety of sales and
marketing positions over an 11 year period. Kotsanis earned a bachelor of science degree from Monash University, Melbourne
and a master’s degree in business from the University of Technology, Sydney.
SPEAKERS
Michael Kotsanis, Chief Commerical Officer, Synthon BV
t back :: next u
Mette Kirstine Agger was a broad a broad international experience within biotech / life science covering business development
and licensing, management and financing, including as CEO and co-founder of 7TM Pharma. Prior to founding 7TM Pharma,
Mette was part of the management team of NeuroSearch A/S responsible for business development and licensing. She
started her carrier as Patent Agent and has over the years co-founded several biotech companies. Mette has been appointed
to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the
University of Copenhagen and has an MBA. Mette Kirstine work as board member including position as board of director in
Allocure, PsiOxus and Veloxis.
WELCOME
Speakers
Ole Henrik Brekke, CEO, Vaccibody AS
Ora Dar, Head of the Life Sciences Sector, Office of the Chief Scientist,
Ministry of Industry, Trade and Labor, Israel
Paola Casarosa, Global Head Business Development and Licensing Respiratory, Boehringer Ingelheim
Paola Casarosa received a master degree in medicinal chemistry at the University of Torino, Italy, and a Ph.D. in molecular
pharmacology, at Vrije Universiteit in Amsterdam. After a Post-Doc experience at Bichat Hospital in Paris, she joined Organon
NV/ Schering Plough, as laboratory head in the therapeutic area of Reumathoid Arthritis. Since 2007 Paola has been working
in Boehringer Ingelheim, where she covered different positions within Research and Development for respiratory indications
and then within the Business Development & Licensing group, as global head of Licensing for Respiratory Diseases. Recently
she took over additional responsibilities in the area of PM Strategy and Portfolio-management.
Dr Ora Dar is the Head of the Life Sciences Sector at the Office of the Chief Scientist at the Israeli Ministry of Industry, Trade
& Labor, and the Consultant for Biotechnology to the Chief Scientist. Being the head of the sector, Dr. Dar leads the team of
experts recommending the granting of financial support by the Chief Scientist to projects in the field of Life Sciences. Dr.
Dar is also responsible for defining and implementing tools and new programs required for supporting R&D in Life Sciences
companies, and for enhancing the technology transfer between the Academia and the Industry. This has lead to the initiation
and maturation of several viable programs such as, funding academic applied research, dedicated scheme for biotechnology
incubator(s), tracks enabling collaboration with global Life Sciences companies, tools for upgrading infrastructures, and a
special government backed Bio Funds. Previously she spent 16 years in academic research (mostly at the Weizmann Institute
of Science), several years in the industry, and 10 years as a consultant to venture capital and investment firms as well as foreign
funds and international R&D programs. Dr. Dar is a medical sciences graduate of the Hebrew University of Jerusalem and
holds a Ph.D. from the University of London, UK (St. Mary’s Hospital Medical School, Imperial College of Science, Technology
and Medicine).
Olga Potapova is an expert in biotechnology, life sciences business development, biomedical technology transfer and
international alliance management. Since 2003, she is a CEO and Scientific Director of Cureline, Inc., a human biospecimen
CRO specializing in human tissue research projects including study design, regulatory affairs, clinical network management,
specimen collection and analysis, and complete logistics. At Cureline Olga is responsible for strategic development, international
alliance management, new products and services development, and expansion into new markets. Cureline is an international
biomedical project management group of companies working in the areas of preclinical and translational research (www.
Cureline.com), and diagnostic and laboratory services (www.CurelineBioPathology.com). Previously Dr. Potapova worked in
the fields of cancer research (NIA, NIH); human molecular genetics and genomics; oncology drug R&D and translational
medicine (SUGEN/Pfizer). Olga has received multiple AACR/AFLAC awards, NIH and NATO fellowships, and has published
multiple scientific papers in peer-reviewed journals. She has advanced degrees in Physics (M.Sc.) and in Molecular Genetics/
Biochemistry (Ph.D.).
SPEAKERS
Olga Potapova, CEO and Scientific Director, Cureline Inc.
t back :: next u
Ole Henrik Brekke M.Sc , Ph.D 1994 from the Institute of Molecular Cell Biology, University of Oslo. Ole Henrik’s scientific
work has fostered significant understanding to the function of human antibodies and he is author of more than 20 papers
including Nature, PNAS and Nature Reviews in Drug Discovery, and is the inventor on several patents in recombinant antibody
technology. He has been a senior scientist at UiO and National Institute of Public Health and has had R&D director positions
in Affitech and Dynal-Invitrogen. He was in business development at Birkeland Innovation before joining Vaccibody in 2008.
ORGANISERS
WELCOME
Speakers
Pascal Touchon, Director – Scientific Operation & BD, Les Laboratories Servier
SPEAKERS
t back :: next u
Pascal Touchon has 26 years’ experience in the pharmaceutical industry in Research, Marketing and Sales, General
Management and Business Development.
He has extensive international experience in managing commercial operations and as CEO in France, Central & Eastern
Europe, Northern Europe, Asia, Australia, Canada, and South Africa.
As head of Business Development for Servier over the last 3 years, he led the closing of more than 18 partnerships with
biotech companies and academic institutes, managed various existing alliances and conducted two company acquisitions.
Servier is a private research based pharmaceutical company with sales of 3.9 billion euros worldwide and activities in
cardiovascular diseases, type II diabetes, neurology, psychiatry, rheumatology and oncology.
Pascal holds a Doctorate in Veterinary Medicine, a DESS in Management and an MBA from INSEAD.
Patrick Verheyen, Head, Johnson and Johnson Innovation – London, Johnson and Johnson
Patrick Verheyen is Head of the Johnson & Johnson Innovation Center in London – a new organization dedicated to
identifying, fostering and on-boarding early-stage science, technology and products to Johnson & Johnson businesses in the
Pharmaceutical, Consumer and MD&D sectors.
Patrick joined Johnson & Johnson in 1985 at Janssen Pharmaceutica N.V. in Beerse, Belgium. In 1996, he relocated to the
USA as Director, Business Development, Pharmaceuticals Group, and in 1997, was promoted to Vice President, Corporate
Development, Ortho-McNeil Pharmaceutical. He studied bio-engineering at the University of Leuven, Belgium.
Peter plays an important role in supporting innovation in Northwestern Switzerland. His main focus is life sciences start-ups.
Peter is CEO of “EVA the Basel Life Sciences Start-up agency”. This company was founded in 1996 with the aim to support
life sciences start-ups with coaching, access to a high value network and providing seed money. In addition he is CEO of the
BASEL INCUBATOR, which he helped to establish 2 years ago. The BASEL INCUBATOR is a joint venture of the University of
Basel, the University of Applied Sciences of Northwestern Switzerland (FHNW) and the Canton of Basel-Stadt. To complement
his activities, Peter is the president of the BioValley Business Angel Club, the only Business Angel’s Club in Switzerland focusing
entirely on life sciences / MedTech. Peter has a PhD in chemistry from the University of Basel and joined Ciba-Geigy / Novartis
1984 as a research chemist. Throughout his professional career he had managerial positions with worldwide responsibility in
technical development, regulatory affairs, manufacturing, production and communication and was the CEO of the subsidiary
of a sector of Novartis in Germany. He joined EVA in 2006.
Peter E. Burckhardt, CEO, EVA the Basel Life Sciences Start-up agency
Patrick was most recently Vice President, New Ventures within Janssen Pharmaceutical Companies of Johnson & Johnson.
In this role, he led a nimble and diverse team that facilitated divestitures, established strategic collaborations and identified
investments that provided Janssen with access to external innovation and early product flow. Prior to that, Patrick was Vice
President, Mergers & Acquisitions within the Pharmaceuticals Group. In this role, Patrick facilitated strategic collaborations
and acquisitions including Crucell, Elan and Cougar Biotechnology, and established a spin-out company, Movetis, based on
Johnson & Johnson’s gastrointestinal pipeline portfolio. Patrick has provided expertise on most of the major M&A deals in the
biotech, specialty pharmaceutical and large cap space, and assessed various risk sharing and funding arrangements with
Clinical Research Organizations (CROs), private equity and government institutions.
Philippe Calais, CEO, Antisense Pharma GmbH
ORGANISERS
Dr Philippe Calais is Chief Executive Officer of Antisense Pharma since March 1, 2012. He has over 25 years of biopharmaceutical
and pharmaceutical industry experience in both North America and Europe. Prior to joining Antisense Pharma, he was the
President and CEO of Univalor, the largest technology transfer organization located in Montreal, Canada. He has managed
biopharmaceutical companies in Canada and served as a consultant to life science companies, focusing on corporate strategic
positioning, company deployment and sales optimization strategies. His management expertise, combined with extensive
experience with large pharma companies such as ICI Pharmaceuticals and Roche, covers the full scope of the drug chain –
from discovery to clinical development, commercialization as well as partnership and franchise strategic marketing for several
therapeutic areas. He has a degree and doctorate in pharmacy from the U. F. Rabelais, Tours, France.
WELCOME
Speakers
Rahul Aras, CEO, Juventas Therapeutics, Inc.
SPEAKERS
t back :: next u
Rahul Aras Ph.D. (President and Chief Executive Officer) is the founding CEO for Juventas. He is also a co-founder of SironRX
Therapeutics, a company focused on novel regenerative therapies in the dermal and cosmetic fields. He has raised more
than $35 million in venture capital and grant funding to transition both companies from concept into mid-stage clinical trials.
Prior to Juventas, Rahul was the Director of Life Science Commercialization at Cleveland Clinic Innovations (CCI) where he
is managed commercialization of all biotechnology and pharmaceutical related technologies. He has extensive experience
negotiating licensing deals and strategic partnerships ranging from top 10 pharmaceutical companies to newly formed startups. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University. He has held research
positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several
leading scientific journals.
Rainer Henning, CEO, Biomay AG
Regina Hodits, General Partner, Wellington Partners
Regina Hodits joined Wellington Partners in spring of 2010 as General Partner for Wellington Life Science. With over 12 years
of investing experience and a strong scientific background, she has become an influential investor in the European venture
capital scene, focusing on early-stage and growth deals in Life Sciences.
Prior to joining the Wellington team, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic
venture capital firm. As a Partner at Atlas, she led numerous financing rounds and was the founding investor in Bicycle
Therapeutics, F-star and Jenavalve. Furthermore, she served on the Board of Egalet, Novamed (public on NASDAQ via merger
with SCLN) and U3 Pharma, which was acquired by Daiichi Sankyo Co.,Ltd. in 2008.
From 2000 to 2004, while working for Apax Partners, she was closely involved with investments in Genmab, Silence
Therapeutics and Wilex. She began to build her extensive network in the global healthcare industry during her tenure at
McKinsey from 1997 to 2000. In the 90s, Regina worked as a university lecturer and post-doctoral researcher at the University
of Vienna, Austria and the MRC Cambridge, UK. Regina studied chemical engineering and holds a Ph.D. in biochemistry.
Since joining Wellington, Regina has managed the investment in Oxagen, Oxford, UK; was instrumental in creating the Philips’
spin-out Sapiens, in Munich, Germany and Eindhoven, the Netherlands; and helped to establish Singapore founded Ayoxxa’s
presence in Cologne, Germany. In addition, Regina serves as an external Board member for the GSK’s respiratory therapy
area unit (TAU).
Rainer Henning serves as Chief Executive Officer of Biomay AG since January 2011. He looks back on a distinguished career of
over 30 years in the biotechnology, pharmaceutical and venture capital industry. Before joining Biomay, he was Chief Executive
Officer of Fibrex Medical, Inc., a biopharmaceutical company in the field of critical care medicine, a position he took over after
working as investment manager and partner of two European venture capital funds for several years. His experience in the
pharmaceutical industry encompasses operational and senior executive R&D positions in Hoechst AG, Hoechst Marion Roussel
and Aventis. A chemist by training, he is inventor of over 80 granted patents, which cover among others the blockbuster
antihypertensive ramipril. In addition, he has advised and served on the board of a number of biotechnology companies.
Richard Goodfellow, CEO, Scancell Holdings Plc.
Richard has over 30 years international experience in the pharmaceutical industry, in Big Pharma and with Biotech companies.
During his time at Astra, he oversaw the launch of Losec and other key products internationally. Thereafter, he held the post of
Director of Licensing and New Business Development at Scotia Pharmaceuticals, where he was involved with the company’s
flotation on the London Stock Exchange and successfully negotiated numerous deals.
ORGANISERS
In addition to co-founding Scancell’s ImmunoBody cancer vaccine business, Dr Goodfellow was also a co-founder of Paradigm
Therapeutics, a Cambridge based functional genomics company and was a former Director of Enact Pharma plc.
WELCOME
Speakers
Roberto De Ponti, Senior Director, Corporate Business Development, Helsinn Healthcare SA
SPEAKERS
During his career Dr. De Ponti was instrumental in the development of many oncology drugs, including new formulation of
anthracyclins and sunitinib with Pharmacia/Pfizer, and a variety of other oncology projects working as consultant to several
companies. Under his direction, on a yearly basis he was responsible for investigational supplies to more than 8000 patients
worldwide, and for market production of 50 Million units of oncological drug units per year. Since 2008 he is Head of Corporate
Business Development with Helsinn, a privately owned pharmaceutical group with headquarters in Lugano (Switzerland), and
operating units in Biasca (Switzerland), Ireland, United States, and a representative office in Beijing, China.
t back :: next u
Roberto De Ponti a Pharmacist by training and an EU Qualified Person, started his career in pharmaceutical analysis in the
former Farmitalia Carlo Erba, followed by formulation and drug development. His responsibilities grew while the company
went an impressive series of M&As (from Farmitalia Carlo Erba to Kabi Pharmacia, Pharmacia & Upjohn, Pharmacia with the
merge with Searle, and eventually Pfizer), getting site responsibilities for drug substance and drug product development and
manufacturing of investigational and marketed products. He was also site lead of the R&D Italian site of Pharmacia (specialized
in Oncology) and eventually followed the transition to Pfizer and also the transition to an independent spin-out company
(Nerviano Medical Sciences), where he became responsible for the Pharmaceutical Science section bringing it to break even
offering development services to oncology companies wordwide.
Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products
in therapeutic niche areas.
In the last four years he was instrumental to the acquisition of two oncology related development programs for Helsinn, and
other advanced negotiations are expected to be positively concluded during the current year. In addition, a portfolio of products
filling the integrative medicine needs in oncology has been implemented.
Ron Laufer, Senior Managing Director, Medimmune Ventures
Dr. De Ponti’s current responsibilities include external research of R&D projects mainly in the areas of Cancer Supportive Care
and Cancer Therapeutics focusing on Phase II completed programs, and execute the due diligence and negotiation activities
for in-licensing products.
Dr Ron Laufer is the head and Senior Managing Director of MedImmune Ventures, a $400M evergreen venture capital fund.
The fund, which is a subsidiary of the AstraZeneca Group, invests in BiopParmaceutical, MedTech and Healthcare IT start-up
companies in North America, Europe, Israel and Australia.
Ron received his B.Sci., M.D. and M.P.H. from Hebrew University, and an M.B.A. from the Harvard Business School. He is
currently an adjunct Professor of business administration at the Kelley Business School of Indiana University
Ron Nager, President & CEO, Insuline-Medical Ltd
An experienced healthcare investor, Ron started his career as a physician before moving into venture capital. He was a
co-founder of Lilly Ventures, the venture capital arm of Eli Lilly & Company, and later a Managing Director at Visium Asset
Management, a private healthcare-focused investment firm, before joining MedImmune Ventures in 2010.
ORGANISERS
WELCOME
Speakers
Rudi Neirinckx, CEO, Ennar Pharma AG
Rudi D Neirinckx is an experienced pharmaceutical industry executive and author of over 100 scientific publications and more
than a dozen patents. He worked in most aspects of the pharmaceutical business, i.e. research, clinical development, licensing,
business development, etc. in the diagnostic as well as the therapeutic side of the business. He also was a consultant for the
NASA’s Space Shuttle program.
SPEAKERS
t back :: next u
After an academic career in Nuclear Medicine and radiology, producing radioisotopes with a cyclotron and developing novel
radiodiagnostic products, he headed up the R&D operations of Amersham International (UK) and Serono (Geneva). He was
responsible for reorganizing the M&A Department of Merck KGaA, where he made numerous license and M&A deals, including
a major license deal with Imclone Systems. He founded an OTC Company (Agys Pharma, Belgium), based on his invention of
an effective treatment of dental sensitivity and was COO of a Generics Company (PAR Pharmaceuticals, USA), which he helped
turn around. He also was CEO of atugen, a Berlin high-tech start-up, before he became a full-time consultant in Oncology to
the President of Altana Pharma. Subsequently he has exclusively worked on the psoriasis project, which is now property of and
developed by Ennar Pharma AG.
Rustam Ixanov, Vice-President of Strategic Development, AKRIKHIN OJSC
Rustam Ixanov was born in 1973 in Nizhniy Novgorod, Russia. In 1996 graduated from State Medical Academy.
From 2000 till 2002 he was a Head of Medical department of «Nizhpharm», STADA Group. Later he was R&D Director
(«Nizhpharm», STADA Group, 2002-2006).
Before «AKRIKHIN» Rustam was a Development Portfolio Director of pharmaceutical company ”Izvarino Pharma” (Ferring
Pharmaceuticals is the most significant investor of this company).
From September 2010 he has been the Vice-president of strategic development at “AKRIKHIN” OJSC with responsibilities
for: Strategic Portfolio Development, Product Development, Business Development, Intellectual Property, Regulatory Affairs,
Preclinical/Clinical trials, Pharmacovigilance.
Rustam began his career in pharmaceutical business as a manager of medical information in pharmaceutical company
«Nizhpharm», STADA Group(1999-2000).
Saira Ramasastry, Managing Partner, Life Sciences Advisory LLC
Saira is a recognized thought leader on public-private alliances and is frequently called upon as a speaker. She serves on
the Industry Advisory Board of the Michael J Fox Foundation for Parkinson’s Research, the Board of the American Liver
Foundation and as a Special Advisor to the California Institute for Regenerative Medicine.
Saira has a B.A. in Economics with Honors and Distinction from Stanford University where she graduated Phi Beta Kappa,
and advanced degrees in Management Science & Engineering and Management Studies from Stanford University and the
University of Cambridge. She currently serves on the Advisory Council for the Cambridge Judge Business School and was
recently named to the Silicon Valley/San Jose Business Journal’s 40 under 40 list.
Saira Ramasastry, Managing Partner of Life Sciences Advisory, is a seasoned industry insider with approximately 15 years
experience and who has advised on over 80 transactions. Prior to LSA, Saira led emerging biotech coverage at Merrill Lynch
for over a decade where she helped establish the leading life sciences franchise on Wall Street. Prior to Merrill Lynch, Saira
worked in M&A and Restructuring at Wasserstein Perella.
ORGANISERS
WELCOME
Speakers
Sarah Holland, Global Head, Strategic Partnering, Roche Partnering
SPEAKERS
Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast cancer during US
and EU launch. She held various commercial and strategic roles over her ten years there, including Global Strategic Planning
Manager for early compounds, Pricing Strategist and Health Economist. Before AstraZeneca, she held local and international
sales and marketing roles in diagnostics, biotech and pharmaceutical companies.
t back :: next u
Sarah Holland is the Global head, Strategic Partnering for Roche Partnering based in Basel, Switzerland. Her team’s
projects include broad strategic landscapes of M&A and late stage opportunities, transactional support for all pharma M&A
transactions, initiatives to generate income through divestments, spin-outs and strategic partnerships, and development and
delivery of creative deal structures to address key business needs. In 2010 the team acquired world-wide rights to danoprevir
from Intermune and supported the acquisition of Marcadia Biotech. Since joining Roche in 2005, Sarah has held various
responsibilities in business development, such as Global Head of CNS Partnering, and has led projects in a range of disease
areas, including the Plexxikon deal on b-raf inhibitors.
Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D.Phil and first
degree at Oxford University.
Søren Moller, Managing Investment Director, Novo A/S
Prior to joining Novo Seeds, Søren served as global manager of Bioinformatics and Genomics at Novozymes. Before
Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S where he was responsible for development of microRNA
based products for life science research, pharma services and diagnostics. In 2007 Exiqon completed an IPO on NASDAQ
OMX Copenhagen raising 400 mio DKK to develop and commercialize life science and diagnostic products. Previously, Søren
worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.
Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark). Søren
serves on the board of directors of Denator AB, a Swedish based biotech company.
Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology
in 1997 from the Technical University of Denmark for a project on molecular microbiology. In addition to his PhD, Søren has
academic training as postdoctoral fellow at Stanford University School of Medicine.
Stan Yakatan, Chaiman & Co-Founder, Katan Associates
New England Nuclear • EI Dupont • ICN Pharma • New Brunswick Scientific • Biosearch
These experiences have provided him with management skills and a corporate finance acumen that he enjoys sharing with
others.
Stan has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany. In
many cases he has also served as the initial CEO, and Chairman of these companies. In his career, he has advised several of
the world’s leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA), and Biocapital (Canada). During
the decade of the 1990’s Biocapital was the most successful venture capital fund in Canada.
Stan currently serves in a business development capacity for the XL TechGroup (AIM: XLT). The XL Tech Group systematically
discovers unmet business needs, then creates, selects, and develops new technology businesses, and scales them to liquidity.
Stan assisted XL TechGroup in the development of its business model, and advised on the overall capitalization strategy for XL
Tech Group. In October 2004, XL TechGroup undertook an Initial Public Offering in connection with its listing on the Alternative
Investment Market (“AIM”), raising in excess of $40.0 million.
Stan is currently the Chairman of Grant Life Sciences, Inc., (OTCBB:GLIF) a company developing a revolutionary test for the
screening of cervical cancer. Stan is also a member of the Board of Directors of Biophan, Inc. (OTC.BB). Stan serves as the
strategic advisor to the State Government of Victoria, Australia. Stan is also the Executive Director and Chairman of Biocomm,
in Melbourne, Australia, the first of its kind regional business development agency and early-stage capital pool. Stan currently
sits on the Board of Mercury Therapeutics, Inc. which is developing new drugs for diabetes and obesity, and Phenomenome
Discoveries, Inc., a novel biomarker company.
ORGANISERS
Stan has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0
billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology
conferences throughout the world speaking on topics including, “Capital Raising for the Technology-Based Start-Up” and “The
Need to be Global in the Quest for Capital and Partners”. Rick Biondi, Editor of Lab Business Magazine stated,” Mr. Yakatan
is a venture capital raising Guru and it is part of his genetic make up.”
After 30 years as a successful CEO, entrepreneur, and operational manager, Stan Yakatan has dedicated the last 12 years
of his career to sharing his experiences with management teams interested in building technology based companies. His
experience as a “C” level executive is far reaching he has served in such a capacity with:
WELCOME
Speakers
Stephanie Léouzon, Senior Advisor, Torreya Partners
Stephanie is a Senior Advisor at Torreya Partners, a life sciences advisory boutique.
She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology,
pharmaceutical and speciality pharmaceutical sectors.
SPEAKERS
Prior to joining Credit Suisse in 1998, Stephanie’s experience included working in Health Care at Lehman Brothers, JP Morgan
and Salomon Brothers (now Citigroup). Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at
the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.
t back :: next u
She has advised clients on a number of strategic transactions, valued at over $70 billion, and she has been involved in
financing transactions to provide over $7 billion to healthcare clients.
Thomas Kündig, CoChair, Colby Pharmaceutical SAB
Dr. Kündig pioneered studies on the biology of cytotoxic T lymphocytes together with Dr. Rolf Zinkernagel. Dr. Kündig completed
medical school at the University of Zurich in 1987 and went on to earn a medial thesis in respiratory physiology, also at the
University of Zurich. Enrolled in the postgraduate course for experimental medicine and biology, he studied immunology as a
post-doctoral fellow in the laboratory of Nobel laureate Professor Zinkernagel, where his work began on understanding how
immune responses are stimulated and maintained.
Dr. Kündig has published numerous scientific papers in leading journals such as Nature, Science, Cell and Immunity with
cumulative citations >11’000 and an h-index of 47. He has received several fellowships from the Swiss National Research
Foundation and the Cancer League. Since 1998 Dr. Kündig lectures in dermatology, allergology and immunology at the
University of Zurich. He was given the Georg Friedrich Götz Award for outstanding medical research in 1999, and was
nominated in 2000 by the Ludwig Institute for Cancer Research as an affiliate researcher.
From 1992-95 Kündig trained in molecular biology and immunology with Dr. Pamela Ohashi and Dr. Tak Mak in the Department
of Medical Biophysics at the Princess Margret Hospital in Toronto. Since 1995 he has worked as a clinical dermatologist and
allergologist/clinical immunologist at the University Hospital in Zurich, where his research group specializes in allergen and
cancer immunotherapy.
Dr. Kündig spends 50% of his time in the clinics, where he supervises and is responsible for the outpatient dermatology clinics,
including general dermatology, radiotherapy unit, UV therapy unit, Laser unit, oncology unit, unit for autoimmune diseases, hair
clinics, epicutaneous testing unit, allergy unit, the center for inflammatory skin diseases, the dermatology emergency unit, and
the unit for sexually transmitted diseases.
Dr. Kündig currently is the head of research and the routine laboratories of the Dermatology Department. Overall the laboratory
and research department has a size of approx. 50 employees, with approx. one third technical staff and two third academics.
Dr. Kündig’s own research group currently consists of 2 PhD post docs, 2 PhD students, and 3 MDs and focuses on translational
research. His research group develops products and strategies taking them from basic immunology to preclinical animal
models and finally into the clinics. As translation into the clinics requires extensive regulatory work, toxicology studies and
funding for GMP production, the research group closely collaborates with the industry. When developing products for which
no industrial partners can be found, Dr. Kündig was and still is also involved in founding spin-off companies as vehicles to
fund further clinical development. Dr. Kündig’s research group is certified by the Swiss Medical Society as a teaching site for
pharmaceutical development. In very close collaboration with the center for clinical trials he is currently performing numerous
phase I and II studies in immunotherapy, allergy and dermatology.
Thomas van Elzakker, COO, i-Optics
ORGANISERS
Thomas van Elzakker joined i-Optics in July 2012 as COO with responsibilities for R&D, product management and global
supply chain operations. His move to i-Optics followed 16 years with Philips Healthcare, where he held positions in marketing
and general management in various business units and field organizations. From November 2000 to December 2005, Thomas
lived and worked in the USA and was the global marketing and strategy executive for the Philips CT scanner business in
Radiology. More recently, he was General Manager for New Ventures in the Global Services organization of Philips Healthcare,
building a successful new professional services venture. Thomas holds an MSc in Applied Computer Science from Leiden
University in the Netherlands..
WELCOME
Speakers
Thomas Taapken, CFO, Epigenomics AG
SPEAKERS
t back :: next u
Dr Thomas Taapken is acting as sole member of the Executive Board of the Epigenomics AG since September 30, 2012. He
joined Epigenomics on April 1, 2011 as Chief Financial Officer from Biotie Therapies (Finland), where he held the position of
CFO and was a member of the Executive Management Team. He was appointed to this position in 2008, following a business
combination between Biotie Therapies and elbion NV, where Thomas had been CFO since 2005. His extensive international
experience in the life sciences industry includes previous positions as Investment Partner at DVC Deutsche Venture Capital
from 2003 to 2005 and San Francisco-based US venture capital firm Burrill & Company from 1998 – 2002. He also worked
several years at Sanofi-Aventis in the U.S.A. and Germany, managing corporate venture capital activities, as well as in the areas
of corporate & business development and research. Throughout his career, he has been involved in numerous transactions
spanning acquisitions, mergers, divestitures, as well as private and public offerings.
Timothy Herpin, VP SPBD Oncology & STL, AstraZeneca
Timo Veromma, President & CEO, Biotie Therapies Corp.
Timo Veromma, President and CEO from May 2005, Vice President, R&D 1998-2005; Medical Director, Schering AG (Finland;
1996-1998); Program Director at Collagen Corporation (California, USA, 1994-1996); Postdoc Fellow at Stanford University
(California, USA, 1990-1993).
Timothy Herpin joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for CNS
& Pain and more recently for Oncology & STL. In this role, he leads a team of business development professionals involved in
all aspects of deal making for the Oncology franchise. Prior to AstraZeneca, Tim spent eight years in the business development
organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction execution in multiple disease
areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacopeia. Tim
grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University
College London and an MBA in Finance from NYU Stern.
Finnish Bioindustries, Chairman of the Board. Chairman of the Steering Committee for HealthBIO, a national cluster program
focusing on health applications of biotechnology. Chemical Industry Federation of Finland, Member of the Board of Directors.
Hermo Pharma Ltd, Member of the Board of Directors.
Thomas Stockman is a Director in the Global Healthcare Group. He joined Citi in 2002 and has more than 10 years of
investment banking experience.
He has worked with many companies in the biopharma and healthcare services sectors, including advising GSK on its increase
in ownership of GSK Consumer Nigeria, Nabriva on its option agreement pursuant to sale with Forest Laboratories, Roche
on its acquisition of Anadys, Hikma on its acquisition of Promopharm, Solvay on the sale of its pharmaceutical business to
Abbott, Huvepharma on the sale of a 38% stake to CVCI, Montagu on its acquisition of a stake in Euromedic, BUPA on the sale
of its hospitals to Cinven, Numico on its sale to Danone, Savient Pharmaceuticals on the sale of Rosemont to Close Brothers
Private Equity, KPC on the sale of its stake in Aventis to Sanofi-Synthelabo, Sante Luxembourg (Cinven, Vivendi and ABN) on
the disposal of its stake in General de Sante to Sante Holdings; Roche, AstraZeneca, Bayer and Merck KGaA’s bonds; financing
EQT and Investor’s LBO of Gambro, Hikma’s UK IPO and subsequent AEO. He also worked on the Halfords IPO in the retail
sector.
Thomas Stockman, Director Healthcare Investment Banking, Citi Group.
Thomas has a degree in Biological Sciences from Oxford University.
ORGANISERS
WELCOME
Speakers
Tomer Kariv, Co-Founder & CEO,, Pontifax Corp.
Tomer Kariv is the co-founder and Chief Executive Officer of Pontifax, a group of Israeli based life sciences venture funds
focusing on investments in development stage bio-pharmaceutical and med-tech technologies. Mr. Kariv serves as an active
board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning.
SPEAKERS
t back :: next u
Among others, Mr. Kariv serves as the Chairman of Check-Cap Ltd and is a board member of Macrocure Ltd, Arno Therapeutics
Inc. and Aposense Ltd. During the 10 years prior to establishing Pontifax, Mr. Kariv played a key role in investing, managing
and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial
institutions. Mr. Kariv practiced law with Sullivan & Cromwell, a leading corporate law firm in New York, and holds a B.A. in
Economics from Harvard University and a J.D. from Harvard Law School.
Vasily Ignatiev, CEO,, R-Pharm
Vincenç Tur, CEO, Lipopharma
Vincent Charlon, CEO, Anergis
Vincent Charlon joined Anergis in January 2009 as Chief Executive Officer (CEO), bringing over 20 years of global clinical
development and management experience. From 1990 to 1998, at Hoffmann La Roche in Basel and then in Nutley, USA,
Vincent Charlon held clinical development responsibilities for several international projects. From 1998 to 2006, Vincent
Charlon was CEO of Hesperion Ltd., the contract research organization (CRO) who designed and conducted all initial clinical
trials for Actelion’s [SWX, ATLN] products. In this capacity, Vincent Charlon designed the first clinical trials of Tracleer® in
pulmonary hypertension, today Actelion’s biggest product with sales well over CHF 1 billion/year. Vincent Charlon developed
Hesperion into a profitable CRO from 3 to 200 employees serving over a hundred clients, mostly European and North American
biotechs. In 2007-2008, Vincent Charlon was CEO of the drug repositioning start-up company LS Pharma International SA
before joining Anergis where he led the round A financing of CHF 18 M early 2011.
Economist by training, his previous professional career has been in a financial institution (Bank of Ibiza) and at the Confederation
of Industries in the Balearic Islands (CAEB), as chief economist. During his 20 years at CAEB he has been a reputed regional
economist and has gained significant experience in managing research projects and promoting initiatives to drive innovation into
leading regional companies with strong international implantation. He has also been directly involved in the start-up of several
Technology-based companies. As co-funder of Lipopharma, since 2006 he has significantly contributed to the consolidation
of an academic spin-off into a sound global biopharmaceutical company. As Lipopharma’s CEO he has negotiated and signed
several licensing deals, including 3 in-licensing agreements with the University of the Balearic Islands (three patents related to
oncology indications of Minerval and other modified lipids), one in-licensing deal with the Paraplejic General Hospital in Toledo
(for Spinal Cord injury and Pain program) and one out-licensing deal with AB-Therapeutics (now Ability Pharmaceuticals) for
cancer indications of a family of synthetic lipids protected by a patent filed by Lipopharma in October 2009.
Since 2008 works at R-Pharm as Director for Business Development, then CEO. 5 years at the Russian headquarters of
the international pharmaceutical company AstraZeneca in the positions of Marketing Director, Sales and Marketing Director,
National Sales Director. 7 years at the Russian headquarters of the international pharmaceutical company Bristol-Myers Squibb
in the positions of Product Manager, Franchise Manager, Marketing Director. In 1998-1999 spent 7 months on secondment
at the global marketing group of BMS corporate headquarters in Princeton, NJ. MD – diploma with honors, Moscow Sechenov
Medical Academy (incl. 6 months elective courses at Columbia University College of Physicians and Surgeons (Ney York, NY)).
Major in clinical pharmacology. PhD – Moscow Sechenov Medical Academy & Russian Academy of Medical Sciences. MBA –
Moscow MIRBIS business school & London Guildhall University.
ORGANISERS
WELCOME
Speakers
Vladimir Kovalskiy, Co-Founder & CEO, TN LLC
Vladimir is a Computer Science graduate born in the family of doctors. Medical environment he was grown in influenced his
vision and passion for the healthy lifestyle. He started company together with his partner Dmitry Lazutkin back in 2008. In
course of 5 years Medesk solution was developed with the idea to integrate all players of the healthcare market and provide
the better care for patients.
.
SPEAKERS
Vladimir has relative experience working in Japan. Speaks Russian, English and Japanese.
t back :: next u
He is an avid supported of digital healthcare adoption. Looking for the technology to help more people in getting access to
medical treatment and diagnostics.
ORGANISERS
WELCOME
Ability Pharmaceuticals
www.abilitypharma.com
CONTACT
Carles Domènech, PhD
Chief Executive Officer
TELEPHONE
+ 34 93 586 8977
EMAIL
[email protected]
The company is developing a patented new drugs class called Lipid Analogue Therapeutics, which is highly
differentiated and has an innovative mechanism of action. Abilitpy Pharmaceuticals currently has two candidates
in development: ABTL0812, which is finishing preclinical development and is expected to move into phase
Ib, First in Man clinical trials for lung and pancreatic cancer in the second quarter of 2013, and
ABTL1014, which is expected to start preclinical development in spring 2013.
ABTL0812 is an antiproliferative and cytotoxic drug with a novel mechanism of action (MoA). It was selected for
preclinical development because, a) its activity over a wide panel of tumor cell lines (lung, pancreatic, lymphatic,
liver, melanoma and glioma); b) its good efficacy in animal models of cancer; c) its low in vivo toxicity; and d)
once dayly oral administration. Importantly, it shows synergistic properties with standard of care (SOC) drugs
such as docetaxel and gemcitabine.
ABTL0812 affects two major cell processes related with cellular division, and thereby with proliferation of
tumor cells: a) inhibition of akt phosphorylation and mTORC1 and mTORC2 pathways, and b) DNA synthesis
through the inhibition of dihydrofolate reductase (DHFR) gene expression. The modulation of these main cellular
functions induces cell death by autophagy, a mechanism of self-digestion of the cell.
PhD in Cell Biology & Business Training. 13 yrs in BDL at Almirall & Lacer. 2.5 yrs in biotech venture capital (Barcelona Emprèn
and CIDEM). 8 yrs in science research, incl.2 yrs at Memorial Sloan-Kettering Cancer Center (New York). BS/MS Biology.
José Alfón, PhD, VP Research & Development
4 yrs. Team leader drug development (pre-clinical and clinical) at the biotech Palau Pharma, SA. 8 yrs, team leader drug
discovery at the pharmaceutical company Uriach, SA. PhD in Pharmacology , Research at Hebrew Univ. of Jerusalem and
Universitat de Barcelona. BS/MS Pharmacology.
t back :: next u
MANAGEMENT
Carles Domènech, PhD, Chief Executive Officer - Co-founder.
YEAR FOUNDED
2009
Ability Pharmaceuticals, SL is a biopharmaceutical company founded on November 28, 2009. The company is
based in Bellaterra (Barcelona), on the Autonomous University of Barcelona campus.
SPEAKERS
ADDRESS
Edifici Eureka
– Campus de la UAB
08193 Bellaterra (Barcelona
Catalonia
Spain
COMPANY PROFILE
Vanessa Ruz, Director, Finance & Administration
Prior to Ability pharma years she was the Chief Financial Officer of Sevibe Cells, SL. BEc/MEc in Economics.
ORGANISERS
WELCOME
Abliance (B Cell Design)
b-cell-design.com
CONTACT
Dr Jean Sainte-Laudy
FINANCIAL SUMMARY
2011 Balance 320k€
COMPANY PROFILE
B Cell Design is specialized in the conception and production of chimeric antibodies for clinical diagnosis and
immunotherapy on the basis of patented KI mouse models producing IgG1, IgA1, IgM and IgE. B Cell Design
having the capacity of producing human secretory piece, secretory IgA1 is also available.
TELEPHONE
+(33) 555 123 021
Pre-clinical phase has started in vitro and in vivo in mice for dimeric and secretory IgA1 anti-human CEA and
specific and neutralizing IgA1 and IgG1 are available for different influenza strains in order to set up vaccination
protocols.
FAX
+(33) 970 611 557
B Cell Design is also involved in other protocols as HIV and bacterial mucosal infections.
SPEAKERS
ADDRESS
98, rue Legendre, 87000
Limoges,
France
The main application of the secretory IgA1 is the direct mucosal treatment including the oral route due to it’s
exceptional resistance to local proteases. Specific IgEs will have a major place in allegro-oncology.
MANAGEMENT
EMAIL
[email protected]
t back :: next u
YEAR FOUNDED
2007
Dr J Sainte-Laudy, immuno-allergist, CEO
Dr Armelle Cuvillier, specialized in molecular biology, CSO
Dr Gaël Champier, specialized molecular biology applied to microbiology, CTO
ORGANISERS
WELCOME
AKRIKHIN OJSC
www.akrikhin.ru
CONTACT
Business development
department contact details
E-mail: [email protected]
Tel.: +7 (495) 702-95-13
Sales 2012: ≈6 bln rubles (≈150 mln EURO)
COMPANY PROFILE
Part of Polpharma group, 150+ products (OTC, generics, original products) in several key therapeutic areas, R&D
capabilities, manufacturing of solid, semisolid and liquid forms, Sales Force, sales in Russia and CIS.
SPEAKERS
ADDRESS
AKRIKHIN Moscow Office
Riverside Towers Business Center
115054, Russia, Moscow,
Kosmodamianskaya Naberezhnaya,
52
bld 5, “AKRIKHIN”
FINANCIAL SUMMARY
TELEPHONE
+7 (495) 721 36 97
YEAR FOUNDED
1936
t back :: next u
EMAIL
+ 7(495) 723 72 82
FAX
+ 7(495) 723 72 82
ORGANISERS
WELCOME
Amakem N.V.
www.amakem.com
CONTACT
Kieran Rooney, PhD
Chief Business Officer
FINANCIAL SUMMARY
ADDRESS
Amakem N.V.
BioVille
Agoralaan bldg. A bis
3590 Diepenbeek
Belgium
COMPANY PROFILE
FAX
+32 (0) 11 490-209
MANAGEMENT
Jack Elands, PhD, CEO
Dirk Leysen, CSO
Steve Pakola, MD, CMO
Olivier Defert, PhD, Director, Preclinical Product Development
Maarten van Geffen, Head of CMC and Operations
Kieran Rooney, PhD, CBO
t back :: next u
YEAR FOUNDED
2010
Amakem is an ophthalmology company developing new treatments for serious eye conditions. Amakem’s
product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe
and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
Amakem’s lead candidate, AMA0076, is for glaucoma and the Company is working to apply the Localized Drug
Action approach to a range of other eye diseases. AMA0076 is currently undergoing Phase 2a proof of concept
trials. The Company has a second ophthalmology asset in preclinical development in an undisclosed indication.
Beyond ophthalmology, Amakem has preclinical development programs in asthma/COPD and inflammatory
bowel disease.
EMAIL
[email protected]
€18M Series A round (Aug 2011)
SPEAKERS
TELEPHONE
+ 32 (0) 11 286-982
€1.5M Seed round (Jan 2010)
ORGANISERS
WELCOME
Anergis
www.anergis.ch
CONTACTS
Vincent Charlon PhD,
CEO
FINANCIAL SUMMARY
Zoltan Czigler MBA,
Finance Director
COMPANY PROFILE
TELEPHONE
+41 21 651 9220
FAX
+41 21 651 9221
Anergis COPs reproduce the full-length amino acid sequence of the allergen in separate long peptides. COPs
do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs
can be safely administered at high doses to induce tolerance to the allergen after few injections only. Studies
of COPs in vitro, in animals and in humans have confirmed the safety (no immediate allergic reaction) and
immunogenicity (production of specific IgG4 antibodies and cytokines against the original allergen) of ANERGIS
COPs. In a Phase I/IIA trial with AllerT, a trend for symptom improvement was observed during the season and
long term follow-ups of the same patients demonstrated that antibodies against the birch pollen major allergen
bet v 1 were still significantly elevated in comparison with placebo-treated patients, two and four seasons after
the very short one-time preseasonal treatment (5 SC injections in 2 months) with AllerT.
A large double-blind, placebo-controlled, randomized, multicentre European trial is underway with AllerT
to demonstrate the efficacy of AllerT using recommended regulatory endpoints of combined symptom and
medication scores in real-life conditions, i.e. during the natural birch pollen season. Results of this trial are
expected in Q3 2013. At this time, Anergis intends to partner AllerT for Phase III and/or to finance it through a
round B with current and new investors.
YEAR FOUNDED
2001
Anergis’ lead-product AllerT, a vaccine to treat birch pollen allergy, is in Phase II clinical development. AllerR, its
vaccine candidate for the treatment of patients with allergy to ragweed pollen has received positive feedback
from the U.S. FDA for the final preclinical and early clinical program and AllerDM, Anergis’ vaccine candidate
for patients with house dust mite allergy, is progressing through preclinical development. Anergis has raised
over CHF 22 million from Renaissance PME-Vinci Capital, Sunstone Capital, BioMedInvest and other investors
including Esperante Ventures and Defi Gestion.
t back :: next u
EMAIL
[email protected]
Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel
allergy vaccines targeting the most frequent allergies. Anergis´ vaccines are based on its proprietary Continuous
Overlapping Peptides (“COP”) technology. Allergies are the most prevalent and the fastest growing chronic
conditions in the industrialized world, with over 500 million people affected.
SPEAKERS
ADDRESS
BioPole III
Route de la Corniche 9B
CH-1066 Epalinges
Switzerland
CHF 22M funding received from venture capital and private investors
MANAGEMENT
Vincent Charlon, PhD, CEO
Christophe Reymond, PhD, CSO
François Spertini, MD, Allergy Expert, Founder
Gilles Della Corte, MD, Clinical Development
Eva Castagnetti, PhD, Product Development
Gerard Farmer, PhD, Regulatory Affairs
Jean Paul Rohmer, PhD, Business Development
Zoltan Czigler, MBA, Finance
ORGANISERS
WELCOME
Antisense Pharma GmbH
www.antisense-pharma.com
CONTACTS
Dr Philippe Calais
CEO
FINANCIAL SUMMARY
Dr Andrea Kottke
Head Medical Affairs &
Communication
Others are S-Refit and Bayern Kapital.
Or:
Leopoldstrasse 244
80807 Munich
Germany
COMPANY PROFILE
Antisense Pharma is a biotech company based in Regensburg and Munich, Germany, developing innovative
therapies targeting the TGF-ß pathway to treat tumor diseases with high unmet medical need. The company’s
lead compound, the anti¬sense oligonucleotide trabedersen, has been granted orphan designation for three
tumor indications. Trabedersen has been found to be safe in several clinical trials and has shown encouraging
clinical activity in patients suffering from high grade glioma, pancreatic cancer, or malignant melanoma. The
target of trabedersen, TGF-ß2, is a key component of the TGF-ß signaling complex, and a key promoter of
cancer-derived immuno¬suppression. Trabedersen, by down-regulating its expression, is believed to reverse
the immuno¬suppressive effects, rendering the tumor visible to the patient’s immune system and resulting
in priming and specific activation of the patient’s anti-tumor immune response. Antisense Pharma intends to
further validate this promising drug candidate in selected indications. In addition, the company is expanding its
pipeline through the development of a “Next Generation” oligo-nucleotide program identifying novel proprietary
compounds to target cancer.
EMAIL
[email protected]
Dr. Philippe Calais, Chief Executive Officer
t back :: next u
MANAGEMENT
FAX
+49-941-9201329
TELEPHONE
+49-941-920130
Equity lead investor is MIG fund.
SPEAKERS
ADDRESS
Josef-Engert-Str. 9
93053 Regensburg
Germany
Privately held company.
YEAR FOUNDED
1998
ORGANISERS
WELCOME
APIM Therapeutics AS
www.apimtherapeutics.com
CONTACT
Kostas Alevizopoulos PhD
TELEPHONE
+41 78 752 7002
COMPANY PROFILE
APIM Therapeutics AS is a Norwegian biotech company set to develop and commercialize novel anti-cancer
therapies potentiating chemotherapy-induced responses in cancer cells.
We offer a unique physiological intervention point targeting a cellular “hub” protein called Proliferating cell
Nuclear Antigen (PCNA). PCNA acts a master regulator of replication, repair, cell cycle control and apoptosis,
ultimately controlling responses to pathological (cancer) and pharmacological (chemotherapy) stress in cells.
ATX-101, the company’s current preclinical lead, features a novel PCNA-interacting Stress Switch Peptide
Motif termed APIM. This motif, being incorporated in peptide sequence, interferes with several cellular defense
systems dealing with stress resulting in both hypersensitivity to chemotherapy and direct induction of apoptosis
in selected cancer cells.
Overall, ATX-101 has shown potent preclinical efficacy including single agent activity and potentiation of the
action of >15 clinical drugs in vitro (cisplatin, melphalan, bleomycin, cytarabine, decitabine, dasatinib, vorinostat,
bortezomib and others) as well as proof-of-efficacy in animal models of blood cancer and solid tumor indications.
Currently, ATX-101 is being developed as a novel candidate drug for various oncology indications.
MANAGEMENT
Kostas Alevizopoulos Ph.D., Chief Executive Officer
Marit Otterlei Ph.D., Chief Scientific Officer
t back :: next u
YEAR FOUNDED
Founded in 2009 as a spin out
from the Norwegian University
of Science and Technology in
Trondheim (NTNU), Norway.
Current investors include: • Sarsia Seed • Birk Venture • Ro Invest • Norsk Innovasjonskapital AS
EMAIL
[email protected]
[email protected]
Venture Capital Financed.
SPEAKERS
ADDRESS
APIM Therapeutics AS
c/o NTNU Tech Transfer AS
Sem Sælandsvei 14
Kjemiblokk 1, 3etg
N-7491 Trondheim
Norway
FINANCIAL SUMMARY
ORGANISERS
WELCOME
Apogenix GmbH
www.apogenix.com
CONTACT
Dr Thomas Höger, CEFA
CEO/CFO
FINANCIAL SUMMARY
ADDRESS
Im Neuenheimer Feld 584
69120 Heidelberg
Germany
COMPANY PROFILE
FAX
+49 6221 5860810
EMAIL
[email protected]
Apogenix is a clinical stage biopharmaceutical company developing novel protein therapeutics for cancer
treatment. The company’s therapeutic candidates target either pathways inducing apoptosis or a pathway
stimulating tumor cell growth and migration. The lead product candidate, Apocept™ (APG101), is a CD95-Fc
fusion protein that blocks the interaction between CD95 and its ligand CD95L, thereby inhibiting in cancer cells
their proliferation and migration. Apogenix announced in 2012 that Apocept has reached all clinical endpoints in
an actively controlled Phase II proof-of-concept study in patients with recurrent glioblastoma multiforme (GBM).
The primary endpoint was progression free survival (PFS) at six months. Achieved secondary endpoints include
PFS, overall survival (OS), safety and tolerability. The outstanding efficacy was combined with an excellent safety
profile; no drug-related serious adverse events have been observed in all clinical studies conducted so far with
Apocept. It is the first compound in more than a decade to clearly deliver a PFS as well as an OS benefit in an
actively controlled trial. The inhibition of CD95L by Apocept holds great promise in other tumor indications such
as myelodysplastic syndromes (MDS) and pancreatic cancer. To explore Apocept´s potential in MDS, a phase I
study in MDS patients has been initiated in January 2013. Additonal studies in GBM are in preparation.
MANAGEMENT
Dr. Thomas Höger, CEO/CFO
He joined Apogenix GmbH as CEO and CFO in November 2005. Prior to this, he worked as a stock analyst for DZ BANK,
Frankfurt. From 1997 to 2000, he headed the CNS research at BASF AG and Knoll AG. From 1992 to 1996, he held various
research and management positions at BASF AG.
Dr. Höger obtained his Ph.D. in 1991 for the doctoral work performed at the German Cancer Research Center (DKFZ) after
having studied biology at the Universities of Kiel and Heidelberg, and as a Fulbright Scholar at the Massachusetts Institute of
Technology (Cambridge, USA).
Apogenix was founded as a spin-out from the German Cancer Research Center (DKFZ). The company is based in
Heidelberg, Germany, and employs currently 27 people.
t back :: next u
YEAR FOUNDED
2005
8.5m € public grants raised
SPEAKERS
TELEPHONE
+49 6221 586080
50m € raised in three financing rounds, led by dievini
Harald Fricke, M.D./Ph.D., CMO/COO
He joined Apogenix GmbH as CMO and COO in January 2006. Previously, he was responsible for global clinical development at
Fresenius Biotech GmbH. Prior to this, he was head of Baxter Oncology’s clinical development department. From 1996 to 2001
he held various national and international management positions at SmithKline Beecham and GlaxoSmithKline, respectively.
Dr. Fricke obtained his M.D. in 1987 after having studied medicine at the University of Aachen and the University Lübeck.
ORGANISERS
WELCOME
Biomay AG
www.biomay.com
CONTACT
Rainer Henning
CEO
FINANCIAL SUMMARY
Biomay is privately held with a share capital of EUR 14.6 million, exclusively provided by private investors.
COMPANY PROFILE
TELEPHONE
+43-1-7966-296-100
FAX
+43-1-7966-296-222
The clinical efficacy of our products is demonstrated under the highest medical standards. We cooperate with
leading allergy specialists and industrial partners to revolutionize allergy treatment solutions for the patients’
benefit.
Manufacturing of our own and our clients’ development products complies with the highest quality standards.
Additionally, we support our clients by offering highly professional GMP contract manufacturing services.
MANAGEMENT
Rainer Henning, CEO
Karl Fister, CFO
Hans Huber, COO
Angela Neubauer, Head of Product Development
t back :: next u
YEAR FOUNDED
1984
We discover and develop recombinant allergy vaccines with a superior efficacy and safety profile. These
innovative vaccines are based on cutting edge science for immunotherapy and prophylaxis that we generate in
close cooperation with our academic partners. Our technology platform is based on a novel peptide carrier fusion
protein approach and is broadly patent protected. Our lead product, the grass pollen allergy vaccine BM32, is
currently in phase IIb clinical trials. In addition, we have candidate vaccines for house dust mite, cat dander and
birch pollen allergies in preclinical development.
EMAIL
[email protected]
Biomay aspires to be a worldwide leader in research, discovery and development of disease modifying allergy
therapeutics. Our products will dramatically improve the quality of life of patients by offering long-term cure for
their disease.
SPEAKERS
ADDRESS
Vienna Competence Center
Lazarettgasse 19/1
A-1090 Vienna
Austria
ORGANISERS
WELCOME
Biotie Therapies Corp.
www.biotie.com
CONTACT
Dr Timo Veromaa
President & CEO
TELEPHONE
+358-2-274 8900
FAX
+358-2-2748 910
Cash position (liquid assets): Q3-2012: EUR 41.7 million
COMPANY PROFILE
Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative
and psychiatric disorders (e.g. Parkinson’s disease, Alzheimer’s disease and other cognitive disorders, alcohol
and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease.
The company has a strong and balanced development portfolio with several innovative small molecule and
biological drug candidates at different stages of clinical development. Biotie’s products address diseases with
high unmet medical need and significant market potential.
Biotie’s most advanced product, SelincroTM (nalmefene), licensed to Lundbeck A/S, has on 14 December
2012 received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) recommending marketing authorization of Selincro(TM) for the reduction of
alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. In
addition, Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant which has successfully
completed a Phase 2b study in 420 patients with advanced Parkinson’s disease. Biotie shares are listed on
NASDAQ OMX Helsinki Ltd
MANAGEMENT
Management Team
Timo Veromaa, President and CEO
Ian Massey, COO
David Cook, CFO (effective February 25, 2013)
Stephen Bandak, CMO
Chris Piggott, CBO
Board of Directors:
Peter Fellner, Chairman
William M. Burns, Merja Karhapää, Bernd Kastler, Ismail Kola and Guido Magni
t back :: next u
YEAR FOUNDED
2002; Listing date 31/10/2002
Market cap: ~EUR 200 million
EMAIL
[email protected]
Listed on NASDAQ OMX Helsinki Ltd (BTHV1)
SPEAKERS
ADDRESS
Biotie Therapies Corp.
Tykistökatu 6
FI-20520 Turku
Finland
FINANCIAL SUMMARY
ORGANISERS
WELCOME
BONESUPPORT AB
www.bonesupport.com
CONTACT
Lloyd Diamond
CEO
TELEPHONE
+46 46 286 53 61
FAX
+46 46 286 53 71
Funding will last past cash break-even, which is planned for Q4 2013
COMPANY PROFILE
BONESUPPORT’s mission is to provide an injectable radiopaque bone substitute that has been proven to
remodel into bone, with the potential to be combined with other substances and is capable of being delivered
percutaneously. Its flagship product platform CERAMENT™ is an excellent treatment option to be used as a
synthetic bone substitute. It is clinically proven as it has been used in more than 4000 patients. The latest
advance in the CERAMENT™ platform is CERAMENT™G Gentamicin Eluting Bone Void filler which is indicated
for use as an osteobiologic scaffold and will protect the bone healing process in an infectious environment.
MANAGEMENT
Lloyd Diamond, CEO
Mr. Diamond joined BONESUPPORT in January 2012 as the Chief Excecutive Officer. He is a seasoned medical device
executive with global experience and has worked in both start up and mature companies. He held positions with leading global
companies such as Lumenis, Laserscope, Kyphon and Conmed Linvatec (formerly Zimmer).
Mr. Diamond became involved in his profession when he decided he wanted to work in health care, but on the business side.
He wanted to help improve health care through product development. He now has 20 years of experience developing and
launching disruptive technologies in the health care field. In addition, Mr. Diamond has been involved in several successful
company turn arounds. Through his leadership, he helps companies to deliver better patient and health economic outcomes.
Ultimately, he makes companies provide new standards of care, therefore creating shareholder value.
Mr. Diamond holds a BS Degree in Biochemistry and Marketing as well as an MBA in International Finance from the
Thunderbird School of Global Management. BONESUPPORT, under his leadership, received the Red Herring Global Top 100
citing them as one of the top entrepreneurial companies in the world.
t back :: next u
YEAR FOUNDED
1999
56% of capital was invested by new investors, and 44% by existing investors
EMAIL
[email protected]
[email protected]
The company has raised over €50M since inception. Most recently it raised EUR 19.2m / SEK 171m
(in July 2011) to expand sales and market channels
SPEAKERS
ADDRESS
SCHELEVÄGEN 19A
223 70 Lund
Sweden
FINANCIAL SUMMARY
Offer Nonhoff, CFO
Offer Nonhoff comes to BONESUPPORT from Lumenis, a world market leader in the medical laser industry, where he was
the CFO for the EMEA region for the past 3 years. Beyond finance Offer was also responsible for Human Resources, Sales
Administration and Order Processing.
Prior to Lumenis, Offer worked for Animation Lab, a start up company in the high tech media space, and for Siemens one of
the largest medical and electronic engineering companies in the world.
During his fifteen year career at Siemens, Offer rose up through the ranks to become CFO for Siemens Israel. In this role Offer
enabled the company to achieve market leadership (with multi-million dollar revenues) in several fields of business, and in the
process became ranked in the top 500 in a company with in excess of 500,000 employees. He lead the company to win the
bid to implement Tel Aviv’s first light rail system, five power plants of which three are already in operation, and many bids for
advanced power transmission and medical imaging technologies.
Beginning in Accounts for Siemens in Germany, Offer was promoted to Financial Controller in the networking switching arena
in Israel where he subsequently guided all investments, establishing regional offices that represented the entire portfolio of the
company in Israel and the Palestinian Autonomy. Working with Siemens Israel from start-up provided Offer the opportunity to
perform leadership responsibilities in the areas of corporate management, accounting, controlling, IT and finance.
Offer studied in Germany and the U.S., receiving his BA of Industrial Business Administration from the IHK in Munich.
ORGANISERS
WELCOME
Bone Therapeutics SA
www.bonetherapeutics.com
CONTACT
Enrico Bastianelli MD, MBA
FINANCIAL SUMMARY
Funds raised : 30Mio EUR
COMPANY PROFILE
Bone Therapeutics is a leading international biopharmaceutical company focused on innovative cell therapy
products for the treatment of bone diseases. Utilizing the Company’s unique knowledge of the bone/joint
physiology and long-standing expertise in cell therapy and cell transplantation, Bone Therapeutics has created
a fully integrated business with an advanced product pipeline comprising novel bone cell products, tailored inhouse production methods and minimally invasive treatment techniques.
TELEPHONE
+32 (0) 2 529 59 90
Bone Therapeutics’ lead product, PREOB®, is an autologous bone cell product, currently in Phase III clinical trials
for the treatment of osteonecrosis and non-union fractures. Bone Therapeutics is also developing an allogeneic
bone cell therapy product, ALLOB®, which is expected to enter the clinic in 2013 and MXB, a combined
cell-matrix product for the treatment of large bone defects, currently in preclinical development. All of Bone
Therapeutics’ cell therapy products are manufactured to the highest GMP standards, comply with all regulations
and are protected by a rich IP estate.
FAX
+32 (0) 2 529 59 93
EMAIL
[email protected]
MANAGEMENT
Enrico Bastianelli MD, MBA, CEO
Valérie Gangji MD, PhD, CSO
The bone disease and reconstruction market is one of the largest healthcare markets in the world, with more
than 4 million procedures requiring bone grafts performed annually in Europe and the USA alone. Bone
Therapeutics is operating in areas where demand for new products is high and competition is low.
t back :: next u
YEAR FOUNDED
2006
SPEAKERS
ADDRESS
8, rue Adrienne Bolland
6041 Gosselies
BELGIUM
ORGANISERS
WELCOME
CellMed
www.cellmed.at
CONTACTS
Dr Wolfgang Huber
FINANCIAL SUMMARY
Dr Marianne Imhof
Chief Scientific Officer
COMPANY PROFILE
TELEPHONE
+43 (0) 699 172 494 70
FAX
+43 (0) 2732 70512-50
Results from the phase I study in ovarian cancer prove PROCURE® to be safe and immunologically active (proof
of concept) with a positive trend in clinical efficacy. The autologous dendritic cell therapy is manufactured in a
robust manufacturing process with the potential for automation.
CELLMED plans to conduct a phase II study in cooperation with one of the best clinical cooperative groups in
ovarian cancer and to achieve clinical proof of concept by 2016.
MANAGEMENT
Wolfgang Huber, MD, MBA, CEO
Marianne Imhof, PhD, CSO
YEAR FOUNDED
2006
The company is led by an experienced management team and supported by a group of world renowned clinical
experts in ovarian cancer.
t back :: next u
EMAIL
[email protected]
CELLMED is an Austrian based biotechnology company developing PROCURE®, a high potential dendritic cell
vaccine. The niche indication for this platform technology is ovarian cancer which is applicable for all solid
tumors in general.
SPEAKERS
ADDRESS
Magnesitstraße 1
3500 Krems a.d. Donau
Austria
CellMed is a non public mainly privately funded company with certain national support grants.
ORGANISERS
WELCOME
Ciloa, SAS
www.ciloa.fr
CONTACTS
Robert Z. Mamoun, Ph.D.
CEO/CSO
FINANCIAL SUMMARY
Renaud Burrer, Ph.D.
Senior Scientist
COMPANY PROFILE
TELEPHONE
+ 33 (0) 467 143 997
YEAR FOUNDED
2011
Currently, the challenge to obtain fully native membrane proteins out of cells hampers dramatically the
development of therapeutic mAbs against important membrane protein targets (receptors, ion channels, etc.).
The disruptive technology of Ciloa allows breaking open this lock by producing not only the perfect membrane
antigens but also by providing potent methods to:
1. trigger specific immune response against receptor ectodomains,
2. select efficiently scFv phage library,
3. screen easily mAbs (ELISA),
4. characterize all mAbs-receptor interaction parameters (SPR).
More, Ciloa exosomes can help also in drug screening, immuno-therapeutic, therapeutic, diagnostic,
and vaccine developments.
MANAGEMENT
Robert Z. Mamoun, Ph.D., CEO/CSO
Coralie Philippe, Ph. D., CFO
Renaud Burrer, Ph. D., Senior Scientist
Manuela Lotierzo, Ph. D., Senior Scientist
Maëlle Prorok-Hamon, Ph. D., Senior Scientist
EMAIL
[email protected]
[email protected]
Exosomes are tailored by Ciloa to express any type of membrane proteins (with single or multi-transmembrane
domains), at high concentrations, embedded in a membrane, with their:
• fully native conformation,
• natural post-translational modifications (glycosylation, homo- and hetero-oligomerization, cleavage, etc.),
• accessory proteins.
t back :: next u
FAX
+ 33 (0) 467 144 286
Ciloa is an innovative company with a patented proprietary technology that provides fully native
transmembrane proteins on natural nanovesicles called exosomes. Using these recombinant exosomes
Ciloa develops mAbs against challenging targets such as GPCR, Kinase Receptors, Ion Channels and
more. Exosomes are small lipid membrane vesicles that are secreted by many cell types, that carry both
proteins and RNA and that possess potent immuno-stimulatory functions.
SPEAKERS
ADDRESS
Ciloa, SAS
Bat. 24, cc107
Universite Montpellier 2
Place E. Bataillon
34095 Montpellier cedex 5
France
Private ownerships.
ORGANISERS
WELCOME
Colby Pharmaceutical Company
& SILKI AG
CONTACTS
Colby European
Thomas M. Kündig MD
Colby Pharmaceutical SAB,
CoChair
FINANCIAL SUMMARY
Mobile 078 609 35 36
Phone 04 255 34 71
Colby is an immunology and chemistry-driven drug company developing, marketing, and selling small molecule
drugs or biologics modulating inflammation. Colby’s novel drugs and vaccines treat disease and inflammatory
conditions, especially, cancer, infection and pain. The Company leverages capital from investors and asset outlicenses and sales. Colby continues to acquire, reset and resell clinical stage assets. The Company is accessing
data generated from contracts, grants, investments, acquisitions, and in-licensed or reset assets. Colby intends
on advancing these drug candidates through the clinic to commercialization, either independently or with a
partner.
Thomas M. Kündig MD
Colby Pharmaceuticals SAB,
Co-chair
Colby Pharma US Telephone
Co Phone (650) 323-6215
Cell Phone (650) 333-3150
Lab Phone (408) 960-7466
Colby Pharma US EMail
tkuendig
@colbypharmaceuticals.comknarducy
@colbypharmaceuticals.com
YEAR FOUNDED
2004
COLBY PHARMA EUROPEAN MANAGEMENT
Ken Narducy PhD MBA, Colby Pharmaceutical COO
Ken is a biopharmaceutical executive and positioned several companies to increase business value and competitive advantage
via R&D, IP generation and commercialization, M&A analysis, and venture funding. He developed new biotech/pharmaceutical
business for startups (Oculex, Centaur, St. Charles) and biomedical/chemical products for divisions of Abbott Labs, ScheringPlough, and The Cooper Companies. Ken has completed over $1B in prior transactions,, including bringing colored contact
lenses to market.
Thomas Kündig MD, Colby Pharmaceutical SAB CoChair & SILKI AG Chief Scientific Officer
Colby Pharma US Fax
Corp Fax (650)644-0440
Lab Fax (408) 960-3822
Colby and collaborators have consistently recorded JVRS-mediated-dose-dependent human cancer patient
therapeutic responses, some with anecdotal increases in human patient survival to be confirmed by follow-up
Phase II trials. The Company has a significant supply of JVRS-100 clinical grade material ready for initiation of
multiple Phase II human clinical trials.. To accelerate the company’s growth plans and facilitate its transition
to focus on Phase II efficacy data in multiple disease indications, Colby management has secured significant
clinical assets, partners, collaborators), and is recruiting additional professional staff and new collaborators.
Colby Pharma US Address
5941 Optical Court
San Jose, CA 95138
Immune Modulator Biologics US Based Division
In September, 2011, the immune modulator-biologics division of Colby was formed via a worldwide exclusive
in-license acquisition of all the human health assets of Juvaris BioTherapeutics from KPCB (Kleiner Perkins
Caulfield Byers), SV Life Sciences, and Abbott Bioventures (see 2011 press releases). Colby’s immune
modulator division is expecting to enter additional new Phase II hematology and oncology clinical trials. In
addition Colby’s standalone immune activators or adjuvants for disease specific antigen vaccines can be
synergistic with Intra Lymph Node Immunization, ILNI, including protocols being developed with assets from the
Colby Pharmaceutical subsidiary, SILKI AG, Zürich.
t back :: next u
ADDRESS
Colby European
Colby Pharmaceuticals SAB
Gloriastrasse 31,
8091 Zürich
Switzerland
COLBY PHARMA COMPANY PROFILE
SPEAKERS
Colby Pharma US
Ken Narducy PhD MBA
Colby Pharmaceutical COO
San Jose California, USA-based Colby Pharmaceutical Company, is a Delaware C Corporation in good standing in
DE and CA.
ORGANISERS
WELCOME
Covagen AG
www.covagen.com
CONTACTS
Dr Julian Bertschinger
Dr Dragan Grabulovski
Chief Scientific Officer
ADDRESS
Covagen AG
Wagistrasse 25
Schlieren, 8952
Switzerland
TELEPHONE
+41 44 732 46 60
YEAR FOUNDED
2007
Covagen develops bispecific FynomAbs™ by fusing its human Fynomer™ binding proteins to antibodies
resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory
diseases and cancer. The ability to fuse Fynomers™ to multiple sites on an antibody allows Covagen to create
FynomAbs™ with tailored architecture to maximize efficacy.
Covagen’s lead program is a bispecific TNF/IL-17 inhibitor (in preclinical development) for the treatment of
inflammatory diseases such as psoriasis, psoriatic arthritis and rheumatoid arthritis.
MANAGEMENT
Board of Directors
Franz Hefti, Chairman
Ray Hill, Anja König, Gilles Nobécourt, Mounia Chaoui, Jon Hepple, Julian Bertschinger
Scientific Advisory Board
Greg Winter, Ulrich Feige, Thierry Hercend, Christoph Heusser, Christoph Lengauer
EMAIL
[email protected]
COMPANY PROFILE
t back :: next u
FAX
+41 44 732 46 64
Investors: • Novartis Venture Fund • Edmond de Rothschild Investment Partners • Ventech
• Seroba Kernel Life Sciences • MP Healthcare Venture Management
SPEAKERS
Dr Fabian Buller
Director Business Development
FINANCIAL SUMMARY
ORGANISERS
WELCOME
Cristal Delivery B.V.
www.cristaldelivery.com
CONTACT
Dr Cristianne Rijcken
TELEPHONE
+31 30 430 0222
EMAIL
Cristianne.rijcken
@cristaldelivery.com
Joost.holthuis
@cristaldelivery.com
COMPANY PROFILE
Cristal Delivery is a pharmaceutical company that develops first-in-class nanomedicinal products on the
base of its proprietary polymeric technologies (CriPec®). CriPec® enables the development products with a
clear competitive edge as a result of their anticipated superior efficacy and improved tolerability profile. The
customisable platform allows for an improved disposition of the entrapped drug, preferential accumulation of
CriPec® in tumour and inflammatory sites, the possibility to be combined with ligands for active targeting and is
easily manufactured.
CriPec® is a unique approach to transform drugs into nanomedicines of around 70 nm and which possess
multiple beneficial properties resulting in an improved efficacy and safety profile as already demonstrated in
various preclinical studies. Both small molecules and peptides can be combined with CriPec® which comprises
all key factors for a successful drug: it allows for tailor-made products that take the (physico)chemical properties
of the drug, the desired concentration at the target site and the route of administration into account.
2012 was a really exciting year as noteworthy progress has been made in the development of CriPec® as well
as the first product. Last year milestones were:
• Development of sophisticated GMP-manufacturing process of CriPec® nanoparticles
• Generation of highly promising in vivo efficacy and safety data with CriPec® docetaxel when compared
with Taxotere
• Expansion of CriPec® approach to peptides: increasing the in vivo half-life time 50-fold.
Dr Cristianne Rijcken, CEO
Dr Joost Holthuis, Executive Director
MANAGEMENT
The combination of CriPec® ‘s enabling technology with new or existing drugs will expand opportunities in
various therapeutic areas. The resulting products will also open up new areas in diseases that have been so
far hard to treat. The company strategy is to leverage its technologies by building a small product portfolio for
various indications. A first clinical trial is scheduled with CriPec® docetaxel early 2014. Next, Cristal Delivery
is actively pursuing strategic partnerships with pharmaceutical companies to conduct custom-made feasibility
studies to create innovative products with compelling competitive advantages.
t back :: next u
YEAR FOUNDED
2011
Cristal Delivery has closed in 2012 a financing round with two Dutch VC firms, BioGeneration Ventures and
Thuja. The company is presently in the process of raising additional funds that will enable the finalisation of
clinical phase I/IIa.
SPEAKERS
ADDRESS
Padualaan 8
3584 CH Utrecht
The Netherlands
FINANCIAL SUMMARY
ORGANISERS
WELCOME
Cureline, Inc.
www.cureline.com
CONTACT
Olga Potapova, PhD
CEO and Scientific Director
FINANCIAL SUMMARY
Privately owned company.
COMPANY PROFILE
TELEPHONE
+1-650-875-6400 x 221
FAX
+1-650-875-6484
Olga Potapova, PhD, CEO and Scientific Director
Alexander Lituev, MD, SVP Biospecimen Operations
Kathleen Talmadge, SVP Finance and Operations
Irina Zaytseva, MBA, VP Business Development
t back :: next u
YEAR FOUNDED
2003
MANAGEMENT
EMAIL
[email protected]
Cureline is a biomarker and diagnostics CRO specializing since 2003 in human biospecimens acquisition and
tissue research projects including study design, regulatory affairs, clinical network management, specimen
collection and analysis, and complete logistics. Our areas of expertise are oncology, immunology, inflammation,
cardiovascular conditions, metabolic conditions, infectious diseases/sepsis/HIV. We collaborate with major clinical
centers in Europe, Asia, and the USA and maintain an extensive biorepository of human biospecimens in South
San Francisco (USA). Cureline BioPathology (translational histology CLIA/GLP laboratory) provides high-end
tissue research services including IHC protocol development, clinical specimens processing and diagnostics, and
digital pathology. European clinical outreach group in St. Petersburg (Russia) supports regulatory affairs, patient
enrollment and retention services, clinical site relation management, and marketing research. All our managers
have advanced degrees and are experienced in clinical trial operations, research and healthcare management
and international business development..
SPEAKERS
ADDRESS
290 Utah Ave Ste 300,
South San Francisco,
CA 94080
USA
ORGANISERS
WELCOME
Domain Therapeutics
www.domaintherapeutics.com
CONTACTS
Mrs Aurelie Maisner
CEO Assistant
Dr Marjorie Sidhoum
Business Manager
TELEPHONE
+33 39 040 6150
FAX
+33 39 040 6155
2012 – 2.0m€
COMPANY PROFILE
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery
and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best
classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform to
identify orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that represent a unique
source of compounds that cannot be discovered by standard technologies. The platform is also able to address
difficult GPCRs such as orphans and peptidic receptors. The company’s pipeline is composed of new chemical
entities ranging from hits to optimized leads targeting hot GPCRs for leading indications such as schizophrenia,
Parkinson’s disease and diabetes..
MANAGEMENT
Pascal Neuville, CEO, CSO
Gregory Chapron, CFO
Stephan Schann, Head of Research
t back :: next u
EMAIL
contact
@domaintherapeutics.com
amaisner
msidhoum
2008 – 2.1m€
SPEAKERS
ADDRESS
BioParc
850 Bld Sebastien Brand
67400 Illkirch
France
FINANCIAL SUMMARY
YEAR FOUNDED
2008 (restart)
ORGANISERS
WELCOME
Dualsystems Biotech AG
www.dualsystems.com
CONTACT
Dr Andreas J. Schulze
CEO
COMPANY PROFILE
ADDRESS
Grabenstrasse 11a
8952 Schlieren
Together with our partners, we identify and characterize novel mechanisms of action for drugs using cell based
screening assays.
FAX
+41 44 738 55 05
EMAIL
[email protected]
Dualsystems Biotech is a provider of custom screening services for industry and academia, specializing in
Yeast two-Hybrid, CaptiVate AP/MS-MS and cDNA Library Construction.
In addition, Dualsystems provides kits and reagents for a range of research applications, including protein
expression, protein-protein interaction and protein activity measurement
MANAGEMENT
Dr Andreas J. Schulze, CEO, Business Development, Finance
Dr Daniel Auerbach, CEO, Operations
Mrs Katrin Rutschmann, Director Services
t back :: next u
YEAR FOUNDED
2000
SPEAKERS
TELEPHONE
+41 44 738 50 01
Dualsystems Biotech is a Contract Research Organization in the areas of drug and target profiling and
proteomics. We provide innovative and flexible solutions to characterize protein complexes and small molecule –
target interactions in any cellular setting.
ORGANISERS
WELCOME
Ennar Pharma AG
www.ennarpharma.com
CONTACTS
Dr Rudi D Neirinckx
Dr Peter Burckhardt
Board Member
TELEPHONE
061 283 8485
EMAIL
[email protected]
COMPANY PROFILE
Ennar Pharma was founded in July 2010 to develop a better and safer topical treatment for mild-to-moderate
psoriasis. Patents, protecting the technology, have been granted in Europe and the USA. The company is
financially supported by an investment by EVA- a Basel based venture capital company- and has developed the
production of pure EGF and a stable cream-based pharmaceutical product. The cGMP production of high-quality
EGF (epidermal growth factor) is carried out by a third-party collaborator. The IMPD for the topical product is
Swissmedic-approved and the Proof-of-Concept trial is running at the Dermatology Clinic of the University of
Zurich. The trial, which is carried out with mild-to-moderate psoriasis patients, aims to establish the validity
of the mode-of-action proposed for the EGF-based topical formulation and test the optimised formulation for
clinical efficacy and safety. Results of the trial are expected by the end of Q1 2013.
MANAGEMENT
Dr Rudi D Neirinckx, Chief Executive Officer
Dr Peter Burckhardt, Board Member
t back :: next u
YEAR FOUNDED
2010
The company is financially supported by an investment by EVA- a Basel based venture capital company and by
the private funds of the founder.
SPEAKERS
ADDRESS
Hochbergerstrasse 60c
CH-4057 Basel
Switzerland
FINANCIAL SUMMARY
ORGANISERS
WELCOME
Epigenomics AG
www.epigenomics.com
CONTACT
Antje Zeise
Manager IR | PR
FINANCIAL SUMMARY
ADDRESS
Epigenomics AG
Kleine Präsidentenstr. 1
10178 Berlin
Germany
COMPANY PROFILE
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary
products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately,
leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test
for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the
U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading
global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.
FAX
+49 30 24 34 5 - 555
MANAGEMENT
EMAIL
[email protected]
The team is headed by Dr. Thomas Taapken (formerly Biotie Therapies, Deutsche Venture, Burrill & Company).
Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the
U.S. and Europe.
Dr Thomas Taapken, CEO/CFO
t back :: next u
YEAR FOUNDED
1998
SPEAKERS
TELEPHONE
+49 30 24 34 5 - 0
Epigenomics is publicly listed at the Frankfurt Stock Exchange, Prime Standard: (ECX, ISIN DE000A1K0516).
For financial information please refer to the Investor Relations section of the Company’s website.
ORGANISERS
WELCOME
ERA BIOTECH S.A.
www.erabiotech.com
CONTACTS
Dr Miriam Bastida
CBO
FINANCIAL SUMMARY
Mr Dídac Marco
Business Developer
COMPANY PROFILE
ADDRESS
Parc Científic de Barcelona
C.Baldiri i Reixac, 15-21 - 08028
Barcelona, Spain
We call ourselves a science-based commercial organization and are with 20 highly educated, international
scientists and product developers, based in Barcelona at the Science Park
Privately held.
ERA BIOTECH® is a mid-size biotechnology company, developing break-through innovations for existing
enzymes and step-changes for novel recombinant protein and DNA vaccines.
SPEAKERS
Please, visit at http://www.erabiotech.com
MANAGEMENT
TELEPHONE
Office: +34 93 403 47 73
Mr Lieven De Smedt, CEO
Dr Miriam Bastida, CBO
Dr Pau Marzábal, IP Manager
FAX
+34 93 403 47 72
YEAR FOUNDED
2002
t back :: next u
EMAIL
[email protected]
[email protected]
[email protected]
ORGANISERS
WELCOME
Glycotope
www.glycotope.com
CONTACTS
Steffen Goletz
CEO/CSO
FINANCIAL SUMMARY
Franzpeter Bracht
CFO/CBO
COMPANY PROFILE
Total investment €125m.
FAX
+ 49 30 9489 2630
MANAGEMENT
EMAIL
[email protected]
YEAR FOUNDED
2001
Dr Steffen Goletz, CEO/CSO, Founder
• CEO/Co-Founder of Nemod GmbH (merged to Glycotope)
• Ph.D. in Biochemistry
• Scientific Career: Max-Delbrück-Centre for Molecular Medicine (Berlin), MRC Centre for Protein Engineering (Cambridge, UK),
German Cancer Research Centre (Heidelberg)
Dr Franzpeter Bracht, CFO/CBO
• AplaGen GmbH, Co-Founder & former CEO/CFO
• Co-Founder and Investor in other small Biotechs
• Kienbaum Management Consultants Principal, Head of Pharma & Life Sciences
• Ernst &Young, Consultant
In addition, two second generation antibodies are exhibiting superior features as compared to their originals:
the 2 most advanced, CetuGEX, a 2nd generation Cetuximab and TrasGEX, an improved Trastuzumab will enter
phase II in Q3/2013. FSH-GEX finished Phase II in Q3/2013 and will start Phase III in Q1 2014.
SPEAKERS
TELEPHONE
+ 49 30 9489 2600
Marcel Kuehnert
Operations
t back :: next u
ADDRESS
Glycotope GmbH
Robert-Roessle-Str. 10
13125 Berlin
Germany
GLYCOTOPE GmbH is a German biotech company founded in 2001 with new technologies and 4 phase I/II
products. Today the company has more than 150 employees at two sites in Berlin and Heidelberg and a total
investment of €125m. First product comes out of a technology developing new antibodies against glyco-targets
(GlycoBodies). With GlycoExpress, we own a novel and regulatory approved system based on human cell lines
that confers a fully human and, if desired, an optimized glycosylation, leading to higher activity, prolonged half
life time and reduced immunogenicity. Using this technology, GLYCOTOPE develops NBEs and second generation
antibodies and other non-antibody proteins, such as GT-MAB 2.5-GEX, a monoclonal antibody (GlycoBody)
that recognizes a combination of its target protein backbone as well as the attached glycosylation, leading to
extremely specific target recognition combined with a high binding affinity. PankoMab is scheduled to proceed to
phase II in ovarial cancer in Q2/2013.
ORGANISERS
WELCOME
GRL Inc.
www.grl-inc.com
CONTACTS
Mike Ghias
CEO
FINANCIAL SUMMARY
David Evans
CSO
COMPANY PROFILE
TELEPHONE
+301-740-1730
FAX
+301-740-1731
YEAR FOUNDED
2006
AnaViRx (founded in 2013) has inlicensed worldwide rights for development of a novel orally available
therapeutic against Influenza A and B. This small molecule is easily manufactured, has a good safety profile and
has demonstrated a 50% reduction in the time for symptoms in flu in patients with type A or type B infection
with a reduction in viral load in these patients. The compound has shown efficacy against a wide array of flu
strains (including H1N1, H3N2 and H5N1). We are seeking partners and/or funding to drive clinical development
of these molecules through USFDA and EMEA.
t back :: next u
EMAIL
[email protected]
[email protected]
GRL has founded, acquired and built companies focused in detection, diagnosis and therapeutic treatment of
disease. The company has partnership relationships with CustomArray Inc (Semiconductor based microarray
platform for rapid disease/biothreat detection and identification – privatized from Combimatrix), founded
AnaViRx Inc (orally available antiviral that has shown excellent efficacy against Influenza A and B through
novel mechanism) and was an angel investor in Sirnaomics (siRNA therapeutic development using proprietary
nanoparticle delivery systems).
SPEAKERS
ADDRESS
Suite 130
401 Professional Dr.,
Gaithersburg, MD 20879
USA
GRL is privately held.
ORGANISERS
WELCOME
Helsinn Healthcare SA
www.helsinn.com
CONTACT
Roberto De Ponti
Head of Corporate Business
Development
FINANCIAL SUMMARY
ADDRESS
Helsinn Healthcare SA
Via Pian Scairolo,
6912 Lugano-Pazzallo
Switzerland
Helsinn Group’s Staff: Total = 455
Switzerland = 277
Ireland = 141
USA = 37
TELEPHONE
+41 91 985 21 21
Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating
subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of
pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn Group
in-licenses early-to-late stage new chemical entities, completes their development through the performance
of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and
attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing
and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists
and supports by providing a full range of product and scientific management services, including commercial,
regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished
products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s
GMP facilities in Switzerland and Ireland and supplied worldwide to its customers.
YEAR FOUNDED
1976
COMPANY PROFILE
Further information on Helsinn Group is available at www.helsinn.com.
MANAGEMENT
Dr Gabriele Braglia, Founder & Chairman
Dr Riccardo Braglia, Helsinn Group CEO, Board Member & US Chairman
Dr Luigi Caletti, Group Chief Financial Officer, Board Member & US Board Member
Dr Giorgio Calderari, Group General Manager & Chief Operating Officer & US Board Member
Dr Roberto De Ponti, Senior Director, Head of Corporate Business Development
Dr Andrea Meoli, Chief Commercial Officer
Dr Sergio Cantoreggi, Chief Scientific Officer
Dr Matteo Missaglia, Senior Director, General Counsel, Corporate Legal Affairs
Dr Daniele Bonadeo, Senior Director, Head of Corporate Technical
Dr Paolo Guainazzi, Local General Manager, Chemical Business, Helsinn Advanced Synthesis
Dr Padraig Somers, Local General Manager, Pharma Business, Helsinn Birex Pharmaceuticals, Ireland
Dr William Mann, Local President & CEO & Board Member US Pharma Business, Helsinn Therapeutics (U.S.), Inc.
t back :: next u
EMAIL
[email protected]
[email protected]
Helsinn Group’s R&D Investments in last 5 years: CHF 298.5M
FAX
+41 91 993 21 22
Helsinn Group’s 2011 Total Assets: CHF 436.1M – EUR 359.2M
SPEAKERS
Roberto De Ponti
Direct line: +41 91 985 21 21
Helsinn Group’s 2011 Total Net Turnover: CHF 300.2M – EUR 243.9M
ORGANISERS
WELCOME
HemaCore LLC
www.hemacore.com
CONTACT
Anna Dushina
TELEPHONE
+ 7 495 258 25 38
FAX
+7 499 152 37 54
Company raised $19M round A financing in 2010 from Rusnano and Sberbank Capital. Currently company
finished the development, started serial manufacturing and started sales in Russia. HemaCore looks for round B
in 2013 for GCP clinical trials in Europe and CE-IVD certification.
COMPANY PROFILE
HemaCore LLC is a biotech company, developing medical devices and methods for hematology. The main
product is Thrombodynamics – a new global assay for blood clotting monitoring and anticoagulant control, which
is highly sensitive to hypercoagulation. Thrombodynamics analyser and disposables sales in Russia started in
November 2012.
SPEAKERS
ADDRESS
3, 4th 8 Marta street,
Moscow 125319,
Russia
FINANCIAL SUMMARY
MANAGEMENT
Igor Pivovarov, CEO
• Physicist, Physics department MSU
EMAIL
[email protected]
• Physicist, Physics department MSU
Fazly Ataullakhanov, CTO
Michail Panteleev, CSO
• Dr.Sc., PhD, Prof
• Moscow State University
• Chief of laboratory of molecular mechanisms in CTP PCP RAS
Ilya Serebriysky, CMO
• MD, hematologist
• Dr. Sc., PhD, Prof.
• Moscow State University
• Head of blood biochemical laboratory HSC RAS
t back :: next u
YEAR FOUNDED
April 2010
Andrey Kondratovich, COO
ORGANISERS
WELCOME
Heptares Therapeutics Ltd
www.heptares.com
CONTACT
Malcolm Weir
FINANCIAL SUMMARY
ADDRESS
Heptares Therapeutics Ltd
BioPark
Broadwater Road
Welwyn Garden City
Hertfordshire AL7 3AX
COMPANY PROFILE
TELEPHONE
+44 (0)1707 358 629 (dl)
+44 (0)7968947268 (m)
Our in-house pipeline is led by our selective muscarinic M1 programme for cognition in Alzheimer’s disease
and Schizophrenia, which is in preclinical development and slated for Phase 1 studies in 2013. Our adenosine
A2a antagonist candidate, licensed to Shire, is also in development for neurological disorders. Further discovery
programmes include oral GLP-1 agonists for T2DM, driven by our proprietary first-ever Family B crystal
structure, and CGRP antagonists for prophylaxis and treatment of migraine.
YEAR FOUNDED
2007
The Heptares technology platform represents a unique GPCR capability in the industry today, opening up new
possibilities for both small molecule and antibody therapeutics across the GPCR target universe. Heptares
is the first and only company transforming GPCRs, which are typically highly unstable when removed from
cellular membranes, into stabilised receptors or StaRs®. StaRs® enable GPCR structures in their natural
pharmacological conformations to be determined, thereby overcoming a major historical barrier to structurebased GPCR drug discovery. Heptares has also invented Biophysical Mapping™, which provides superior
elucidation of GPCR-ligand interactions, and has engineered new fragment-based and in silico technologies
specifically tailored to GPCR lead discovery and optimisation. These technology breakthroughs, coupled with
deep expertise in GPCR chemistry and biology, form the nucleus of a powerful and fully-integrated drug
discovery platform.
t back :: next u
EMAIL
[email protected]
Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of
receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs,
leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based
discovery. Our partners include Shire, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad
pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease,
Parkinson’s disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.
SPEAKERS
FAX
+44 (0)1707 35840
$40M venture finance to date from Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund and
Takeda Ventures.
To learn more about the Heptares pipeline and technology platform, please visit www.heptares.com
MANAGEMENT
Dr Malcolm Weir, Co-Founder and CEO
Dr Fiona Marshall, Co-Founder and CSO
Dr Barry Kenny, CBO
Dan Grau, President
Dr Miles Congreve, VP Chemistry
Dr David McGibney, CMO and Head of Development
ORGANISERS
WELCOME
immatics biotechnologies
www.immatics.com
CONTACTS
Mark Bleckmann
Director & Head of Finance
Nikola Wiegeler
Communications
TELEPHONE
+49 7071 5397-0
immatics successfully concluded a total of three financing rounds, raising a total of €108m.
The company is backed by a particularly strong investor group, comprised of family offices and VCs.
COMPANY PROFILE
immatics is a clinical stage biopharmaceutical company, active in the field of cancer immunotherapy. immatics
is developing TUMAP-based (=Tumor Associated Peptides) therapeutic vaccines that are active against cancers
with a high unmet medical need. Three product candidates, all of which were developed with its proprietary
technology platform XPRESIDENT™ are currently in clinical development. Phase II results from its products
IMA901 in RCC and IMA910 in CRC showed a correlation of the number of peptides that patients responded to
and the clinical benefit these patients experienced. The furthest advanced product, IMA901 in RCC, is presently
in a clinical Phase III trial, which is fully recruited. All of immatics’ current products are off the shelf products.
SPEAKERS
ADDRESS
immatics biotechnologies GmbH
Paul-Ehrlich-Straße 15
72076 Tuebingen
Germany
FINANCIAL SUMMARY
Please visit our website at www.immatics.com to find out more about immatics.
MANAGEMENT
FAX
+49 7071 5397-900
YEAR FOUNDED
2000
t back :: next u
EMAIL
[email protected]
Paul Higham, CEO
Harpreet Singh, CSO
Carsten Reinhardt, CMO
Rainer Kramer, CBO
ORGANISERS
WELCOME
Immune Pharmaceuticals
www.immunepharma.com
CONTACTS
Daniel Teper
Anna Baran
USA:
1120 Avenue of the Americas,
14th Floor
New York, NY 10036
TELEPHONE
Israel: +972-9 8866612
USA: +646-588-5430
IMMUNE pipeline includes:
• Bertilimumab Ulcerative Colitis, Severe Asthma, Bullous Pemphigoid, VKC – Phase II
• Ferritin targeted combo Gem-Pac NanomAbs
EPICEPT pipeline includes:
• AMIKET Chemotherapy Induced Peripheral Neuropathy – Phase III
• Azixa – Brain Tumors – Phase II
• Crolibulin – Solid Tumors – Phase II
TECHNOLOGY
NanomAbs are conjugates of drug loaded nano-particles and monoclonal antibodies, a novel alternative to
Antibody Drug Conjugates. They allow targeted delivery of anti-cancer agents to tumor cells. This technology
was developed by Professor Benita at Hebrew University of Jerusalem and has been licensed by IMMUNE from
YISSUM. IMMUNE is advancing its own candidates toward the clinic. IMMUNE is also making the technology
available as part of co-development agreements.
Dr Daniel Teper, Chairman and CEO
Dr David Sidransky, Vice Chairman of the Board
Robert Cook, will become the combined company’s CFO
Suzy Jones, Chief Business Development Officer
Dr Isaac Kobrin, Board Member
Dr Stephane Allard,CMO
Serge Goldner, SVP & COO
Dr Oshrat Frenkel, Director of Research
MANAGEMENT
YEAR FOUNDED
2010
Status
t back :: next u
EMAIL
[email protected]
[email protected]
IMMUNE Pharmaceuticals is a global clinical stage bio-pharmaceutical company resulting from the merger of
a privately held Israeli company, and EpiCept Corporation (“EpiCept”) (NASDAQ OMX Stockholm Exchange and
OTCQX: EPCT). The combined company is focused on developing antibody therapeutics and other targeted drugs
for the treatment of inflammatory diseases and cancer. IMMUNE’s lead product candidate, BERTILIMUMAB, is
a first in class fully human monoclonal antibody that targets eotaxin-1, a chemokine involved in eosinophilic
inflammation, angiogenesis and neurogenesis. Immune has initiated a placebo-controlled, double-blind Phase
II clinical trial with bertilimumab for the treatment of ulcerative colitis and plans to initiate in 2013 additional
clinical studies in severe asthma, in bullous phemphigoid, a dermatological orphan condition and in Verneal
Kerato-conjunctivitis, an ocular orphan condition. The companies’ collective oncology portfolios comprise:
Immune’s NanomAbs®, a new generation of antibody drug conjugates, and EpiCept’s vascular disruptive agents.
Immune Pharmaceuticals will continue efforts to secure a development partner for EpiCept’s Phase III clinical
development candidate AmiKet™, for which the FDA has granted Fast Track designation for the treatment of
chemotherapy-induced neuropathic pain
SPEAKERS
ADDRESS
Israel:
Aba Even 15, Herzliya
COMPANY PROFILE
ORGANISERS
WELCOME
Immunovaccine Inc.
www.imvaccine.com
CONTACTS
John J. Trizzino
FINANCIAL SUMMARY
Vicki Morgan
VP, Business Development
Recent share price: $0.37
TELEPHONE
902-492-1819
FAX
902-492-0888
Average Daily Volume: 32,000
Cash & Other Cash Resources (30/09/12): $3.6M
COMPANY PROFILE
Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to
the development of vaccines for cancer therapy and infectious diseases. The Company’s DepoVax™ platform
is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged
period and has the potential to enhance immune responses. Immunovaccine has advanced its platform
technology and proprietary cancer vaccines through Phase I clinical trials. These trials were successfully
completed demonstrating both safety and immunogenicity potential in two cancer vaccine programs.
Immunovaccine is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based
vaccines through multiple development collaborations with corporate, academic, and government partners.
In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health
vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an
agreement with Pfizer Animal Health, which has licensed the Company’s delivery technology platform to develop
vaccines for livestock.
MANAGEMENT
John J. Trizzino, CEO
Vicki Morgan, VP, Business Development
Kimberly Stephens, CFO
Marc Mansour, Ph.D., CSO
Board of Directors
Albert Scardino, Chairman, Communications Strategist, Pulitzer Prize Recipient
William Cochrane, MD, 2010 Inductee Canadian Medical Hall of Fame
Wade Dawe, CEO of Brigus Gold
James Hall, CA, Sr.VP of Investments GrowthWorks
Stephanie Léouzon, Senior Advisor to Torreya Partners
Wayne Pisano, Former President and CEO of Sanofi Pasteur
Brad Thompson, CEO of Oncolytics
YEAR FOUNDED
2000
52 Week Range: $0.20 – $0.45
t back :: next u
EMAIL
[email protected]
[email protected]
Recent Market Cap: $23.5M
SPEAKERS
ADDRESS
1344 Summer Street, Suite 412
Halifax, Nova Scotia
B3H 0A8
CANADA
Shares outstanding: 63.5M
ORGANISERS
WELCOME
Implandata Ophthalmic Products GmbH
www.implandata.com
CONTACT
Max G. Ostermeier
CEO
TELEPHONE
+49 511 2204 2581
€3.7m raised in seed and series A round.
Currently the company is going to raise a €5m serious B round for market launch in Europe and
US regulatory approval.
First revenues are expected in 2014, profitability in 2016.
COMPANY PROFILE
SPEAKERS
ADDRESS
Kokenstrasse 5
0159 Hannover
Germany
FINANCIAL SUMMARY
Implandata is a medical device start-up company, developing ophthalmic products for monitoring and improved
management of glaucoma patients.
Reduction of intraocular pressure (IOP) is the main goal of any glaucoma therapy. By continuous monitoring of
IOP, therapy and compliance of glaucoma patients can be dramatically improved.
EMAIL
[email protected]
[email protected]
The company has developed an implantable micro sensor, which is continuously and telemetrically monitoring
the IOP. The measured data is sent to an external device for data display and storage. This data is sent to the eye
doctor’s office via tele-medical integration.
YEAR FOUNDED
2010
The company is currently conducting clinical studies for attaining CE mark for its first product in 2013.
Thereafter the company will perform a first launch in Europe. Regulatory approval for the US market is expected
in 2015, followed by the market launch.
The company has further products in the R&D pipeline and can trust on a sound IP position and collaboration
with prestigious sites and world class clinicians and scientists.
MANAGEMENT
Max G. Ostermeier, CEO
Stefan Meyer, CTO
Prof. Robert N. Weinreb (UCSD), Head of SAB
24h IOP measurements and measurement between office visits will reveal vital IOP information on the therapy
outcome and ensure early on “titration” of therapy. Remote patient management allows more efficient patient
care.
t back :: next u
FAX
+49 511 2204 2589
ORGANISERS
WELCOME
Insuline-Medical Ltd
www.insuline-medical.com
CONTACT
Mr Ron Nagar
President & CEO
TELEPHONE
+972-3-9301094
FAX
+972-3-9341094
We have recently submitted our FDA application for the infusion pump device (InsuPatch). We have recently
published Interim results from large study conducted with device for insulin injections (InsuPad) in Germany.
This study was planned with the BARMER sick fund for purposes of reimbursement. The primary end point was
reduction in prandial Insulin dose when the InsuPad device is used. The interim analysis showed reduction of
about 30% in prandial insulin dose between test and control groups.
We have CE mark for our products and we are building independent go-to-market ability in Germany first, to
be expanded later on, to Europe and the US. In preparation for launching the injection product in Germany we
have formed a fully owned subsidiary (InsuLine-Medical GmbH), and are gearing up towards manufacturing and
pre-marketing studies.
MANAGEMENT
Ron Nager, President & CEO
David Ben-Naim, CFO
Gabriel Bitton, VP R&D
Noam Kfir, VP Operations
t back :: next u
YEAR FOUNDED
2007
The technology, while seemingly straight forward requires balancing blood perfusion effectiveness while also
avoiding overheating the insulin itself above the allowed threshold. It is protected by pending patents globally,
and involves significant device knowhow.
EMAIL
[email protected]
Insuline Medical Ltd. is a Public Israeli company (TASE – INSL) focused on improving the performance of current
insulin treatment methods for diabetic subjects, by trying to better approximate human physiology. Even with
today’s rapid acting insulin analogs, injected insulin kinetics is still slow compared to normal physiology. Our
solutions are disposable devices which treat with heat the point of injection, in order to improve and stabilize
blood perfusion. It can be integrated into catheters used with insulin pumps, or as a standalone disposable
compatible with syringe or pen delivery.
SPEAKERS
ADDRESS
70 Pinsker Street
P.O.Box 10299
Petach Tikva
Israel 4900202
COMPANY PROFILE
ORGANISERS
WELCOME
i-Optics
www.i-optics.com
CONTACTS
Jeroen Cammeraat
FINANCIAL SUMMARY
Tanja Hubert
PA
COMPANY PROFILE
TELEPHONE
+31 70 399 3112
EMAIL
[email protected]
[email protected]
EasyScan (CE, FDA cleared). A fast and easy to use retinal imaging system based on SLO technology for
the diagnosis of diabetic retinopathy, age-related macular degeneration and glaucoma.
Cassini (CE, FDA cleared). A first of its kind corneal topographer based on the principle of color LED
topography (CLT), that supports premium contact lens fitting and planning of refractive and cateract surgery
(IOL placements).
EyePrevent. An integrated service for screening diabetes patients and others for retinal diseases that could
lead to blindness.
MANAGEMENT
Jeroen Cammeraat, CEO
Thomas van Elzakker, COO
Egbert Houwer, CFO
t back :: next u
YEAR FOUNDED
2007
i-Optics is a leading pioneer in smart and superior eye diagnosis solutions. Our products are designed to
be affordable, fast and easy to use by care providers all over the world to better serve patients in the most
convenient way. We sell our products through our direct sales force in Netherlands, Germany and USA and
have distributors in other key markets. Our product portfolio includes:
SPEAKERS
ADDRESS
Mauritskade 35
2514 HD Den Haag
Netherlands
Not disclosed.
ORGANISERS
WELCOME
Juventas Therapeutics, Inc.
www.juventasinc.com
CONTACT
Rahul Aras, Ph.D.
President and CEO
TELEPHONE
+216 273 4000
FAX
+216 359 0099
EMAIL
[email protected]
COMPANY PROFILE
Juventas Therapeutics is a clinical-stage regenerative medicine company developing novel therapies for
ischemic disease. The company’s lead product, JVS-100, is a non-viral plasmid that encodes for stromal cellderived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue
injury by promoting cell survival, recruiting endogenous stem cells to the damaged region, and promoting new
blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems including the
heart, brain, kidney, dermis, vasculature, and nervous system providing the opportunity to impact a broad range
of diseases. Target clinical indications address large markets with high unmet medical need and significant
market potential.
MANAGEMENT
Rahul Aras, Ph.D., President and CEO
Marc Penn, M.D., Ph.D., Chief Medical Officer
Joseph Pastore, Ph.D., Vice President, Product Development
Paul Resnick, M.D., Vice President, Business Development
In 2012 the company initiated two Phase II clinical trials for use of JVS-100 to treat patients with critical limb
ischemia (CLI) and to treat patients with heart failure (HF). Together, the trials are being conducted at 16 sites
in the US and abroad. Phase I study results in patients with heart failure demonstrated that JVS-100 is well
tolerated, with patients showing significant improvements in key functional parameters including six minute walk
distance (6MWd), Quality of Life (QOL), and NYHA class. Juventas has raised sufficient funds to complete the two
Phase II clinical trials.
t back :: next u
YEAR FOUNDED
2007
The Company has raised $30.2 million in venture funding. Investors include: Triathlon Medical Venture Partners,
Fletcher Spaght Ventures, Early Stage Partners, New Science Ventures, Takeda Ventures, Reservoir Venture
Partners, Venture Investors, Blue Chip Venture Co., North Coast Angel Fund and JumpStart. The Company has
brought in an additional $2.5 million in grant funding through the Ohio BioValidation Fund, Global Cardiovascular
Innovation Center, the Center for Stem Cell and Regenerative Medicine, and the QTDP Grant.
SPEAKERS
ADDRESS
3615 Superior Avenue
Suite 4403C
Cleveland, OH 44114
FINANCIAL SUMMARY
ORGANISERS
WELCOME
KLOX Technologies
www.kloxtechnologies.com
CONTACTS
Dr Lise Hebert
President & CEO
FINANCIAL SUMMARY
Lise Pharand
Executive Secretary
COMPANY PROFILE
ADDRESS
275 Armand Frappier
Laval, Quebec
H7V 4A7
KLOX Technologies has succeeded in evolving the use of light in therapeutic treatments to a new level. It has
developed an innovative technology platform; the KLOX Biophotonic System, which consists of a primary multiLED light device and a topical photo converter gel. The element-rich photo converter gel is applied to the area
being treated, which is then illuminated by the lamp. The interactions that take place aid in the creation of an
environment favoring repair.
TELEPHONE
Lise Pharand: 450-680-4571
The innovative Biophotonic System is being evaluated in clinical studies for the treatment of acne, and other
medical applications such as wound healing. It has shown itself to be non-abrasive, non-thermal, and noninvasive, with an encouraging safety profile to date.
FAX
450-680-4549
KLOX Technologies™ is dedicated to growing commercial activities across varied fields; the sale of the cosmetic
dental products to Valeant Pharmaceuticals allows the company to streamline efforts and focus energies on
becoming a leader in medical applications in dermatology, wound healing and dental.
Invested $25M to date.
Based in Canada, KLOX Technologies™ is a privately-owned company currently developing innovative and highly
effective therapeutic and cosmetic solutions for use in the fields of Dermatology, Tissue Repair and Dentistry.
Acne: completed randomized, controlled split face trial in Europe with results expected in Q1 2013; submission
for regulatory approval in Europe for moderate to severe acne expected in Q2 2013.
Ready for worldwide or regional partnering
Wound Healing: Initiating and completing U.S. and Canadian pressure ulcer Stage II and III pilot study in 2013.
Initiating European pressure ulcer Stage III registration trial in 2013
YEAR FOUNDED
2007
Skin Rejuvenation: cleared for commercialisation in US, Europe and Canada and is ready for worldwide or
regional partnering
SPEAKERS
PIPELINE
t back :: next u
EMAIL
[email protected]
[email protected]
Management
Dr Lise Hebert, President & CEO
Mariano Rodriguez, VP & Chief of Finance and Operations
David Burroughes, Head, Wound Healing
Denis Vezina, Head, Clinical
Tuba Yamac, Director, IP
Eric Desrosiers, Director, R&D
Jody Engel, Director, BD
Flor del Pilar Arana, Director, Regulatory
Isabelle Harvey, Director, Operations
ORGANISERS
WELCOME
Lipopharma Therapeutics
www.lipopharma.com
CONTACTS
Vicenç Tur
CEO & Co-founder
FINANCIAL SUMMARY
Prof. Pablo Escriba
CSO & Co-founder
Lipopharma has so far raised Eur. 7M+ in capital (seed + series A) and research grants and is now looking for
8 million Euros investment to complete PII trials of Minerval in cancer in Europe and US and to start regulatory
preclinical development of AD and SCI products.
ADDRESS
Ctra. Valldemossa, Km.7,4.
ParcBIT. Edif.17. 2º C-8
07121 – Palma de Mallorca.
Spain
Venture capital, partnership or IPO are currently being considered.
FAX
+34 97 143 9886
COMPANY PROFILE
Other MLT based programs (in preclinical testing) are in Alzheimer’s disease (AD), Spinal Cord Injury (SCI) and
Inflammation. Initial results in two different animal models of AD suggest that LP226A1 has a very significant
disease modifying capacity and neurogenesis activity.
Lipopharma Inc. was established in Boston area as a US subsidiary in 2011.
YEAR FOUNDED
2006
Lipopharma is currently seeking for new partnership opportunities with leading players in the pharmaceutical
market in order to complete the clinical development and commercialization of Minerval in oncology and advance
our programs in AD and SCI, as well as to further develop the promising MLT based pipeline
Lipopharma is a pioneering biopharmaceutical company based in Palma de Mallorca, Spain that is developing
a new generation of medicines associated with the Membrane Lipid Therapy (MLT), a novel and unique
approach developed by our team of world reputed scientists targeting the membrane lipids of the cell. The lead
product, Minerval, regulates the lipid structure and composition of cancer cell membranes through activation of
sphingomyelin synthase (SMS), resulting in 1) PKC mild activation, which causes an important reduction of Cyclin
D-associated cell proliferation and 2) a normalization of the Ras/MAPK and PI3/Akt signaling pathways, leading
to cancer cell differentiation and selective death by autophagy/apoptosis. In pre-clinical studies Minerval® has
demonstrated very high anticancer activity and lack of toxicity, outperforming the drugs of reference. MIN-0011203, the first clinical PI/IIa study with Minerval in Glioma and other advanced solid tumors has already been
authorized by the UK and Spanish Regulatory Agencies and first patients will be enrolled in Q1 2013.
t back :: next u
EMAIL
[email protected]
[email protected]
[email protected]
SPEAKERS
TELEPHONE
+34 97 143 9886
Lipopharma is a private company founded in 2006, headquartered in Palma de Mallorca, Spain. The company is
financed by independent private investors and founders.
MANAGEMENT
Vicenç Tur, MBA., CEO & Co-founder
Prof. Pablo Escriba, Ph.D., CSO & Co-founder
Prof. Xavier Busquets, Ph.D., Research Director
Grahaem Brown, MD, Ph.D., Development Director (consultant)
Marco A. Moreno, Ph.D, QP., Quality and regulatory affairs (consultant)
Neil Dey, Ph.D, Development & Director of US operations.
ORGANISERS
WELCOME
Mabimmune Diagnostics AG www.mabimmune.com
CONTACT
Dr Chad Brokopp
TELEPHONE
+41 (0)78 901 22 93
FAX
+41 44 755 46 47
EMAIL
[email protected]
COMPANY PROFILE
The Problem: Today’s best infarction-prevention medications reduce the risk of cardiovascular death by
approximately 20% after one year.
Product: InfarctPrevent is a clinical theranostic package consisting of: 1. a human antibody medication
anticipated to reduce the risk of infarction by 34% based on pre-clinical trails, and 2. a companion diagnostic
blood test that identifies patients who will respond to the treatment. The blood test identifies the enzymatic
activity of F17 one of Mabimmune’s proprietary molecular targets found to significantly contribute to both heart
attack and stroke. The medication (FlowMab) is a best-in-class human-derived antibody that neutralizes F17 and
is anticipated to significantly lower the risk of infarction. FlowMab is designed to be administered intravenously at
a personalized dose determined by the companion diagnostic blood test every 1-3 months.
Mabimmune is directed by a team with over 70 years of combined bioentrapreneurial experience and a
proven track record of extraordinary value-generation for early biopharmaceutical startups. As an expert in
cardiovascular molecular medicine, Dr. Chad Brokopp, PhD (CEO) has discovered Mabimmune’s target portfolio
and contributes 7 years of entrepreneurial experience. Prof. Simon P. Hoerstrup MD, PhD (chairman) is a
seasoned expert in cardiovascular medicine and a serial bioentrepreneur who provides clinical and marketing
expertise in cardiovascular products and a long-standing expertise in clinical regulatory affairs. Prof. Roger M.
Nitsch, MD (board member) is a seasoned bioentrepreneur of several successful corporations and has acquired,
negotiated, and executed successful human antibody partnering deals in combined value of over $1bn. Prof.
Christoph Hock, MD (board member), has a proven track record of conducting human antibody-based clinical
trials. Dr. Jan Grimm, PhD (board member) is a seasoned biopharmaceutical executive who has designed and
executed successful business activities for human-derived antibodies and has brought numerous products into
lucrative co-development and partnering deals with the world’s largest pharmaceutical companies.
MANAGEMENT
t back :: next u
YEAR FOUNDED
2011
The Mabimmune technology was built upon a publically-funded 6 year $1.2 million academic research effort at
the University of Zurich. Further Series A financing has been opened to investors in Q1-2013 for raising upper
single digit financing for completing pre-IND studies and phase I trials for Mabimmune’s flagship infarction
prevention medication and companion diagnostic.
SPEAKERS
ADDRESS
Wagistrasse 13
8952 Schlieren
Switzerland
FINANCIAL SUMMARY
ORGANISERS
WELCOME
MedGenesis Therapeutix Inc
www.medgenesis.com
CONTACTS
Erich Mohr, Ph.D., R.Psych
Chairman & Chief Executive Officer
FINANCIAL SUMMARY
MedGenesis is privately held.
COMPANY PROFILE
TELEPHONE
+1 (250) 386-3000
FAX
+1 (250) 386-3777
MedGenesis Therapeutix (MedGenesis) is a privately-held biopharmaceutical company committed to developing
and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious
neurologic diseases. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), a minimally
invasive technique that provides for targeted, local treatment of CNS conditions such as Parkinson’s disease,
Epilepsy, Brain Cancer and other severely debilitating diseases of the CNS. MedGenesis lead product GDNF for
the definitive treatment of Parkinson’s disease is currently in Clinical Phase II.
SPEAKERS
ADDRESS
MedGenesis Therapeutix Inc.
730-730 View Street
Victoria, BC, V8W 3Y7
Canada
MANAGEMENT
Erich Mohr, Ph.D., R.Psych., Chairman & Chief Executive Officer, Founder of MedGenesis Therapeutix Inc.
H. Christian Fibiger, Ph.D., Chief Scientific Officer
Greg A. Johnson, M.Sc., PMP, FICR, President and Chief Financial Officer
MatthiasMatthias Luz, M.D., Chief Medical Officer
t back :: next u
YEAR FOUNDED
2006
EMAIL
[email protected]
ORGANISERS
WELCOME
NeuroPhage Pharmaceuticals
www.neurophage.com
CONTACTS
Hampus Hillerstrom (speaker
Executive VP &
Chief Financial Officer
ADDRESS
222 Third Street
Suite 3120
Cambridge, MA 02142
USA
TELEPHONE
+617-412 5171
YEAR FOUNDED
2007
Series B-1: $9.0M
COMPANY PROFILE
NeuroPhage is developing a breakthrough platform for treating protein aggregation diseases. The company has a
broad pipeline of drug candidates that uniquely target multiple misfolded amyloids (tau, alpha synuclein, amyloid
beta, PrP) in several neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS and multiple other
orphan and ultra-orphan neurology indications such as Creuzfeldt Jacobs disease and tauopathies.
The lead drug candidate NPT002, has also shown recently strong activity in an alpha synuclein study sponsored
by the Michael J. Fox Foundation and is poised to enter Phase 1 clinical trials in 2014. Based on the discovery
of the mechanism of action of NPT002, NeuroPhage is developing second generation Ig fusions displaying the
active motif GAIM (General Amyloid Interaction Motif) and has already shown in-vitro and in-vivo efficacy with
these compounds.
NeuroPhage raised $28.6M since its inception in 2007 with lead investors Mérieux Développement and
Shire LLC.
MANAGEMENT
Jonathan Solomon, President & CEO
Hampus Hillerstrom, EVP & CFO
Richard Fisher, Ph.D., CSO
Michael Grundman, M.D., Clinical Development Lead
Kim Gannon, Ph.D., SVP Preclinical R&D
Roxanne Bales, VP Regulatory
Jason Right, Ph.D., VP Manufacturing
Ram Krishnan Ph.D., Director of Research
Haim Tsubery Ph.D., Director of Research
EMAIL
[email protected]
Series B: $12.5M
t back :: next u
FAX
+617-714 5469
Series A: $7.0M
SPEAKERS
Jonathan Solomon
President &
FINANCIAL SUMMARY
ORGANISERS
WELCOME
Numab AB
www.numab.com
CONTACT
Oliver Middendorp
CBO & Co-CEO
FINANCIAL SUMMARY
Up to CHF 5 million seed money provided through industry collaboration.
COMPANY PROFILE
TELEPHONE
+41 44 533 0471
FAX
+41 44 533 0470
Numab’s technology has been designed to gain mayimal flexibility in antibody-based drug design. This is
achieved by engineering highly potent and drug-like antibody variable domains that allow for modular assembly
of molecules having the desired pharmacodynamic and pharmacokinetic properties. These may be mono- or
bispecific molecules of low (26-50 kDa) or high (150-200 kDa) molecular weight, depending on the targeted
product profile.
Numab is led by a Management with proven track record in the biotech industry (4 out of 5 Management
members have been long lasting employees in key positions at ESBATech).
MANAGEMENT
David Urech, PhD, CSO & Co-CEO
Oliver Middendorp, PhD, CBO & Co-CEO
Tea Gunde, PhD, Head of Pharmacology
Sebastian Meyer, PhD, Head of Biochemistry
Roland Helfenstein, Head of Finance and Administration
t back :: next u
YEAR FOUNDED
2011
Numab is pursuing two proprietary antibody programs to develop first-in-class therapeutics for autoimmune
diseases and pain. Numab has an ongoing multi-target collaboration with Sucampo, under which Numab
discovers novel antibody-based development leads.
EMAIL
[email protected]
Numab is a Swiss biotech company that discovers and develops innovative antibody-based therapeutics.
SPEAKERS
ADDRESS
Numab AG
Einsiedlerstrasse 34
CH-8820 Wädenswil
Switzerland
ORGANISERS
WELCOME
OBS Medical
www.obsmedical.com
CONTACT
Chris Weatherall
Head Global QA/RA
Director BioQT Bus. Unit
Only available on request.
COMPANY PROFILE
OBS Medical, is a medical device and software innovation company that provides intelligent solutions to
hospitals, primary care practices, pharmaceutical, biotechnology and clinical research companies.
SPEAKERS
ADDRESS
Brook House
174 Brook Drive
Milton Park
Abingdon
Oxfordshire
OX14 4SD
FINANCIAL SUMMARY
MANAGEMENT
Peter Leyland, CEO
Crispin Quail, CFO
TELEPHONE
01235 432050
YEAR FOUNDED
2000
t back :: next u
EMAIL
[email protected]
FAX
0800 130 3108
ORGANISERS
WELCOME
Opexa Therapeutics, Inc.
www.opexatherpautics.co.uk
CONTACTS
Neil K Warma
President & CEO
TELEPHONE
+1 281-775-0600
As of its most recent periodic reporting for the quarter ended September 30, 2012, Opexa had approximately
$2.2 million in cash. Opexa recently announced a strategic partnership with Merck Serono which generated an
upfront fee of $5 million and potential milestones of $225 million. The company recently priced a private offering
which generated $3.25 million in gross proceeds.
COMPANY PROFILE
SPEAKERS
ADDRESS
2635 Technology Forest Blvd
The Woodlands
TX 77381
USA
FINANCIAL SUMMARY
Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publicly traded biotechnology company dedicated to the
development of patient-specific cellular therapies for the treatment of autoimmune diseases. The company’s
leading product candidate, TcelnaTM, has the potential to address the significant unmet medical needs of the
large multiple sclerosis (MS) patient population.
MANAGEMENT
FAX
+1 281-872-8585
t back :: next u
YEAR FOUNDED
2004
EMAIL
[email protected]
Neil K. Warma, President & CEO
Jaye Thompson, PhD, SVP Clinical Development & Regulatory Affairs
Donna R. Rill, SVP Operations & Quality Systems
Don Healey, PhD, VP Scientific Development & Manufacturing
ORGANISERS
WELCOME
Opsona Therapuetics Ltd
www.opsona.com
CONTACTS
Martin Welschof
Anne Jensen
Executive Assistant
TELEPHONE
+353 1 677 0223
YEAR FOUNDED
2004
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to
key targets of the innate immune system associated with a wide range of major human diseases, including
autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer’s disease and
atherosclerosis.
The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin one of
Ireland’s leading academic institution with a core focus on immunology research. Opsona’s lead product, a fully
human monoclonal IgG4 antibody (OPN-305) targeting Toll-like-receptor-2 (TLR2) has demonstrated activity in
a number of animal models & recently was tested successfully in a phase 1 clinical trial in healthy volunteers.
The Company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to
evaluate the safety, tolerability and efficacy of OPN 305 in renal transplant patients at high risk of Delayed Graft
Function(DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.
The Company is supported by an international venture consortium including Novartis Venture Fund, Roche
Venture Fund, Seroba-Kernel Life Sciences, Fountain Healthcare Partners, Inventages Venture Capital and
Enterprise Ireland.
MANAGEMENT
Bernd Seizinger, Executive Chairman
Martin Welschof, CEO
Mary Reilly, VP Pharmaceutical Development & Operations
Luke O’Neill, Co-Founder, Director and CSO
Conor Dalton, Finance Director
Dr Robert M Miller, Consultant Chief Medical Officer
t back :: next u
EMAIL
[email protected]
[email protected]
COMPANY PROFILE
FAX
+ 353 1 677 8949
Biotechnology Company
0-20 Employees
Private Company
Latest Round of Funding – B Round
Funding Total to date – $35M
SPEAKERS
ADDRESS
OPSONA Therapeutics Ltd
Second Floor Ashford House
Tara Street
Dublin 2
Ireland
FINANCIAL SUMMARY
ORGANISERS
WELCOME
Palobiofarma S.L.
www.palobiofarma.com
CONTACT
Dr Julio Castro Palomino
TELEPHONE
+34 903 402 0815
EMAIL
[email protected]
YEAR FOUNDED
2006
2010 First financing round
2012 Seed financing round
2013 Series A financing round
COMPANY PROFILE
SPEAKERS
ADDRESS
Baldiri i Reixac 15-21
08028 Barcelona
Spain
FINANCIAL SUMMARY
Palobiofarma is a biotech company founded in 2006 and based in Barcelona, Spain.
The company´s mission is to discover and develop new medicines based on the modulation of the adenosine
receptors.
Palobiofarma´s team has designed, synthesized and patented several series of drug-like compounds as
adenosine receptor modulators.
Starting from this proprietary chemical space, the company has been able to build up a balanced and diversified
pipeline, with promising candidates as:
PBF-509: A novel potent adenosine A2a receptor antagonist as a best in class treatment of Parkinson’s Disease
in Phase I clinical trials.
PBF-999: A novel potent dual A1/PDE-10 inhibitor as a fist in class treatment for cognitive disorders facing
IND-enabling studies.
MANAGEMENT
Dr Julio Castro Palomino, CEO
15+ years experience in drug discovery in pharmaceutical companies like Bayer and Almirall
t back :: next u
PBF-695: A novel potent adenosine A3 receptor antagonist as a fist in class oral Glaucoma treatment facing
IND-enabling studies.
PBF-680: A novel potent adenosine A1 receptor antagonist as a first in class oral asthma treatment in Phase I
clinical trials.
Dr Juan Camacho, CSO
15+ years experience in projects
ORGANISERS
WELCOME
ProteoMediX AG
www.proteomedix.com
CONTACTS
Ralph Schiess
CEO & Co-Founder
Christian Bruehlmann
CFO & Co-Founder
TELEPHONE
+41 44 733 40 90
FAX
+41 44 733 40 99
Series A (January 2012): CHF 2.6m (€ 2.1m) from a group of experienced life science investors.
Prize money from various start-up competitions: CHF 250k (€ 200k).
COMPANY PROFILE
ProteoMediX is a privately held diagnostic company that was founded in March 2010 as a spin-off company
from ETH Zurich.
SPEAKERS
ADDRESS
ProteoMediX AG
Wagistrasse 23
8952 Schlieren
Switzerland
FINANCIAL SUMMARY
ProteoMediX enables personalized medicine by developing non-invasive diagnostic tests to detect and assess
the prognosis of cancer, as well as to match patients with safer and more effective therapies.
The first products are focusing on prostate cancer, the most frequently diagnosed cancer in men, where neither
the detection nor the effective treatment is currently guaranteed. ProteoMediX owns the exclusive commercial
rights on a set of protein-based biomarkers that were discovered with state-of-the-art proteomics technology
developed at the ETH Zurich. These biomarkers are directly linked to the origin of cancer on a molecular level
and allow to capture the complexity of the disease by combining multiple biomarkers. A combination of these
showed superior results for the accurate detection of prostate cancer when compared to the current standard
PSA test in a clinical proof of concept study.
YEAR FOUNDED
2010
Ralph Schiess, CEO & Co-Founder
Christian Bruehlmann, CFO & Co-Founder
Board of Directors
Werner Schaefer, Chairman
Isaac Kobrin, Director
Wilhelm Krek, Director & Co-Founder
Ralph Schiess, Director & Co-Founder
Christian Bruehlmann, Director & Co-Founder
t back :: next u
EMAIL
[email protected]
[email protected]
MANAGEMENT
ORGANISERS
WELCOME
Resverlogix Corp
www.resverlogix.com
CONTACT
Donald J. McCaffrey
President & CEO
TELEPHONE
+403-254-9252
FAX
+403-256-8495
15 MM Cash
25 MM Equity line
Market Cap.: 218,178,820 (Feb. 6, 2013)
COMPANY PROFILE
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology
that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the
treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds
arising from Resverlogix’s epigenetic drug discovery platform function by inhibiting BET bromodomains and have
the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases
and diabetes mellitus. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further
information please visit www.resverlogix.com. Follow us on our blog at http://www.resverlogix.com/blog/
SPEAKERS
ADDRESS
202, 279 Midpark Way SE
Calgary, AB
T2X 1M2
CANADA
FINANCIAL SUMMARY
Current cash position (as of January 2013)
MANAGEMENT
t back :: next u
YEAR FOUNDED
2001
Donald J McCaffrey, President and CEO, Co-Founder
Dr Norman C W Wong, M.D., FRCP, Chief Scientific Officer & Co-Founder
A. Brad Cann, CA, Chief Financial Officer
Dr Jan O. Johansson, M.D., PH.D., Senior Vice President Medical Affairs
Kenneth Lebioda, BA, Senior VP Business & Corporate Development
Dr Gregory S. Wagner, PH.D., DABT, Senior VP Research & Development
Dr F. Allan Gordon, M.D., PH.D, Senior Vice President of Clinical Development
Dr Peter R. Young, PH.D., Senior Vice President of Discovery Research
Tina M. Rarick, M.B.A, Vice President of Project Management & Business Operations
Dr Henrik C. Hansen, PH.D., Vice President of Pharmaceutical Development
EMAIL
[email protected]
ORGANISERS
WELCOME
R-Pharm
www.r-pharm.com
CONTACT
Vasily Ignatiev
10, Testovskaya st.,
123317, Moscow
TELEPHONE
+7 (495) 956 79 37
+7 (495) 956 79 38
EMAIL
[email protected]
Key areas of R-Pharm’s competence include: manufacturing of finished drugs and APIs, R&D of innovative
medicines and technologies, training and education for industry and health care specialists, venture investments
in promising scientific data and research, cooperation with major international pharmaceutical companies and
international universities in the field of drug development and combined clinical trials in Russia. Since foundation
not less than 85% of profits reinvested into infrastructure and products development.
MANAGEMENT
Alexy Repik, Chairman of the Board
Vasily Ignatiev, CEO
Valery Pereletov, VP, Commercial Affairs
Mikhail Samsonov, Chief Medical Officer
Alexey Ordzhonikidze, Marketing & Business Development Director
Andrey Artemov, Commercial Director
Anna Surova, Customer Service Director
t back :: next u
YEAR FOUNDED
2001
Founded in 2001 in Moscow. Employs over 2600 highly qualified specialists, has 36 branches across Russian
Federation and the CIS countries. Turnover reached over $1,6 billion in 2011.
SPEAKERS
ADDRESS
19-1, Berzarina st.,
123154, Moscow
COMPANY PROFILE
ORGANISERS
WELCOME
Scancell Holdings Plc.
www.scancell.co.uk
CONTACT
Dr Richard Goodfellow
TELEPHONE
0115 823 1863
FAX
0115 823 1863
Although the study was not designed primarily to measure tumour response, one patient in the 4mg dose cohort
with multiple tumour lesions at study entry had a differential response to treatment including partial or complete
regression of all lung metastases. A further two patients who had all their tumours surgically removed prior to
SCIB1 treatment have remained disease-free more than a year after first dosing. The vaccine produced very few
side effects, none of which were serious.
These encouraging results provide the first evidence that Scancell’s ImmunoBody® vaccine approach is
producing an immune response in cancer patients which may also be associated with clinical benefit. In view of
the positive results and minimal side effects seen with the 4mg dose Scancell intends to evaluate an 8mg dose
in parallel with Part 2 of the Phase1/2 study.
The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also
be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4
that destroy tumours without toxicity. The Moditope™ platform could have a profound effect on the way that
cancer vaccines are developed.
MANAGEMENT
Professor Lindy Durrant, Joint CEO
Dr Richard Goodfellow, Joint CEO
t back :: next u
YEAR FOUNDED
1997
Scancell’s first cancer vaccine SCIB1 is a DNA vaccine being developed for the treatment of melanoma.
Preliminary results from Part 1 of the Phase 1/2 clinical trial of SCIB1 in patients with Stage III/IV malignant
melanoma produced a vaccine induced T cell response to treatment in four out of the six patients treated with
either the 2mg or 4mg dose.
EMAIL
[email protected]
Scancell is developing novel therapeutic vaccines for the treatment of cancer based on its groundbreaking
ImmunoBody® and Moditope™ technology platforms.
SPEAKERS
ADDRESS
Scancell Ltd
Dept Clinical Oncology
City Hospital
Hucknall Road
Nottingham NG5 1PB
COMPANY PROFILE
ORGANISERS
WELCOME
Serpin Pharma
www.serpinpharma.com
CONTACT
Cohava Gelber, PhD, MBA
President & Chairman
TELEPHONE
+1-703 343 3258
EMAIL
[email protected]
[email protected]
YEAR FOUNDED
2010
Serpin Pharma secured its initial funding from private investors in May of 2011 and follow-on financing in April
of 2012. In December 2012, Serpin Pharma was awarded a Phase I SBIR grant from the NIH to develop SP16
for type I diabetes.
COMPANY PROFILE
Serpin Pharma is a privately held biotech company with research facilities in Northern Virginia, USA. The
company is developing a family of first-in-class anti-inflammatory and immune modulating peptide drugs derived
from human alpha-1-antitrypsin. The peptide drugs have broad application in inflammatory and autoimmune
diseases, and potentially represent a superior alternative to alpha-1-antitrypsin in select indications.
SPEAKERS
ADDRESS
14645 Sulky Run Ct.
Nokesville, VA 20181
FINANCIAL SUMMARY
TECHNOLOGY
Serpin Pharma’s first-in-class peptide platform was derived from the abundant acute phase protein alpha-1antitrypsin and similar Serpin proteins. The peptide drugs are predicted to control an inflammatory master switch
at the interface between the innate and adaptive immune systems. They potentially provide a paradigm shift in
disease management, by reducing autoimmunity without the detrimental general immunosuppression induced by
some anti-inflammatory drugs.
MANAGEMENT
Critical safety studies, including hERG assays and human receptor panning studies, predict the SP16 drug will
have an excellent safety profile. Serpin Pharma aims to initiate formal, IND-enabling safety studies in 2013 with
the goal of starting Phase I Clinical trials in 2014.
t back :: next u
The lead drug candidate, SP16, is a 17 amino acid peptide and the drug provides protection from disease in
mouse models of type II diabetes, rheumatoid arthritis and lethal endotoxemia. Recent data support that SP16
works via the TLR2 receptor, and it is predicted to induce expansion of tolerogenic T-cells (Tregs) and to promote
an anti-inflammatory cytokine profile.
Cohava Gelber, PhD, MBA, President & Chairman
Soren Mogelsvang, PhD, VP of R&D
Scientific and Business Advisors
Alexander Fleming, MD, President & CEO at Kinexum
Jonathan Zenilman, MD, Chief of the Infections Diseases Division, Johns Hopkins University School of Medicine
John Abeles, MD, Venture Investor, Director, Entrepreneur
Jacqui Brandwynne, Business strategist, Director
ORGANISERS
WELCOME
Synthena AG
www.synthena.com
CONTACT
Dr Wolfgang Renner
Chief Executive Office
FINANCIAL SUMMARY
Synthena raised over CHF 5 million in a series A founding round.
COMPANY PROFILE
TELEPHONE
+41 79 219 96 70
EMAIL
[email protected]
YEAR FOUNDED
2012
Synthena AG is a development stage biotechnology company aiming to develop and commercialize new
life saving drugs for the treatment of severe neuromuscular diseases based on the modulation of RNA. Its
proprietary tricyclo-DNA technology platform offers broad advantages over state of the art oligonucleotide
chemistries for new RNA intervention strategies like splice switching, and other antisense approaches. Its most
advanced preclinical drug development program focuses on Duchenne Muscular Dystrophy, a genetic disorder
which affects 1/3,500 boys and which leads to death in early adulthood.
SPEAKERS
ADDRESS
Freiestrasse 3
3012 Bern
Switzerland
Modulation of RNA for therapeutic purposes holds the promise of opening up entirely new concepts for
pharmaceutical intervention, however, current oligo-nucleotide chemistries to modulate RNA do not meet the
requirements for efficient delivery, pharmacokinetics and tolerability. Synthena’s mission is to establish its
proprietary tricyclo-DNA technology as the leading platform for RNA modulation.
MANAGEMENT
Dr Wolfgang Renner, Chief Executive Officer
Holds a PhD degree in chemistry since 2005. He was involved in the development and expansion the bicyclo- and tricycloDNA molecular platforms.
Dr Branislav Dugovic, Chief Technology Officer
t back :: next u
Has over 15 years of biotech industry experience as founder and CEO of Cytos Biotechnology AG, where he raised over
CHF 270 million, and helped to bring 10 novel product candidates into clinical development of which four are currently in
phases I – IIb and one is marketed.
ORGANISERS
WELCOME
Synthon BV
www.synthon.com
CONTACT
Michael Kotsanis
Chief Commercial Officer
FINANCIAL SUMMARY
Revenue in 2012 of €260 million
COMPANY PROFILE
TELEPHONE
+31 24 372 7700
FAX
+31 24 372 7705
Synthon, with headquarters in Nijmegen, the Netherlands is an international fast-growing pharmaceutical
company and a leader in the field of generic medicines. Synthon has been working in biotechnology since
2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of
auto-immune diseases – particularly multiple sclerosis – and oncology. Our products are currently approved
by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and – in
dedicated areas – through direct sales. Synthon employs about 1,400 staff at 11 sites worldwide, and in 2011 it
recorded a turnover of EUR 260 million.
SPEAKERS
ADDRESS
Microweg 22
Nijmegen 6545 CM
The Netherlands
MANAGEMENT
Jacques Lemmens, CEO/Founder
Michael Kotsanis, Chief Commercial Officer
EMAIL
[email protected]
t back :: next u
YEAR FOUNDED
1991
ORGANISERS
WELCOME
TELORMEDIX SA
www.telomedix.com
CONTACT
Dr Johanna Holldack, MD
TELEPHONE
+41 (0)91 610 7000
Telormedix founded in October 2007, is a biopharmaceutical company focused on targeted immunity and
modulation of the innate immune system for treating cancer and autoimmune diseases. The Company’s lead
product, TMX-101, will shortly commence a Phase II clinical trial for the treatment of CIS (carcinoma in situ)
in the bladder. In addition, Telormedix is developing novel TLR7-targeted agonists. One of these molecules,
TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other
indications. Telormedix also has a pipeline of programs for inflammatory and autoimmune diseases, which
includes TMX-302, a TLR7-binding small molecule showing anti-inflammatory properties in vivo.
SPEAKERS
ADDRESS
TELORMEDIX SA
Via della Posta 10
CH-6934 Bioggio
Switzerland
COMPANY PROFILE
Located in Switzerland, Telormedix is led by a highly experienced management team and backed by an
international consortium of venture capitalists including Aravis Venture (Basel, Switzerland) and Proquest
Investments (Princeton-San Diego, USA).
MANAGEMENT
FAX
+41 (0)91 610 7031
Board of Directors
Jean-Philippe Tripet, Aravis, Lombard-Odier Immunology Fund
Stuart Holden, MD, Director Cedars-Sinai Prostate Cancer Center
Johanna Holldack, MD Behringwerke, Chiron, MediGene, Borean Pharma
Alain Schreiber, MD ProQuest, Vical, RhônePoulenc
t back :: next u
YEAR FOUNDED
2007
EMAIL
[email protected]
[email protected]
Management Team
Johanna Holldack, MD, CEO (Behringwerke, Chiron, MediGene, Borean Pharma)
Roberto Maj, PharmD, Founder/Head of Drug Development (Pharmacia, Newron, Brane)
Alcide Barberis, PhD, Head of Research and Collaborations (ESBATech, Oncalis)
Nadia Passini, PhD, Project Management Director (Bioxell, Italfarmaco, Roche)
Raffaella Pozzi, PharmD, Head of Clinical Operations (Servier, IBSA )
Filippo Riva, MBA, CFO (Bmob, Waterline, NemeriX, UBS)
ORGANISERS
WELCOME
TheraKine Ltd
www.therakine.com
CONTACTS
Stan Yakatan
CEO
Andreas Voigt, PhD
CSO
MAGNUS Str. 11
12489 Berlin, Germany
Private Company
Raising $ 2.5 million
COMPANY PROFILE
TheraKine LTD. Has developed the first in class sustained release, tunable delivery technology for drugs,
biological and cosmetics.
SPEAKERS
ADDRESS
215 33 Rd St
Hemosa Beach California 90254
FINANCIAL SUMMARY
MANAGEMENT
Stan Yakatan, CEO
Andreas Voigt, PhD, CSO
TELEPHONE
310 374 0808 Office
786 229 9795 Cell
YEAR FOUNDED
2009
t back :: next u
EMAIL
[email protected]
FAX
310 374 0803
ORGANISERS
WELCOME
TN LLC
www.tncor.com
CONTACTS
Vladimir Kovalskiy
CEO
COMPANY PROFILE
Dmitry Lazutkin
CTO
Medesk is the first EMR management company in Russia originally designed and developed for us in the cloud.
In addition to the electronic management of medical records, the system allows for the provision of diagnostic
services.
ADDRESS
Moscow, Bersenevskiy per. 5 bld. 4
The purpose of MEDESK is to allow for the maximum freedom from the influence of human factors on the
activities and results of medical work.
EMAIL
[email protected]
[email protected]
[email protected]
The MEDESK technology provides access to features such as patient notification via SMS, remote sensing,
sensing of functional and radiographic imaging, automatic calulation of the risk od cardiovascular disease,
interaction with contactors and numerous other services.
The MEDESK system has all the necessary functions to provide and record all types of outpatient visits for any
funding source including non-operating activitites ,and paid services for all categories of people.Thus MEDESK is
a complete tool for the clinics.
MEDESK came to Sachs looking to expand and devop the platfrom throught out Russia and Europe.
MANAGEMENT
Vladimir Kovalskiy, CEO
Dmitry Lazutkin, CTO
Cloud technology allows MEDESK to provide this system to the maximum number of users in the shortest period
of time. Using a traditional outsourced service based sales model, the system is percieved as a bargain for the
end user as it allows for the insitution to minimize the cost of services.
t back :: next u
YEAR FOUNDED
2008
SPEAKERS
TELEPHONE
Vladimir Kovalskiy
+79242085076
MEDESK is a privately held medical heath records (EMR) management company that uses its proprietaty system
to currently offer its program to in excess of 17 medical clinics in Russia.
ORGANISERS
WELCOME
uniQure B.V.
www.uniqure.com
CONTACT
Jörn Aldag
TELEPHONE
+ 31 20 566 24 02
FAX
+31 20 566 9272
J Aldag, Chief Executive Officer
P Morgan, Chief Financial Officer
C Meyer, Chief Medical Officer
H C Rohde, Chief Commercial Officer
H Petry, Research & Development
H Preusting, Business Development:
t back :: next u
YEAR FOUNDED
2012
MANAGEMENT
EMAIL
[email protected]
[email protected]
uniQure is a world leader in the research and early development of human gene based therapies. Its lead
product, Glybera, for the treatment of lipoprotein lipase deficiency was approved by the European Commission in
November, 2012. Glybera is the first gene therapy approved in the Western world. uniQure has a product pipeline
with several gene therapies: for hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo
B. uniQure is based in Amsterdam, the Netherlands. The company employs a staff with extensive scientific and
industry experience, and is the world leader in manufacturing of AAV-based products on a commercial scale,
meeting cGMP requirements, and has extensive experience in the regulatory process for gene therapies.
SPEAKERS
ADDRESS
Meibergdreef 61
1105 BA Amsterdam
The Netherlands
COMPANY PROFILE
ORGANISERS
WELCOME
UroTiss GmbH
www. urotiss.com
CONTACTS
Soeren Liebig
CEO
Dr Torsten Fahrig
CFO
The capital requirements of UroTiss for EMA approval are 5.5 million €. The additional costs for a phase III
study in the US for FDA approval are estimated about 4-6 million US$.
COMPANY PROFILE
UroTiss provides products with highest safety and quality as well as unique specialized urologic Know-How. The
company’s patented technologies are related to the emerging field of Tissue-Engineering and apply the patients’
own cells for the treatment of his urologic diseases. Current indication is urethral stricture. Indications under
development include ureteral stricture, hypospadias, oral-maxillofacial-surgery and bladder diseases.
SPEAKERS
ADDRESS
Budapester Straße 3
01069 Dresden
Germany
FINANCIAL SUMMARY
We are the first supplier of this kind of therapeutic product worldwide for the treatment of diseased urethra and
keep working on the development to treat complex diseases in the field of urogenital system.
TELEPHONE
+49 (0) 351 43 83 2999
Leading specialized urologic centers use our first product MukoCell in the treatment of urethral stricture.
FAX
+49 (0) 351 43 83 2997
MANAGEMENT
Product MukoCell (Tissue Engineering (TEP) – area ATMPs, regenerative medicine), phase III clinical stage.
Sören Liebig, CEO
Attorney at law with specialty in Medical Law.
YEAR FOUNDED
2005
Dr Torsten Fahrig, CFO
Human Medicine, clinical experience in Urology, extensive know-how in Regenerative Medicine. Responsibilities include
overseeing Research, Development and Production.
Engineer, oversees Finance, Marketing and Operating Business. Many years of experience in Biotechnology/Pharma.
Dr Jürgen Bednarz, Regulatory Affairs & Quality Management
Qualified Biologist, many years of experience in Quality Control, Development and Approval of Human Tissues and Tissue
Products.
Dr Gouya Ram-Liebig, CSO
t back :: next u
EMAIL
[email protected]
ORGANISERS
WELCOME
Vaccibody AS
www.vaccibody.com
CONTACT
Ole Henrik Brekke
FINANCIAL SUMMARY
ADDRESS
Gaustadalleen 21
0349 Oslo, Norway
COMPANY PROFILE
FAX
+47 2260 4427
EMAIL
[email protected]
[email protected]
• Vaccibody has a unique vaccine platform targeting dendritic cells in vivo establishing a unique high cellular and
antibody responses
• A versatile vaccine platform with numerous product opportunities: Many fall-back strategies
• Vast market potential from multiple market segments: Risk reduction through planned early partnerships in
human infectious and veterinary medicine
•H
ighly capable team, international network of collaborators, experienced board of directors with a unique
technology
• Small, flexible and cost efficient organization.
MANAGEMENT
Dr Ole Henrik Brekke, CEO
Dr Agnete Brunsvik Fredriksen, CSO
t back :: next u
YEAR FOUNDED
2007
• Is seeking 3 M€ to take VB 1016 through completion of a Phase-I/IIa study for precancerous lesions.
SPEAKERS
TELEPHONE
+47 2295 8193
Vaccibody is seeking 3 M€ to finalize clinical PhaseI/II trial of a therapeutic vaccine against precancerous
lesions of the cervix.
ORGANISERS
WELCOME
Vifor Pharma Ltd
www.viforpharma.com
CONTACT
Dr Roland Pfeiffer
Head of Business Development,
Europe
Susanne Menzi
Assistant
TELEPHONE
+41 58 851 8000
Dr Roland Pfeiffer
Tel. +41 58 851 8070
Vifor Pharma generated SFr 633Mn sales in 2012, reflecting above market growth of +8% in local currencies.
Prescription products accounted for approximately 65% of sales. Our IV iron products, Ferinject and Venofer,
contributed SFr 270Mn. In 2011, our company generated an operational profitability of SFr 254Mn or an
operating margin of 43%. The figures for the year ended 2012 will be reported March 12, 2013 along with the
Galenica Group full year report.
COMPANY PROFILE
Vifor Pharma is world market leader in iron replacement therapeutics and oral immunostimulation for the
respiratory tract. Vifor is expanding its regional presence beyond our base, Switzerland, and Europe. We operate
in France, Germany, Spain, Belgium, Netherlands, Scandinavia, the United Kingdom, Austria, Portugal, Romania,
Singapore and Australia.
We offer:
Co-promotion, fee-for-services etc. to the target groups nephrologists, hematologists, gastro-enterologists,
oncologists, gynecologists & hospital-based specialists. Out-licensing in selected territories – please inquire.
FAX
+41 58 851 8001
We are NOT interested in:
Generics, OTC, consultancy services
We are interested in:
Development-stage projects or approved or marketed products in the fields of anemia & iron deficiency,
nephrology, gastro-enterology, gynaecology and oncology supportive care throughout the aforementioned
territories.
t back :: next u
Susanne Menzi
Tel. +41 58 851 8299
EMAIL
[email protected]
[email protected]
SPEAKERS
ADDRESS
Flughofstrasse 61
CH-8152 Glattbrugg
FINANCIAL SUMMARY
YEAR FOUNDED
1944
ORGANISERS
WELCOME
ViroGates
www.virogates.com
CONTACT
Jakob Knudsen
COMPANY PROFILE
ViroGates A/S is committed to improve the screening and monitoring of patients in a hospital setting and healthy
individuals in risk of developing life style related diseases.
ViroGates has developed an ELISA (enzyme-linked immunosorbent assay) based suPAR (soluble urokinase
Plasminogen Activator Receptor) test that, in clinical settings, has shown to predict mortality and disease
progression. More than 120.000 patients have to date been tested with suPARnostic®. ViroGates has recently
(2013) launched its suPARnostic Quick Triage test based on lateral flow technology. The Quick Triage products
provide results in 20 minutes.
TELEPHONE
+45 22 261 355
ViroGates product portfolio consists of three fully developed products with CE-IVD approvals. The ELISA Standard
kit marketed for clinical research and the ELISA Flex kit marketed for routine use at central laboratories in
addition to the ELISA products.
EMAIL
[email protected]
YEAR FOUNDED
2001
SPEAKERS
ADDRESS
Blokken 45
3460 Birkerød
Denmark
Sales and marketing is carried out through ViroGates’ network of distributors. ViroGates has more than 20
distribution partners worldwide.
MANAGEMENT
Jakob Knudsen, Chief Executive Officer
t back :: next u
ORGANISERS
WELCOME
Virometix
www.virometix.com
CONTACT
Dr Arin Ghasparian
TELEPHONE
+41 44 63 56117
EMAIL
[email protected]
COMPANY PROFILE
Virometix AG is an innovative Swiss bio-nanotechnology company that aims to be a leader in the design and
development of safe and effective next generation vaccines and nanomedicines.
Virometix developed the Synthetic Virus-Like Particle (SVLP) technology, a breakthrough in the bottom-up
creation of chemically defined homogenous nano-structures useful for highly efficient vaccine delivery and
nanomedicine.
Virometix is focusing on: 1. Establishing SVLPs as a safe and effective antigen delivery system for vaccines, and
2. Developing high-value products for chronic non-communicable and emerging infectious diseases.
Virometix was founded as a spin-out company from the University of Zurich in October 2009, and is based in
Zurich, Switzerland.
MANAGEMENT
Dr Arin Ghasparian, CEO and co-founder
Prof. Klaus Kutz, MD, Chief Development Officer
Claudia Dittmar, Chief Business Development Officer
t back :: next u
Virometix has been awarded by the Swiss confederation two CTI Projects for more than 1 million CHF, enabling
financing the R&D of the company until now. Virometix has also obtained seed financing from the Zurcher
Kantonalbank and won several business and entrepreneurship prizes, including the W.A. de Vigier Award in
2012.
YEAR FOUNDED
2009
Virometix is now seeking financing of at least 2.5 million CHF, and additional financing of at least 7.5 million after
first preclinical studies (pharm/tox) have been completed, to develop first vaccine candidates until phase I human
clinical trials and diversify its proprietary SVLP nanotechnology platform.
SPEAKERS
ADDRESS
Virometix AG
Winterthurerstrasse 190
8057 Zurich
Switzerland
FINANCIAL SUMMARY
ORGANISERS
WELCOME
Supporting Organisations
BioTOP Berlin-Brandenburg
www.biotop.de
BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning
biotechnology in the German capital region.
SPEAKERS
It is our objective to coordinate all regional activities in biotechnology by networking with all key
players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life
science cluster.
The services provided by BioTOP include:
• Technology transfer science - industry
• Initiation and support of networks
• Support for technology-oriented start-ups
• Funding support for innovative projects
• Providing information on biotechnology
• Building and coordination of scientific and interdisciplinary networks
• Establishing contacts between experts from all disciplines
• Design and organization of events
• Public relations work for the biotech region Berlin-Brandenburg
For more information, including a database with comprehensive profiles of all companies and
scientific work groups, please visit our website at www.biotop.de.
t back :: next u
Tel: +49 30 318 622 11
Fax + 49 30 318 622 22
Dr. Kai Bindseil
BioTOP Berlin-Brandenburg
Fasanenstr. 85
10623 Berlin - Germany
ORGANISERS
WELCOME
Citigate Dewe Rogerson
www.citigatedr.co.uk
Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial
and corporate communications across the UK, Europe, North America and Asia.
SPEAKERS
Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience
in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance,
journalism and academic science. The team provides sector expertise and forms an integrated part
of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the crossfertilisation of ideas across sectors.
The Citigate Pharma & Biotech team has an established track record in working with biotechnology
companies at all stages in development. As well as core skills in financial calendar work, transactions
support, financial PR and media relations, the team has extensive experience in branding, design and
new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK
and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and
Scandinavia.
Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs,
other public and private fundraisings, and M&As. We have advised on a number of IPO transactions
across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock
Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics
(Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and
PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).
t back :: next u
Tel: +44 (0)-207-638-9571
Citigate Dewe Rogerson
3 London Wall Buildings
London Wall
London EC2M 5SY
ORGANISERS
WELCOME
Life Sciences
College Hill
www.collegehill.com/lifesciences
SPEAKERS
College Hill Life Sciences provides a full service communications consultancy focused on sciencebased sectors. Within the life science field we have established a leadership position by working in
partnership with our clients to deliver high quality communications that build corporate value and
promote leading edge products, technologies and services).
London
Sue Charles
The Registry, Royal Mint Court, London EC3N 4QN, UK
T: +44 (0)20 7457 2020 F: +44 (0)20 7866 7900
Email: [email protected]
Manchester
Dr Eileen Paul / Chris Fisher
Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK
Tel: +44 (0)1260 296500 Fax: +44 (0)1260 296501
Munich
Dr Robert Mayer
Augustenstraße 79, 80333 Munich, Germany
Tel: +49 (0)89 57 00 18 06 Fax: +49 (0)89 52 38 80 06
t back :: next u
Melbourne
Dr Douglas Pretsell
Level 9, 278 Collins Street, Melbourne VIC 3000, Australia
T: +61 (0)3 9657 0706
ORGANISERS
WELCOME
FreeMind
www.freemindconsultants.com
SPEAKERS
FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to
receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting
group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven
long-term strategic approach has garnered its clients over 1.5 billion dollars to date.
Our expertise in applying for grants and contracts extends throughout every government
mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC,
BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and
Susan G Komen.
FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are
dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable
opportunity through to submission and subsequent award. Our team of experts will assist our
clients in making non-dilutive funding a key tool in their long-term financial strategy.
Tel: (617) 648-0340
Fax: (617) 904-1767
Boston
FreeMind Group
423 Brookline Ave. #124
Boston, MA 02215
Jerusalem
FreeMind Group
Hi - Tech Center
Hebrew University
Jerusalem 95702
Israel
t back :: next u
Washington DC
FreeMind Consultants
4094 Majestic lane # 269
Fairfax, VA 22033
ORGANISERS
WELCOME
Life Science Austria
www.lifescienceaustria.at
SPEAKERS
Life Science Austria - LISA - is a program acting as a hub for people from all over the world who
are interested in the life science sector in Austria. Together with its associates in the Austrian
regions, LISA is the first point of contact for anyone with questions about scientific collaboration,
setting up an operation, or funding and sponsoring projects and businesses in Austria.
Working with all existing life science clusters in the Austrian regions – ecoplus, human.
technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life
Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA
and its partners are: contribute to the success of life science enterprises in Austria by helping to
introduce scientific discoveries to the market, assist in the search for funding, and provide general
business consultancy and support to ensure healthy commercial development.
Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the
Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).
Tel.: +43 (1) 501 75 - 0
Fax: +43 (1) 501 75 - 900
Austria Wirtschaftsservice Gesellschaft mbH,
Ungargasse 37,
1030 Wien,
Austria
t back :: next u
ORGANISERS
WELCOME
MedNous
www.mednous.com
MedNous is a print publication and a website for everyone involved in medical research in Europe.
The name is derived from the Greek word for knowledge – nous – and the English word, medical.
SPEAKERS
The website gathers in one place current news and reference information. Under the heading
Research Directory, subscribers can look up past articles from the print publication by title, author,
subject and keyword.
The print publication analyses complex issues that life science professionals need to understand in
order to bring their research into commercial development. These issues relate to regulatory affairs,
patent law, government research policy and funding. The print publication appears 10 times per
year and includes news, company interviews and commentary by corporate executives and other
practicioners in this field.
MedNous is well sourced and presented in clear, logical prose.
Tel: +44 (0)20 7704 1015
264 Banbury Road
Oxford
OX2 7DY
UK
t back :: next u
ORGANISERS
WELCOME
Swiss Biotech Association
www.swissbiotech.org
SwissBiotech – One Nation – One Biotech Cluster
SPEAKERS
Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo
Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss
Exchange which holds a leading position in terms of life-science listings and services.
The National Industry Association named Swiss Biotech Association Represents more than 150
companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech
raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with
its key research institutions and companies.
Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech
locations in the world. This will be achieved by presenting a comprehensive picture of the drivers
of biotechnology including research, education, economics, finance and industry. The bases for
success in biotechnology are the critical mass of research institutes and accelerated technology
transfer. The early integration of industry and well-trained workforce is another critical success
factor for rapid economic growth. More than 40 technology parks throughout the country support
the increasingly important and successful TechTransfer process.
Further inquiries:
SwissBiotech, Executive Office
Tel. +41 (0)44 455 56 78
[email protected]
t back :: next u
ORGANISERS
WELCOME
Tiberend Strategic Advisors, Inc.
www.tiberendstrategicadvisors.com
SPEAKERS
Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and
execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We
work with both public and private emerging growth companies.
1. To enhance valuation
2. To build visibility for partnerships and strategic alliances
Tiberend Strategic Advisors, Inc.
35 W. 35th Street, 5th Floor,
New York, NY 10001-2205
Tel: 212.827.0020
Fax: 212.827.0028 Fax
t back :: next u
ORGANISERS
WELCOME
Torreya Partners LLC
www.torreyapartners.com
SPEAKERS
Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and
assistance with Mergers & Acquisitions, Partnering and Financings to life science companies
worldwide. Torreya Partners provides the long-term thinking and objective advice required for life
science companies to create lasting value. We take great pride in handling complex financial and
strategic matters for some of the most sophisticated private and public life science companies
in the world. Our reputation has been built on quality advice, excellence in deal execution and
good outcomes for our clients. We bring the caliber of people and quality of relationships found in
some of the largest investment banks along with the attentive, detailed service you expect from
a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San
Francisco.
UK
12 St James’s Square
London SW1Y 4LB
+44 0207 104 2310
New York
117 East 55th Street
New York, NY 10022
(212) 331-7843
t back :: next u
ORGANISERS
WELCOME
Organisers
Sachs Associates
www.sachsforum.com
Sachs Associates is a London based international conference organiser which produces high profile events for
the bio-pharmaceutical and financial community. These events are held In Europe and the USA; currently in
Boston and Zurich.
The benefits of conference participation with Sachs Associates may be summarised as follows:
SPEAKERS
The company was established in 1992 and ran emerging growth and emerging market investor forums in
association with Dow Jones and then Bloomberg LP over a ten year period.
Multimedia Exposure
Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well
focused electronic and print media. Regular extensive coverage of all the Company’s conferences is carried out
through video streaming and extensive events coverage through major international financial news agencies,
including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established
relationships with other financial press organisations globally, which allow further effective distribution on
behalf of its clients.
Sponsorship and Marketing Opportunities for forthcoming events
Sachs Associates has developed an extensive knowledge of the key individuals operating within the European
and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the
forefront of the industry and provides a powerful tool by which to increase the position of your company in this
market.
The following sponsorship and marketing opportunities are available at future conferences:
• Conference Sponsor – including workshops and social events
• Exhibition stands
• Distribution of Promotional Material
If your company is interested in exhibiting or sponsorship opportunities please call
Zoe Harris on +44 203 463 4890.
Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients.
All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out
of attending our industry driven events.
Eminent Speakers
Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of
the most eminent speakers from the public and private sectors. Through its reputation and its long-established
local relationships, the Company has attracted the very senior political and economic personalities as speakers
at its events.
ORGANISERS
S C I E N C E
21-22 May 2013 • The Westin Copley Place • Boston
www.sachsforum.com/boston13/index.html
13th Annual
Biotech in Europe Investor Forum
30 September – 1 October 2013
• Hilton Zurich Airport Hotel • Zurich
27 Belsize Lane
London
NW3 5AS
www.sachsforum.com
ORGANISERS
Tel: +44 (0) 203 463 4890
Fax: +44 (0) 207 691 7919
L I F E
Annual
Cancer Bio Partnering Forum
Promoting Public & Private Sector,
Collaboration & Investment in Drug Development
E U R O P E A N
SPEAKERS
C E O
F O R U M
WELCOME
We look forward to seeing you at:

EUROPEAN LIFE SCIENCE CEO FORUM for Conference Guide

Transcription

Similar documents

on Mark Scharenbroich and his Nice Bike message . . .

Competitive Advantages of Siax

Growco Thursday AM Gen Session.pptx

Fact Sheet - Global Retailing Conference

2015 Theme: “Never Stop”

Team Engagement

schedule beach volleyball - Mallorca 2016 First World Company

Children on the move in street situations

Market-at-a-glance - Smart Business Magazine

Sunday,Sept.18,2016 - Carz Cruizin to Cure Cancer